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ABSTRACT 
Background: The Comprehensive Global Monitoring Framework on non-
communicable diseases (NCDs) identifies availability and price of NCD medicines as 
critical indicators of access to treatment. This dissertation project conducted in eight 
counties in Kenya studies the:  
i) availability and prices of NCD medicines in public and non-profit health facilities 
and private drug outlets; 
ii) feasibility and validity of data collection on medicine availability and price 
through telephone interviews compared to in-person; and 
iii) effects Novartis Access, a NCD medicine pricing scheme, on medicine 
consumption patterns. 
Methods: In 2016 medicine availability and price data were collected in-person 
through household and facility surveys. Between 2016 and 2018, monthly telephone 
surveillance data on medicines from health facilities and households were compared with 
data collected in-person. In-depth interviews (IDIs) were conducted with 25 respondents 
and data collectors to understand their perceptions on both modes of data collection. 
Sales data on Novartis Access medicines and their generic and therapeutic 
 
 vii 
equivalents were collected from a major wholesaler. The effects of Novartis Access 
medicines on the consumption generic and therapeutic equivalents and on the 
consumption of medicines not listed in the national Essential Medicines List (EML) were 
estimated using segmented regression analysis.  
Results and discussion: Availability of NCD medicines was low, especially 
among primary care facilities in the public sector. Prices varied substantially by provider 
type and level of care, with prices generally lower in the public sector. Telephone 
interviews were cheaper than in-person interviews; demonstrated high response rates; 
showed statistically significant level of agreement and correlation with medicine 
availability and price data respectively from in-person interviews. Most IDI participants 
mentioned phone interviews were more convenient and yielded good data. Consumption 
of non-EML medicines was widespread. The introduction of Novartis Access had no 
statistically significant effect on the overall level and trend of consumption of generic 
equivalents and non-EML medicines. 
Conclusion: Interventions need to be implemented to address the poor 
availability of NCD medicines and large variation in prices and to ensure that access 
initiatives focus on priority medicines. Phone interviews are reliable and valid for 
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CHAPTER ONE - GENERAL INTRODUCTION 
1. INTRODUCTION 
 
This dissertation examines the availability, price and consumption patterns of 
medicines for non-communicable diseases (NCDs) in Kenya. The study has three main 
objectives. The first objective was to determine the availability and price of medicines in 
health facilities and how these prices compare with international reference prices. The 
second objective was to determine the feasibility and validity of data collection on 
medicine availability and price through telephone interviews compared to in-person 
interviews. The final objective was to determine the effects of Novartis Access, a NCD 
medicine pricing scheme, on medicine consumption patterns. 
1.1 Rationale for the objectives of this dissertation  
The burden of NCDs has been on the rise, especially in low- and middle-income 
countries (LMICs) (1,2). Globally, an estimated 40·5 million deaths in 2016 were due to 
NCDs (2). Eighty percent of these deaths were caused by diseases including cancers, 
cardiovascular diseases, chronic respiratory diseases, and diabetes. Nearly 80% of NCD 
deaths occur in LMICs, and people living in sub-Saharan Africa face the highest risk of 
death (2,3). In 2011, the United Nations General Assembly adopted a resolution for the 
prevention and control of NCDs (4). This commitment was renewed in 2015 with the 
adoption of the Sustainable Development Goals (SDGs), Target 3.4 of which aims to “By 




prevention and treatment and promote mental health and well-being” (5). A global 
monitoring framework (GMF) for the prevention and control of NCDs was also adopted 
by the 66th World Health Assembly in 2013.   
Two of the critical indicators under the GMF were affordability and availability of 
NCD medicines in health facilities (6,7). Availability of medicines is one of the top two 
factors that affect the choice of health care providers in Kenya (8). Findings from this 
objective will supplement existing evidence on the availability and price of NCD 
medicines and inform policies such as mark-up and price controls in Kenya and other low 
and middle income countries.  
The GMF urged Member States of the WHO to develop national targets and 
indicators that can be used to monitor progress towards achieving these targets (6). The 
2016 Lancet Commission on Essential Medicines also recommends the creation and 
maintenance of information systems for collecting routine data on the availability and 
affordability of essential medicines in both public and private sectors (9). However, the 
high cost and level of effort associated with monitoring and evaluating health care 
interventions through in-person data collection has discouraged many stakeholders from 
establishing monitoring and evaluating programs (10). If accurate price and availability 
data can be collected on through telephone interviews, incorporating this into the 
evaluation of access to medicines programs in low and middle income countries will 





Finally, several price schemes and drug donation programs have been 
implemented by pharmaceutical industry as a means of improving access to medicines 
(11). However, little is known about how pricing schemes affect the availability and 
affordability of medicines at facility and household level (12). It is important to monitor 
these initiatives for their intended and unintended consequences to generate evidence that 
will inform the design and scale-up of these initiatives for maximum impact.  
1.2 The burden of non-communicable diseases in Kenya 
One-half of total hospital admissions and over 55% of hospital deaths in Kenya 
are due to NCDs (13).  Cardiovascular diseases are the leading cause of NCD related 
deaths followed by cancer, which accounts for 7% of overall mortality in the country 
(14). Breast cancer, one of the most common cancers among women affects 34 per 
100,000 population (13).  About 2.2% of the population between the ages of 20-70 have 
diabetes which leads to 20,000 deaths every year (15). According to the Kenya Stepwise 
Survey for Non-communicable Diseases Risk Factors 2015 Report, the prevalence of 
hypertension in Kenya stands at 24% (13).  
In 2014, Kenya launched its National Health Policy (NHP) with the goal of 
attaining the “highest possible standard of health in a responsive manner” (16). Among 
the six key objectives of this policy, one directly targets non-communicable diseases: 
“halt and reverse the rising burden of non-communicable conditions”. The three expected 
outputs from the implementation of the 2014 - 2030 health policy are improved access, 




remove all geographical, financial, and sociocultural barriers to health care. The Ministry 
of Health (MOH) estimates implementing the new policy will reduce by 50% the overall 
deaths per 1,000 persons by 2030. This translates to a 62% reduction in deaths due to 
communicable diseases, and 27% reduction each in deaths due to non-communicable 
diseases and violence/injuries (16). One of the eight key action areas where investments 
will be made in order to achieve the above outputs is health products and technologies 
(essential medicines, medical supplies, vaccines, health technologies etc.).  
While there is general evidence of challenges regarding access to NCD medicines, 
studies vary in quantifying the access to medicines gap (17–20). The 2013-2018 Strategic 
Plan identifies frequent stock outs, poor prescribing and dispensing practices, 
inappropriate use of medicines, substandard and counterfeit products and the high out-of-
pocket expenditures on medicines as the major factors affecting the delivery of quality 
health services in the country (17). The findings from this dissertation will add to the 
evidence base needed to inform the design of effective programs and policies to address 
these challenges.  
1.3 The structure of the health care system in Kenya 
In 2010, Kenya devolved its governance system into a new system which consists 
of one national government and 47 county governments (16). The national government is 
responsible for leading health policy development, managing national referral health 
facilities, the provision of technical assistance and capacity building to county 




County governments on the other hand are responsible for health services within their 
counties, pharmacies, ambulance services, promoting primary healthcare, among others.  
The healthcare system in Kenya is hierarchically organized from levels 1 to 6, 
with level 1 facilities being the lowest level of care and level 6 facilities the highest (16): 
Level 1: Community 
Level 2: Dispensaries 
Level 3: Health centers 
Level 4: Primary referral facilities 
Level 5: Secondary referral facilities 
Level 6: Tertiary referral facilities 
Dispensaries and health centers make up the primary care units of the health 
system. The Essential Medicines List (EML) of Kenya restricts most NCD medicines to 
levels 4 and above (21). Previous studies on medicines availability in Kenya did not take 
into account these restrictions, and evaluated medicines availability irrespective of level 
of care (18–20). It is unknown how many countries have similar restrictions and how 
these restrictions were taken into consideration during surveys on medicines availability 
in health facilities. Chapter 2 examines availability of NCD medicines based on the EML 
of Kenya. It also examines availability based on the Standard Treatment Guidelines of 
Kenya, which contain more medicines than the EML, and does not restrict medicines to 




1.4 The Novartis Access program  
During the September 2015 United Nations meeting Novartis/Sandoz launched the 
Novartis Access initiative which aims to provide a basket of 15 medicines for the 
treatment of four NCDs (asthma, breast cancer, diabetes, and cardiovascular disease) in 
30 countries over a period of 5 years. Kenya is the first country to benefit from this 
initiative. It is intended that each of the Novartis Access medicines will be sold at an 
average price of about 100 KES ($1) per monthly course of treatment.  
Boston University is evaluating the impact of Novartis Access on the availability and 
price of NCD medicines at health facilities and households in Kenya, using a cluster-
randomized trial design. The evaluation is taking place in eight counties which have been 
randomized into four control and four intervention counties. Baseline data were collected 
through surveys at health facilities (public, private not-for-profit, and private for profit) 
and a random sample of households in October 2016, prior to the implementation of the 
Novartis Access program. Endline data were collected in February 2018. Since baseline, 
BUSPH has been collecting quarterly telephone surveillance data on price and 
availability of Novartis Access medicines and their equivalents at health facilities and 
households. The evidence generated from this dissertation, which is built around the 





2. OUTLINE OF THE DISSERTATION DOCUMENT 
Chapter 2 of this document focuses on the first dissertation objective – availability 
and prices of NCD medicines in health facilities. Chapter 3 focuses on the second 
objective – validating a method for collecting data on medicines through telephone 
interviews. Chapter 4 examines the effect of Novartis Access on the consumption patterns 
of generic and therapeutic equivalents and on the consumption of non-EML medicines 
(third study objective). Chapter 2 to 4 present a literature review, a detailed description of 
the study methods and results. The discussion section of each of these chapters also 
include an in-depth description of the study limitations. Each of the chapters concludes 
with a series of appendices presenting all study instruments and supporting results. 
Chapter 5 summarizes the key lessons learned from the three study objectives and 
discusses their policy and programmatic implications. Finally, Exhibit 1, presents a 
policy brief to the Ministry of Health of Kenya on how to address the challenge of limited 
access to NCD medicines in the country. While Exhibit 2 presents a policy brief to 
program implementers and policy makers, both in the public and private sector on the use 
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CHAPTER TWO - AVAILABILITY AND PRICE OF MEDICINES FOR NON-
COMMUNICABLE DISEASES IN HEALTH FACILITIES AND RETAIL DRUG 
OUTLETS IN EIGHT COUNTIES IN KENYA 
EXECUTIVE SUMMARY  
Background: Availability and price are important dimensions of access to 
medicines. The objective of this study was to determine the availability and price of 
medicines for NCDs in health facilities and drug outlets in Kenya. Findings from this 
study complement existing evidence on the availability and price of NCD medicines in 
low and middle income countries, which is necessary to inform the design of policies to 
enhance access to all medicines. 
Methods: All public and private non-profit health facilities in eight counties in 
Kenya (Embu, Kakamega, Kwale, Makueni, Narok, Nyeri, Samburu and West Pokot) 
that purchase medicines from the Mission for Essential Drugs and Supplies, a major 
wholesaler in the county, were surveyed. For each health facility, one nearby private-for-
profit drug outlet was also surveyed. Data on availability and price were analyzed for 9 
acute and 32 NCD medicines. Median price ratios were estimated using the International 
Medical Products Price Guide as a reference.   
Results: A total of 272 health care providers were surveyed – 59 public health 
facilities, 78 private non-profit health facilities and 135 private-for-profit drug outlets. 
Availability, defined as the proportion of facilities having a medicine in stock on the day 
of data collection, was analyzed for medicines included in the National Essential 




generally lower in the public sector compared to non-profit facilities and drug outlets. 
Medicines were more available at higher levels of care. For medicines included in the 
EML, the overall mean proportion of availability for NCD medicines (0.55) was not 
significantly different from the overall mean probability of availability for acute 
medicines (0.61). For medicines included in the STGs, the overall mean probability of 
availability for  NCD medicines (0.25)was however significantly lower than the overall 
mean probability of availability for acute medicines (0.62). p<0.0001.  
Prices varied substantially by provider type and level of care. Public facilities 
were more likely to give medicines for free. The mean price ratio of NCD medicines was 
significantly higher than for acute medicines in non-profit facilities (4.2 vs 2.0 
respectively; p=0.0094), and in drug outlets (3.46 vs. 1.66; p=0.0014).  
Discussion and conclusion: While the availability of many EML medicines was 
higher than 50%, the international target of 80% availability was not reached. Our 
findings are consistent with previous studies in Kenya and other low- and middle-income 
countries which have shown lower availability of NCD medicines relative to medicines 
for acute conditions. Considering the high burden of NCDs world-wide, and the rapidly 
increasing burden in low- and middle-income countries, efforts need to be made to ensure 
the reliable supply of affordable NCD medicines in health facilities.  
There were large price variations across and within provider type, as well as level 
of care. Private drug outlets and private non-profit facilities charged higher prices for 
both NCD and acute medicines as compared to public facilities. Given the lower relative 










The objective of this study was to determine the availability and price of medicines 
for non-communicable diseases (NCDs) compared to medicines for acute disease 
conditions in health facilities and drug outlets in Kenya. Findings from this study 
complement existing evidence on the availability and price of NCD medicines in low- 
and middle-income countries, which is necessary to inform the design of policies to 
enhance access to medicines (1–7). 
2. BACKGROUND  
2.1 The structure of the health care system in Kenya 
With the devolution of health care in Kenya, county governments have assumed 
responsibility for the delivery of health services including purchase of medicines, 
ambulance services, promoting primary healthcare, among others. The national 
government still retains the mandate for developing policies and standards such as the 
Essential Medicines List (EML) and Standard Treatment Guidelines (STGs) (8). 
The health care (and pharmaceutical care) providers in Kenya are made up of public 
(government owned) health facilities, not-for-profit health facilities (faith based 
organizations and other not-for-profit non-governmental organizations), private-for-profit 
health facilities and private drug outlets (standalone drug outlets sometimes called 
chemists or private pharmacies) (9). In 2013, public health facilities accounted for a 
greater proportion of outpatient care visits in the country - 66.7% in rural areas and 




facilities was 8% vs. 6.9%; private health facilities 12.4 vs. 29.1 and private drug outlets 
11.5 vs. 15.7 respectively (9).  
Health facilities (public and faith based facilities) in Kenya are hierarchically 
classified into dispensaries (level 2), health centers (level 3), primary (county) referral 
hospitals (level 4), secondary referral hospitals (level 5) and tertiary hospitals (level 6) 
(8). Dispensaries are staffed by enrolled nurses, public health technicians and medical 
assistants, they offer treatment for simple ailments to outpatients, antenatal care, and 
sometimes conduct normal deliveries (10,11). Staff at health centers include nurses, 
midwives, clinical officers, and in some cases doctors. They offer basic curative and 
preventive, reproductive health services in addition to minor surgical services. Primary 
referral facilities are the first referral hospitals at the district level. Secondary referral 
facilities provide specialized services and serve as referral hospitals to the primary 
referral facilities at the provincial level. Tertiary referral hospitals provide specialized 
care that is not available at lower levels of care. They are staffed by surgeons, general 
medical physicians, pediatricians, pharmacists, general and specialized nurses, midwives, 
and public health staff. Tertiary referral facilities are also involved in training health 
workers (10,11).   
2.2 Access to medicines for non-communicable diseases in Kenya  
Availability and affordability are two key dimensions of access to medicines 
(4,12,13). In Kenya availability of medicines is one of the top two factors that affect 
patients’ choice of health care providers (9). There are many challenges regarding access 




NCDs in the country (14–16). Stock-outs of medicines at the Kenya Medical Supplies 
Agency (KEMSA) and the Mission for Essential Drugs and Supplies (MEDS), two major 
suppliers of medicines to hospitals and clinics, have reportedly been minimal (17). The 
scenario is however not the same for health facilities. The availability of medicines in 
health facilities (including dispensaries, health centers and hospitals) is generally poor 
with medicines for NCDs much less available compared with medicines for 
communicable diseases (45.5% vs. 70%) (1). The Kenya Service Delivery and Readiness 
Assessment Report, published in 2014, reported an even lower mean availability of NCD 
medicines at primary care facilities and hospitals: 25% and 32% respectively (6). A 
medicines availability and pricing study conducted in 2012 showed that these figures 
were about two times less than the availability of malaria (55% and 65% at primary care 
facilities and hospitals, respectively), and tuberculosis medicines (51% and 55% at 
primary care facilities and hospitals, respectively). While the availability of medicines for 
communicable diseases is similar in rural and urban areas (72.5% vs. 68.3%), the 
availability of medicines for NCDs is higher in urban compared to rural areas (51.3% vs. 
40.6%) (1).  
Based on data for Kenya in 2009, the prices of medicines are lower in public 
facilities compared to faith based and private facilities, however, stock-outs are about 
three times more common in public facilities (46% vs. 14%). Accordingly, the proportion 
of medicines prescribed that are actually dispensed in public facilities is less than the 
proportion of medicines prescribed that are actually dispensed in faith based facilities 




financed by the government of Kenya, household out-of-pocket expenditure on NCDs is 
still substantial. In 2012/13 63% of total expenditure on NCDs came from public sources 
while 28% as out-of-pocket (18). Similar to other developing countries, health insurance 
coverage is very low in Kenya, with about 17% of the population covered in 2013 (9,19). 
In 2010, only 4% of NCD patients in the country reported having at least partial 
insurance coverage for their medicines costs (5). This means many patients pay for their 
NCD medicines out-of-pocket.   
2.3 Essential medicines list and standard treatment guidelines in Kenya   
Essential medicines are defined by the World Health Organization (WHO) as 
“those that satisfy the priority health care needs of the population” (20). The factors 
considered in selecting essential medicines include disease burden, public health 
relevance, efficacy and safety, comparative costs and cost-effectiveness (21,22). Kenya 
published its first EML in 1981 which has since been updated in 1993, 2003, 2010 and 
2016 (23–25). Essential medicines are expected to be always available in facilities 
(usually public facilities) at affordable prices (20). The EML guides public procurement 
in Kenya, and the 2010 and 2016 editions of the EML (the two most recent editions) 
restrict most NCD medicines to levels 4 and above (23,25). However, it is not clear if 
providers or suppliers follow this restriction. The disparities in access to medicines by 
level of care have also not been documented. Previous studies on the availability of 
medicines did not take into account the EML restriction of medicines to specific levels of 
care.  




Sciences for Health (MSH) as “A systematically developed statement designed to assist 
practitioners and patients in making decisions about appropriate health care for specific 
clinical circumstances” (26). STGs are based on effective treatment options and help 
streamline prescribing patterns in combination with the EML. The most recent editions of 
STGs in Kenya some of which are disease specific, include the following: 
- 2015: Protocol for the identification and management of hypertension in adults in 
primary care (27) 
- 2011: Guidelines for Asthma Management in Kenya (28) 
- 2010: National Clinical Guidelines for the Management of Diabetes Mellitus (29) 
- 2009: Clinical Guidelines for the Management and Referral of Common Conditions 
at Levels 4-6: Hospitals. Volume III (30) 
- 2009: Clinical Guidelines for the Management and Referral of Common Conditions 
at Levels 2-3: Primary Care. Volume II (31)   
Even though the EML and STGs are meant to complement each other in 
standardizing the provision of quality health services in Kenya, there are important 
differences between the two documents, especially regarding the medicines included, 
which can make standardization of health care delivery challenging. For example, while 
the current versions of the EML restricts most NCD medicines, for example amlodipine 
and glibenclamide, to level 4 facilities and above, the STGs do not restrict these 
medicines based on level of facility (23,25,27–30). Additionally, there are some 
medicines that are not in the EML but are included in the STG, for example glimepiride, 
valsartan, and anastrozole. 




diseases by level of care and by provider type (public, private not-for-profit facilities and 
private for-profit outlets) in eight counties in Kenya. Because of the inconsistency 
between the EML and STGs, the study also evaluates separately the availability of 
medicines included in the EML and availability of medicines included in the STGs. 
3. METHODS 
3.1 Study sites 
The data presented in this paper were collected during the baseline study on the 
evaluation of Novartis Access, a low-cost NCD medicines program implemented by 
Novartis Pharmaceuticals Novartis Access targets medicines for four non-communicable 
diseases – cardiovascular disease (dyslipidemia, heart failure and hypertension), diabetes, 
asthma and breast cancer. Data were collected from eight study counties - Embu, 
Kakamega, Kwale, Makueni, Narok, Nyeri, Samburu and West Pokot. The selection of 
these counties had been described by Rockers et al. (32). Data were collected through 
face-to-face interviews with staff in health facilities (public health facilities, private non-
profit health facilities, private-for-profit drug outlets (chemists) in the eight counties.  
3.2 Data collection 
Data were collected in English in September 2016. Data collectors were trained 
on key concepts on price and availability of medicines, ensuring data quality, ethics of 
data collection, maintaining confidentiality of respondents, administering informed 
consent, etc. The training also covered the use of survey instruments which were 




instrument was pilot tested twice by the trained data collectors and revised based on the 
feedback received from each pilot test. 
All of the public and private non-profit health facilities in eight counties that 
purchase medicines through MEDS were surveyed. After data collection at a health 
facility, data collectors asked respondents to identify the nearest private-for-profit drug 
outlet patients are referred to when medicines prescribed are not available at the facility. 
Data collectors then visited these private-for-profit drug outlets and collected data using 
the same data collection instrument used at the health facility.  
Data were collected on price (in Kenyan Shillings – KES) and availability (having 
or not having the medicine in stock on the day of data collection) of 35 chronic disease 
medicine formulations. All chronic medicines selected for inclusion in the study are part 
of the most recent standard treatment guidelines (STG) for hypertension, diabetes or 
asthma in Kenya. The three cancer medicines for which data were also collected 
(anastrozole, letrozole and tamoxifen) were excluded from this study. This was because 
cancer management in Kenya mainly occurs in tertiary health facilities which were not 
the focus of this study. In addition, data were collected on nine acute disease medicine 
formulations that have been used as reference medicines in evaluating the availability and 
price of medicines in health systems (16). The list of medicines on which data was 
collected are shown in Annex 2.1. 
The 2015 edition of the International Medical Products Price Guide (IMPPG) 
(formerly known as International Drug Price Indicator Guide) was used to determine 




(INN), dosage form and strength as the study medicines (34). This price guide is 
published by MSH and contains prices at which major non-profit wholesalers or 
procurement agencies purchase medicines from manufacturers and importers.  
3.3 Data analysis 
Data were analyzed using SAS version 9.4 (The SAS Institute Inc.) (35). The 
following outcome measures were estimated: 1) the probability of availability (defined as 
the proportion of health facilities having each branded or generic version of the medicine 
available in stock), 2) the median price (and minimum and maximum prices) of each 
generic medicine across health facilities, and 3) median price (and minimum and 
maximum prices) of each originator brand across health facilities. The originator brand of 
a medicine was defined as the brand of the medicine that was first authorized worldwide 
for marketing (normally as a patented product) on the basis of the documentation of its 
efficacy, safety and quality, according to requirements at the time of authorization (36).  
Availability was assessed using two approaches. The first approach focused only 
on medicines included in the EMLs and the second approach focused on medicines 
included in the STGs. Each of these two approaches and the analysis of medicines prices 
are described in detail below.  
3.3.1 Availability based on the EML 
Seventeen medicines (nine for NCDs and eight for acute conditions) listed in the 
2010 and/or 2016 EMLs were included in this analysis. The availability of these 




medicines by level of care was analyzed by first taking into consideration the level of 
care the medicines were assigned in the 2010 and 2016 EMLs (Annex 2.1). Thus, 
availability was only assessed in facilities that met the minimum level of care assigned 
the medicine on the EML. In cases where the level of care assigned a medicine varies 
between the two EMLs, the lowest level of care was used for the analysis. A sensitivity 
analysis was performed to estimate availability of all medicines on the EML, irrespective 
of the level of care they were assigned.  
3.3.2 Availability based on the STGs 
Thirty three medicines (24 for NCDs and 9 for acute conditions) which were 
listed on the 2009 to 2015 editions of STGs for asthma, diabetes, hypertension and other 
NCDs were included in this analysis (37–39). As STGs do not restrict medicines to 
specific levels of care, availability was assessed across health facilities regardless of level 
of care.  
For both analyses based on the EML and STGs, the mean probability of having 
medicines in stock was compared among public, private-not-for-profit, and private-for-
profit drug stores, and across levels of care (levels 2, 3, 4 and 5) using analysis-of-
variance (ANOVA) with the Tukey-Kramer adjustment procedure to compare pairs of 
means. Differences in mean availability between acute and NCD medicines were 




3.3.3. Analysis on the prices of medicines 
Median, minimum and maximum prices were estimated for observations for 
which medicines were not given for free (i.e. price was not equal to zero). All price 
analyses were conducted in September 2016 Kenyan Shillings. Using the supplier prices 
from the IMPPG as a reference, the median price ratio for each medicine was estimated. 
Due to the limited availability of originator brands in health facilities, median price ratios 
were estimated for only generics. Only 23 of the study medicines had supplier prices 
reported in the MSH IMPPG which was used for the median price ratio computation. 
First the prices from the MSH IMPPG (in 2015 United States Dollars) were inflated to 
2016 rates, using the average of 2015 and 2016 annual inflation rates (0.7) obtained from 
the US Inflation Calculator (http://www.usinflationcalculator.com/inflation/historical-
inflation-rates/). The September 2016 price data  were converted from Kenyan Shillings 
to United States Dollars using September 15 2016 exchange rate of (1KES= 
$0.00987063) obtained from xe.com.  
Median price ratios were compared among public, private-not-for-profit, and 
private-for-profit drug stores, and across levels of care (levels 2, 3, 4 and 5) using 
analysis-of-variance (ANOVA) with the Tukey-Kramer adjustment procedure to compare 
pairs of means. Differences in mean price ratios between acute and NCD medicines were 
estimated using the two sample t-test. The proportion of facilities giving each medicine 





A total of 272 health facilities were surveyed – 59 public facilities, 78 private non-
profit facilities and 135 private-for-profit drug outlets. The total number of facilities per 
county varied (a minimum of 12 in Samburu and a maximum of 48 in Embu county) 
(Annex 2.2). More than one half (n=77; 61%) of the participating public and non-profit 
facilities were level 2 (dispensaries), 18.3% (n=23) were level 3 (health centers), while 
20.6% (n=26) were level 4 (primary referral facilities). There were few (n=5; 4%) level 5 
(secondary referral) facilities. 
4.1 Availability of medicines included on the EML  
Figure 2.1 summarizes the mean availability of all of the study medicines 
included in the EML for chronic and acute conditions, by provider type. For both types of 
medicines, availability was higher at for-profit drug outlets compared to not-for-profit 
facilities and public facilities. For acute medicines mean availability increased as one 
moves from public to non-profit facilities and to private drug outlets. However, these 
differences were not statistically significant (p=0.1936). Neither was there a significant 
difference in mean availabilities for NCD medicines by provider type (p=0.5611).  
Overall, mean probability of availability of NCD medicines (0.55) was not 
significantly different from mean probability of availability of acute medicines (0.61) 
looking at only medicines on the EML (p=0.5500). Table 2.1 presents the probability of 
availability of chronic and acute disease medicines by level of care – in one scenario  
focusing on only medicines that are supposed to be available at each level of care, based 




in the EML. It is important to note that the EML restricts most NCD medicines to higher 
levels of care and salbutamol inhaler was the only study medicine that the EML has 
assigned a level 2 and above. Generally, the mean availability of medicines increased 
with increasing levels of care.  
Figure 2.1: Average facility level mean percentage availability by provider type for NCD 
and acute medicines included in the EML 
 PU – Public facility; NP=private-non-profit facility; FP=private-for-profit drug outlet 
(The box indicates the mean and the bars indicate the minimum and maximum) 
 
The mean proportion of availability at level 5 facilities was 31% higher than the 
mean availability at level 2 facilities (p=0.0089). Disregarding level of care medicines 
were assigned, there was no statistically significant difference in mean probability of 
























was a difference in mean probability of availability for acute medicines by level of care 
(p=0.0385).  

















































































































































































































































































































































































































































































There is no clear trend comparing mean availability of acute medicines with mean 
availability of chronic medicines across levels of care in both scenarios. 
4.1.1 Non-compliance of public and non-profit facilities with the EML 
Twelve of the NCD medicines in this study were not on the EML. However, each 
of these medicines was found at all levels of care. The probability of health facilities 
stocking these medicines ranged from 0.01 to 0.2. As mentioned earlier, all of the nine 
study NCD medicines included in the EML were assigned level 4 and above except 
salbutamol inhaler which was assigned level 2 and above. There was high proportion of 
availability of these NCD medicines otherwise restricted to level 4 at levels 2 and 3 
facilities (Annex 2.3b and Annex 2.4). The proportion of levels 2 and 3 facilities having 
these medicines in stock ranged from 0.13 (for amlodipine 5mg) to 0.8 (for omeprazole 
20mg). More than one half of levels 2 and 3 facilities were stocking four of these 
medicines (amitriptyline 25mg, furosemide 40mg, metformin 500mg, and omeprazole 
20mg) 
Among acute medicines, diazepam 5mg was restricted to level 4 and above, however, the 
probability of level 2 and level 3 facilities stocking this medicine were 0.5 and 0.6 
respectively.   
4.2 Availability of medicines included on the STGs 
Figure 2.2 summarizes the mean availability of all of the study medicines 
included in the STGs for chronic and acute conditions by provider type. For both types of 




outlets compared to not-for-profit facilities and public facilities. Availability of NCD 
medicines at public facilities is similar to availability at non-profit facilities.  
 
Figure 2.2: Average facility level mean percentage availability by provider for medicines 
included in the STG  
PU – Public facility; NP=private-non-profit facility; FP=private-for-profit drug outlet; 
N=number of medicines surveyed (The box indicates the mean and the bars indicate the 
minimum and maximum) 
 
For acute medicines availability increased as one moves from public to non-profit 
facilities and to private drug outlets. However these differences were not significant 
(p=0.2011). Neither was there any statistically significant difference in mean 


























The overall mean probability of availability of NCD medicines (0.25) was significantly 
lower than the overall mean probability of availability for acute medicines (0.62); 
p<0.0001.  
Figure 2.3 presents the probability of availability of chronic and acute disease 
medicines by level of care based on the STGs. The mean availability of NCD medicines 
in the STGs was consistently lower (comparing similar levels of care) compared to the 
mean availability for acute medicines.  
Figure 2.3: Average facility level mean probability of availability by level of care for 
medicines included in the standard treatment guidelines  
 L2 = Level 2 facilities; L3 = Level 3 facilities; L4 = Level 4 facilities; L5 = Level 5 
facilities; N=number of medicines surveyed (The box indicates the mean and the bars 



















Considering all medicines, there was significant differences in mean availability 
by level of care p=0.1995. There was also no significant differences in mean availability 
of NCD medicines by level of care (p=0.307). Neither was the differences in mean 
availability of acute medicines by level of care significant (p=0.3100).  
It is worth noting that  the mean availability of NCD medicines were lower when 
availability was accessed for all medicines in the STG compared to when availability was 
accessed for all medicines on the EML. For example, mean probability of availability of 
NCD medicines in public facilities was 0.5 based on the EML, but 0.2 based on the STG. 
Table 2.2 presents the overall availability of each study medicine disaggregated 
by provider type and branded versus generic formulations. Generally, generics were more 
common than originator brands across all of the study facilities. Only two originator 
brands of study medicines were available in public facilities compared with 19 in private 
not-for-profit, and 21 in private-for-profit drug outlets. Several medicines included in the 
EML had a probability of availability of over 50%. However, salbutamol, an important 
medicine for asthma relief had an availability of less than 40% across the different types 
of providers. Thirteen medicines had very low availability including CVD medicines 
such as bisoprolol 2.5mg, 5mg and 10mg, ramipril 5mg and 10mg, simvastatin 20mg and 
40mg, valsartan 80mg and 160mg and diabetes medicines and glimeperide 1mg, and 
2mg.  
Annex 2.5 presents the availability of study medicines by county. The mean 





Table 2.2: Availability of medicines (proportion of facilities having medicine available on 
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Bisoprolol 10mg  - - 1.3 
(1) 
- - - 0.4 
(1) 
- 
Bisoprolol 5mg  1.7 
(1) 
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Note: Bisoprolol 2.5mg Tab/Cap, Simvastatin 40mg Tab/Cap, and Valsartan 160mg 
Tab/Cap were not available in any facility. Medicines either on the 2010 or 2016 edition 
of the EML in bold  
 
4.3 Medicine prices  
The mean proportion  of public facilities giving medicines for free (47.3%) was 
significantly higher than the mean proportion of private non-profit facilities giving 
medicines for free (9.4%), p< 0.0001. For example, generic metformin 500mg Tab/Cap 
was provided for free at 38.5% (n=15/39) of public facilities and 14.9% (n=7/47) of 
private-non-profit facilities. Drug outlets did not offer any medicines for free. There was 
large variability in the free provision of medicines among public health facilities which 
was unrelated to county (data not shown). The mean probability of public facilities giving 
NCD medicines for free (0.45) was not significantly different from the mean probability 




probability of non-profit facilities giving NCD medicines for free (0.05) was significantly 
less than the mean probability giving acute medicines for free (0.19), p<0.0001. More 
levels 2 and 3 facilities provided medicines for free compared to level 4 facilities (Annex 
2.6b).  
The median price ratio ranged from 0.6 for paracetamol syrup in private-for-profit 
drug outlets to 8.3 for simvastatin 20mg tablets/caps in private-non-profit health 
facilities. However, there was more variability in median price ratios for NCD medicines 
(Figure 2.4). All of the ratios were greater than 1 except for paracetamol suspension 
(among private-for-profit outlets), and amoxicillin dispersible tablets (among private non-
profit facilities and private-for-profit outlets). The mean of the price ratio was 2.29 in the 
public sector, 3.61 in the private non-profit sector, and 2.95 in drug outlets (Table 2.3 and 
Figure 2.4). There was no significant difference in mean price ratios by provider type 
(p=0.1068). 
The mean price ratio of NCD medicines (1.91) was not significantly different 
from the mean price ratio of acute medicines (2.61) in public facilities p=0.3517. 
However, the mean price ratio of NCD medicines was significantly higher than the mean 
price ratio of acute medicines in non-profit facilities (4.23 vs 2.01 respectively) 
p=0.0094, and in drug outlets (3.46 vs. 1.66).   
No clear trends emerged when mean price ratios were stratified by level of care. 
However, prices tended to be generally higher in level 3 compared to levels 2, 4 and 5 




Figure 2.4: Mean price ratios by provider and medicine type 
PU – Public facility; NP=private-non-profit facility; DS=Private-of-profit drug outlet 
N=number of medicines surveyed (The box indicates the mean and the bars indicate the 
minimum and maximum) 
 
The wide variations in medicine prices was not only prevalent across out types, it 
existed within the same outlet type and within the same level of care. The within provider 
type variations appeared to be more pronounced in private drug outlets compared to 
public sector facilities. For example, the price of 1g vial of generic ceftriaxone ranged 
from 30 to 800 KES in private drug outlets, 10 to 550 in private not-for-profit facilities 
and 50 to 400 in public facilities.  Even the price for the originator brand of this product 
ranged from 930 to 2084 KES among private-non-profit facilities and 1,700 to 2,200 




























Table 2.3 – Percentage dispensing free of charge and median price ratios of study 
medicines (using MSH supplier prices as a reference) 
 Public facilities Non-profit Median price ratios 
Medicine tablets or 






















































































Medicines for CVD  
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- - - - 
Captopril 25mg   0 - 3 0  . 4.4 2.0 
























Ramipril 10mg 0 - 1 0  - - - 
Ramipril 5mg  0 - 1 0  - - - 
Simvastatin 20mg  0 - 1 0  . 8.3 5.7 
Valsartan 80mg   0 - 1 0  - - - 
Medicines for diabetes  
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Medicines for asthma           
Salbutamol 100MCG/DOS 
inhaler  
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Medicine tablets or 


























































































1.3 3.5 2.3 










Acute medicines  
Amoxicillin 250mg 









1.4 0.9 0.9 






1.9 1.9 1.9 




1.5 1.7 1.7 




2.9 3.7 1.7 




2.7 2.7 2.7 
Co-trimoxazole 8+40mg/ml 
Susp. 




1.1 2.1 1.7 
Diazepam 5mg  34 44.1 
(15) 
51  21.6 
(11) 
3.7 2.1 2.1 










Paracetamol 24mg/ml Susp.  44  75.0 
(33) 
57  24.6 
(14) 
1.0 1.0 0.6 
Mean  50.12%  8.7% 2.0 3.3 2.8 
* Refers to the number of facilities that have the medicine in stock and which reported a 
price for it. Medicines on the EML (2010 or 2016) are highlighted in bold  
 
5. DISCUSSION 
This study has revealed important findings on the availability and price of acute and 
chronic medicines in Kenya. It is the first study to report on disparities in availability of 
medicines by level of care within public and non-profit facilities, and takes into account 
the EML restriction with respect to level of care.  These key findings and their potential 




5.1 Medicines availability for chronic and acute conditions 
Even though the availability for many EML medicines was higher than 50%, it 
did not reach the international target of 80% availability (40,41). This is concerning in 
particular for NCD medicines. The low availability of salbutamol for asthmatic relief at 
all levels of care raises questions about the quality of care that patients are receiving.  
Even in the highest level of care the mean availability was only 60% (Annex 2.4). There 
may be fatal consequences for not having salbutamol inhaler in an asthmatic emergency. 
Other studies have also reported suboptimal availability of medicines for treating asthma, 
including salbutamol in health facilities (13,42) 
The results of this study have shown a significantly lower availability of NCD 
medicines compared to medicines for acute conditions based on the STGs. The mean 
availability of NCD medicines included in the STGs we have found in this study was two 
to three times lower than those found in other studies (1,4,6). Studies in Kenya and other 
countries have shown a much higher availability of medicines for acute conditions 
relative to NCD medicines (1,4). This is despite the fact that one-half of total hospital 
admissions and over 55% of hospital deaths in Kenya are due to NCDs (14). However, 
the findings of this study are not directly comparable to other studies since the selection 
of NCDs was different. The low availability of certain NCDs medicines possibly 
indicates low demand; prescribers and patients may prefer other therapeutic options 
within the same classes of medicines which were not selected in our study. Considering 
the high burden of NCDs world-wide, and the rapidly increasing burden in low and 




medicines in health facilities at all levels.  
The Kenya Service Delivery and Readiness Assessment Report compared 
availability of medicines at primary care facilities and hospitals, but results were not 
presented by the specific levels of care (6). Our study assessed the availability of 
medicines specifically at levels 2, 3, 4 and 5 facilities with availability higher at higher 
levels of care (though the differences were not statistically significant). Among the 
programmatic objectives of the EML is the promotion of appropriate use of medicines. 
For this reason several NCD medicines are limited to certain levels of care.  Despite the 
limitation of NCD medicines to level 4 facilities and above, we found many of these 
medicines in several levels 2 and 3 facilities suggesting there is demand for NCD 
medicines at these lower level facilities. This may be because of the fewer numbers of 
levels 4 and 5 health facilities compared to levels 2 and 3, which are much closer to 
patients. If the barrier to availability is the limitation of NCD medicines to level 4 
facilities and above, then additional measures such as building the capacity of lower level 
care facilities to provide these medicines may be needed to ensure access. It is also 
important to note that 12 NCD medicines that were not listed in the EML were available 
across all levels of care. Though the availability of these medicines are lower than those 
on the EML, it still raises the question of whether the EML is being implemented to its 
optimal potential in the country. .  
The generally low popularity of originator brands, especially in the public sector 
is worth noting and in line with international recommendations to promote the use of 




is important to keep in mind that the limited availability of branded medicines in the 
public sector does not necessarily translate into higher rate of prescribing of generics. The 
2012 Pharmaceutical Country Profile of Kenya indicates that prescription by 
International Non-proprietary Names (INN) is neither obligatory in the public sector nor 
in the private sector (45). Only 32% of medicines are prescribed by INN. Thus, it is 
important to promote prescribing by INN to further promote the use of generic medicines.  
5.2 Prices of medicines 
Though it is government policy to provide medicines for free at levels 2 and 3 in 
Kenya, it seems that each facility decided whether to charge for the medicines dispensed. 
The study results show that whether a medicine was dispensed free of charge or not 
varied both across and within provider type (except for drug outlets where no medicine 
was given for free), and level of care. There was no clear pattern in terms of level of care 
(Annex 2.6b). Knowing which facility will charge and which facility will not add to the 
complexity for patients in search of affordable medicines. The factors that determine 
whether medicines are provided for free are not clear. One possible explanation could be 
facilities may run out of the government’s supply of medicines and thus purchase their 
own medicines for selling to patients. It is worth mentioning that there was no hospital in 
which paracetamol syrup and co-trimoxazole suspension were given for free. This is 
concerning because these are medicines for children who are often more vulnerable.  
There were large price variations both across and within provider type, level of 
care and county. Drug outlets and private non-profit facilities exhibited similar patterns in 




significantly lower percentage of private non-profit providers offered medicines for free 
compared to public facilities. Additionally, the mean price ratios of NCD medicines were 
significantly higher than the mean price ratio of acute medicines in both private non-
profit facilities and drug stores, though no significant differences were observed in the 
public sector. This may indicate relatively higher mark-ups on NCD medicines in non-
profit and private drug outlets. Other studies have reported higher prices at private for- 
profit drug outlets (1,17,46). Considering the lower availability of medicines especially in 
public facilities, patients’ best option was likely to access their medicines at private-non-
profit facilities and private drug outlets at higher prices. 
As expected, almost all of the median price ratios obtained when the prices are 
compared with the MSH reference prices were higher than 1 because the MSH prices are 
supplier prices and are expected to be lower than the medicine retail prices. Though the 
government of Kenya does not charge duties on medicines (both active pharmaceutical 
ingredients, and finished products) imported into the country and there is no value-added 
tax directly charged on medicines, import declaration fees are charged, which may lead to 
higher prices (45). 
5.3 Strengths and limitations 
As mentioned earlier, this study is the first study that evaluates availability taking 
into consideration the level of care medicines are assigned in the EML. In addition this 
study also evaluates availability separately for medicines included in the EML and those 
included in the STGs, highlighting the differences between the two documents. The cross 




availability and prices over time.   
6. CONCLUSION 
Availability and price are important factors that determine access to medicines. This 
study has shown that availability of NCD medicines in Kenya is significantly lower than 
the target level of 80%. Availability is poorest in the public sector, and generally highest 
in the private for-profit sector. Availability was also higher at higher levels of care. More 
needs to be done in Kenya to improve the availability of NCD medicines especially in 
level 2 and level 3 facilities, in public facilities and for asthma. Furthermore, medicines 
prices vary substantially in Kenya. Though some level 2 and 3 facilities provide 
medicines for free according to government policy, the majority of facilities charge a fee 
for medicines. Pricing policies or guidelines may be useful to rationalize medicine prices 
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Annex 2.1: List of study medicines, level of care found and level of care assigned in the 
2010 and 2016 essential medicines list (EML) 
 































   
Medicines for CVD (n=15)  
Amlodipine 10mg Tab/Cap X X X X - - 
Amlodipine 5mg Tab/Cap X X X X 4 4 
Atenolol 50mg Tab/Cap  X X X X - 4 
Bisoprolol 10mg Tab/Cap  - - X - - - 
Bisoprolol 5mg Tab/Cap  - X - - - - 
Bisoprolol 2.5mg Tab/Cap - - - - - - 
Captopril 25mg Tab/Cap  X - X - - - 
Furosemide 40mg 
Tab/Cap  
X X X X 4 4 
Hydrochlorothiazide 50mg 
Tab/Cap  
X X X X - - 
Ramipril 10mg Tab/Cap  - - X - - - 
Ramipril 5mg Tab/Cap  - - X - - - 
Simvastatin 20mg 
Tab/Cap1 
- - X - 4 - 
Simvastatin 40mg Tab/Cap - - - - - - 
Valsartan 80mg Tab/Cap  - - X - - - 
Valsartan 160mg Tab/Cap - - - - - - 
Medicines for diabetes (n=6)  
Glibenclamide 5mg 
Tab/Cap 
X X X X 4 4 
Glimeperide 1mg Tab/Cap - - X - - - 
Glimeperide 2mg Tab/Cap  - - X - - - 
Glimeperide 4mg Tab/Cap  - - X - - - 
Metformin 1000mg 
Tab/Cap  
- - X - - - 
Metformin 500mg 
Tab/Cap  
X X X X 4 4 
Medicines for asthma (n=1)  
                                                        



































   
Salbutamol 100mcg/dos 
inhalation 
X X X X 4 2 
Acute medicines (n=8)  
Amoxicillin 250mg 
Dispersible tab   
X X X X 2 - 
Amoxicillin 250mg Tab 
/Cap 
X X X X 2 2 
Amoxicillin 500mg 
Tab/Cap 
X X X X 2 - 
Ceftriaxone 1 g/vial Inj X X X X 2 4 
Ciprofloxacin 500mg 
Tab/Cap 
X X X X 3 - 
Co-trimoxazole 
(8+40mg/ml susp. 
X X X X 2 2 
Diazepam 5mg Tab/Cap X X X X 4 5 
Paracetamol 24mg/ml Susp X X X X 1 1 
- = medicine not available or not in the EML 



















seller  Total 
Embu 6 18 24 48 
Kakamega 6 10 16 32 
Kwale 5 4 12 21 
Makueni 8 17 26 51 
Narok 7 9 15 31 
Nyeri 16 14 30 60 
Samburu 3 4 5 12 
West 
Pokot 8 2 7 17 





Annex 2.3a: Mean availability of STG medicines (originator or generic) by therapeutic 
category and provider type. 
  Mean availability (%) by provider type 
Category of medicine  Public  Private non-
profit 
Private for profit 
drug outlets 
Overall 
Medicines for CVD (N=15) 11.7 12.3 18.8 14.5 
Medicines for diabetes(N=6) 20.6 20.3 34.0 27.2 
Medicines for asthma 
medicine (N=1) 
40.7 44.9 64.4 53.7 
    Overall mean availability 
for the 3 NCD medicines  
15.5 16.0 25.0 19.8 
Acute medicines (N=9) 53.5 63.4 75.9 68.6 
 
Annex 2.3b: Mean availability of STG medicines by therapeutic category and level of 
care 
Mean availability (%) for medicines by category and level of care (%) 
  Level 2 Level 3 Level 4 Level 5 Overall  
CVD medicines(N=15) 8.9 11.8 20.0 22.7 12.1 
Antidiabetic (N=6) 15.2 23.9 33.4 33.3 21.1 
Asthma medicine (N=1) 27.3 50.0 73.1 80.0 42.4 
    Overall mean availability 
for the 3 NCD medicines 
11.5 16.9 26.0 28.2 15.9 




Annex 2.4: Availability of STG medicines (proportion of facilities having medicine 
available on day of visit) by level of care 
































































































Medicines for CVD 





























Bisoprolol 10mg - - - - 3.9 
(1) 
- - - 
Bisoprolol 5mg  - - 4.4 
(1) 
- - - - - 
Captopril 25mg 2.6 
(2) 
- - - 3.85 
(1) 
- - - 




















Ramipril 10mg  - - - - - 3.9 
(1) 
- - 
Ramipril 5mg  - - - - 3.9 
(1) 
- - - 
Simvastatin 20mg  - - - - 3.9 
(1) 
- - - 
Valsartan 80mg - - - - 3.9 
(1) 
- - - 














Glimeperide 1mg  - - - - - 3.9 
(1) 
- - 





Glimeperide 4mg - - - - - 11.5 
(3) 
- - 







































Other NCD medicines 










































































































































Mean 49.0  58.6  64.7  74.6  
Notes: *Tablets or capsules unless otherwise noted; Bisoprolol 2.5mg Tab/Cap, 
Simvastatin 40mg Tab/Cap Valsartan 160mg Tab/Cap were not available in any facility.  











Annex 2.5: Availability of STG medicines (proportion of facilities having medicine 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Annex 2.6a: Prices of study medicines (in Kenyan Shillings per tablet/capsule, or per 
syrup/suspension or per vial) by provider type (where price is greater than zero) 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Note: Bisoprolol 2.5mg, Simvastatin 40mg, and Valsartan 160mg   Tab/Cap were not 






Annex 2.6b: Prices of study medicines (in Kenyan Shillings per tablet/capsule, or per 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Note: Bisoprolol 2.5mg , Simvastatin 40mg, and Valsartan 160mg Tab/Cap were not 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CHAPTER THREE - COLLECTING HEALTH FACILITY AND PATIENT 
MEDICINE INFORMATION THROUGH TELEPHONE INTERVIEWS IN 
KENYA: A VALIDATION STUDY 
 
EXECUTIVE SUMMARY 
Background: High cell phone ownership in low- and middle-income countries 
presents an opportunity for efficient data collection through telephone interviews both for 
surveys and regular surveillance. This study explores the feasibility of collecting 
information on health facility and patient medicines through telephone interviews. The 
specific aims of this study were: 
i) to validate a method for the collection of information on health facility and patient 
medicines through phone interviews;  
ii) to compare the costs associated collecting data on medicines through phone 
interviews and in-person interviews; 
iii) to describe perceptions of data collectors and respondents on each mode of data 
collection. 
Methods: Data on the availability and prices of medicines at 137 health facilities 
and 639 patients with non-communicable diseases were collected in September 2016 via 
in-person interviews during which respondent’s telephone numbers were also collected. 
Medicine price and availability data was collected monthly through structured telephone 
interviews with 122 health facilities and 130 patients between December 2016 and 
December 2017. An unannounced in-person interview was conducted with respondents to 




data was analyzed using SAS version 9.4 (The SAS Institute Inc.). 
A bottom up itemization costing approach was used to estimate costs of both 
telephone and in-person data collection from the perspective of researchers. Cost data 
was analyzed in Microsoft Excel, 2016.  
In-depth interviews were conducted with data collectors and a 15% subsample of 
telephone surveillance respondents to explore their perceptions on data collection through 
telephone and in-person interviews. Qualitative data were analyzed thematically using 
NVivo 11 QSR. 
Findings: The mean response rate for telephone interviews with health facilities 
was 88.2%. For households the mean response rate was 94.5%. Telephone interviews 
with facilities and households took 30.3 minutes and 12.8 minutes, respectively, 
compared to 14.1 minutes and 8.5 minutes for in-person interviews, respectively. 
Medicines availability data showed a statistically significant agreement between data 
collected through telephone and in-person interviews at health facilities (kappa=0.9019; 
CI 0.8848 - 0.9189) and households (kappa=0.4931, CI: 0.3877 - 0.5984). The correlation 
of price of medicines from telephone and in-person interviews was statistically 
significant at health facilities (r=0.9; p<0.0001) and households (r=0.52, p<0.0001). The 
cost per phone interview at health facilities and households were $19.73 and $16.86 
respectively, compared to $186.20 for baseline in-person interview. Participants 
identified the ability to physically confirm responses for in-person data collection to be 
an advantage and poor road networks and the high level of effort involved in travel as 




cost and time. 
Discussion and conclusion: This study demonstrated high response rates and 
high validity for telephone data collection. In countries with high cell phone penetration 
the many advantages of telephone data collection should be considered in designing 








High mobile phone ownership in low- and middle-income countries (LMICs) presents 
an opportunity for efficient data collection through phone interviews both for one-off 
surveys and continuous surveillance. In high-income countries, this mode of data 
collection has been used for a diverse set of purposes, including monitoring illicit drug 
use and consumer market research (1–4). However, there is limited evidence validating 
phone interviews for data collection in LMICs. This study aims to examine the feasibility 
of collecting data on medicine availability and price through phone surveys in rural 
communities Kenya. The objectives of this study were:  
iv) to validate a method for the collection of information on health facility and patient 
medicines through phone interviews;  
v) to compare the costs associated collecting data on medicines through phone 
interviews and in-person interviews; 
vi) to describe perceptions of data collectors and respondents on each mode of data 
collection. 
This study was conducted as part of an evaluation of Novartis Access, a program 
that aims to improve access to medicine for non-communicable diseases in Kenya (5).  
2. BACKGROUND 
2.1 Mobile phone subscription rates in low- and middle-income countries  
In-person interviews have been the primary method of data collection in global 
health research, particularly in LMICs (6,7). However, in high-income countries, phone 




interviewing holds great potential for global health research because it is less expensive, 
less time consuming, and offers flexibility for larger sample size studies (8). The 
dramatic increase in mobile phone ownership in LMICs in recent years has made mobile 
phone surveys much more attractive in these countries (8).  
Figure 3.1: Number of mobile and fixed phone subscriptions per 100 people in low- 
(LIC), lower middle - (LMIC) and high - (HIC) income countries (graph for fixed phones 
in broken lines)  
 
(Data from World Development Indicators database)  
In 2016, there were 96 mobile phone subscriptions per 100 people in LMICs, 
which is close to the worldwide subscription rate of 100.7 per 100 people (9,10). In the 
same year, the subscription of fixed phones stood at 13.5 per 100 worldwide and 8.3 in 
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people in low-, lower middle-, middle-, and high-income countries. Generally, ownership 
of both mobile and fixed phones increases with wealth. However, fixed phone ownership 
decreased from 2006 to 2016 while mobile phone ownership increased over the same 
period across all income groups. With the exception of low income countries which have 
mobile phone subscription rate of about 60 per 100 in 2016, the subscription rate is above 
85% in lower middle, middle-, and high-income countries. 
A household in Kenya owns about 2.4 mobile phones with 80% of individuals 
having their own phone (11). The gap between rich and poor countries in mobile phone 
subscription rates has been narrowing over the past decade. The increased subscription of 
mobile phones in LMICs presents opportunities for phone data collection (12).  
2.2 Mobile phone surveys in low- and middle-income countries  
There is an abundance of literature supporting the use of phone interviews for 
data collection in high income countries (8). However, despite high mobile phone 
ownership in LMICs there has been limited use of phones for surveys and continuous 
surveillance in these settings. A systemic review conducted by Gibson et al. on the use of 
mobile phone surveys (MPS) for collecting population level data in LMICs found only 19 
surveys, 8 each in Latin America and sub-Saharan Africa, 2 in Asia, and 1 in the Middle 
East (13). These countries, which need quality data at low cost, often have less safe 
environments, and limited infrastructure (road network) needed for in-person interviews 
(8,14,15). The following sections discuss the types of phone technology that have been 




2.2.1 Technological choices for data collection via phones  
A variety of technologies may be used to collect data through phone interviews. 
Short messaging services (SMS) technology enables mobile phone to mobile phone 
communication using short messages (maximum of 160 characters) (7). Interactive voice 
response (IVR) is another technology in which a programmed computer application sends 
an audio message to phone lines. Additionally, there is a human operator or computer-
assisted phone interview (CATI) in which respondents are interviewed by a person using 
a phone and the interviewers utilize a software program to record the survey responses 
(13).  
Table 3.1 Advantages and disadvantages of short messaging services (SMS) and phone 
calls 
SMS Voice phone calls  
Advantages  
- May be associated with low cost  
- Could be used in combination with 
phone calls  
Advantages  
- Allows for gathering more 
information  
- Requires less effort to give out 
information 
- Creates a reciprocal relationship 
as data collectors and 
respondents talk to each other   
- Noted for higher response rates  
Disadvantages  
- More skills are required to send or 
receive text messages  
- Not suitable for illiterate recipients  
- Can collect only limited information  
- Data collectors do not know if 
recipients open their text messages  
- Usually a one way communication 
Disadvantages  







Unstructured supplementary services data (USSD) involves transmitting questions 
directly from the server of a telecommunication company to the phone of the respondent. 
There are also web-based mobile phone survey (WAP) technologies that are suitable for 
phones with internet capability (6). 
Two of these technologies have been used more frequently in LMICs - SMS and 
voice phone calls (mainly CATI) (13,16). Table 3.1 shows the advantages and 
disadvantages associated with SMS and phone calls. Compared to phone calls, SMS may 
be more cost effective, but have several limitations including the skills involved in 
sending/reading text messages, the amount of data that can be collected etc. (16). Phone 
calls allow for gathering more data, require less skill etc. Despite its limitations, SMS 
technology has been more frequently used than phone calls to collect data in several 
projects in African countries (7,16–19). In some cases, SMS and phone calls were used 
together. For example, SMS was used to remind respondents of their upcoming phone 
call, or provide feedback or airtime credits to respondents after a phone interview (6).   
The choice of phone technology depends on the type of study, including the 
nature of the questions, the amount of data to be provided, respondents and cost (6,7). For 
example, phone interviews may be the best option for studies requiring long responses to 
many questions; and studies involving older and less educated respondents who may have 
difficulty working with phones. SMS or IVR technologies may be more cost-effective for 
studies with limited number of questions and short responses. An important advantage of 
CATI is that since data are entered directly into a computer, tablet or phone, it allows for 




As part of the Listening to Africa project, the World Bank compared IVR, USSD, 
WAP and voice phone call (call center) technologies for collecting data on a wide range 
of topics including education, electricity, health, nutrition, security, water etc. in 
Tanzania (6). After the first seven rounds of data collection, the investigators decided to 
continue the survey using voice phone calls for all the respondents due to challenges with 
the other three technologies. Only a small proportion of respondents had owned internet 
enabled phones, limiting the use of WAP. USSD was ineffective due to limited support 
from the phone company and IVR was ineffective because the questions had too many 
response options (6).  
Another project by the World Bank, Listening to Latin America and the 
Caribbean (L2L) used SMS, IVR and CATI technologies for phone data collection in 
Peru, where households were randomly assigned to one of the three technologies and in 
Honduras where respondents were exposed to all three (7). Attrition rates were lowest for 
CATI technology in both countries but more pronounced in the case of Honduras. SMS 
responses were also found to be statistically different from in-person interview results, as 
were IVR responses. However, the responses from CATI technology were similar to 
responses from in-person interviews. In terms of reliability, IVR responses were most 
reliable upon repeated measurements, compared to SMS and CATI, though these two 
technologies also showed satisfactory reliability. With the exception of validity for CATI, 
both validity and reliability of these technologies vary by domain of question. For 
example, self-perception of poverty as reported by SMS was higher than was reported in-




(7). This shows that different technologies may be suitable for different types of data.       
While the above MPS were population based, there were other phone surveys that focus 
on specific groups of people e.g. farmers, refugees, internally displaced people (15,16).  
Various studies conducted in low- and middle-income countries used mobile 
phone technology for health purposes (mHealth). The term mHealth refers to the use of 
mobile phone technology to improve health outcomes for example through diagnosis, 
treatment and data collection (12) which will not be discussed in this chapter.  
2.2.2 Various approaches to remote phone interviews 
In addition to the choice of technology, many other factors need to be considered in 
setting up remote phone interviews. This section focusses on some of the key 
considerations, including distribution of phones, sampling, compensation, timing and 
frequency of data collection, supervision, and conducting validation visits.   
Distribution of phones: Various approaches have been used to ensure study 
participants have access to phones. In some studies, the investigators gave out mobile 
phones to all participants for free while others gave phones to only participants who did 
not own mobile phones (7,14–16). Some studies recruited only participants with mobile 
phones, however, this approach may lead to selection bias (6). The drivers behind these 
different approaches included the need to motivate study participants to provide data, 
providing fair compensation to all participants, cell phone penetration rate among the 
study population, budget constraints etc. For example, in order to allow for cheaper 
within network calls, the Listen to Africa study in Tanzania distributed multiple phones 




necessary to conduct follow up visits to change batteries, ensure all phones are working 
properly, and obtain feedback from respondents (11). Measures also need to be 
implemented to prevent moral hazard. For example, the loss or sale of phones by some 
respondents have been reported (11).  
Sampling: A representative mobile phone panel survey can be set up in two ways. 
Representative samples can be created exclusively by relying on MPS – calling potential 
respondents to access their inclusion criteria and interest to participant in the study (6,20). 
However, this method requires high rates of mobile phone ownership and also the 
availability of an unbiased source of phone numbers. The second approach involves 
conducting in-person baseline data collection during which phone numbers of 
respondents can be collected for follow-up data collection (6,7).   
Compensation: One method frequently used to increase response rates (the 
percentage of participants who complete a survey) was to compensate respondents for 
their participation (6). However, there is mixed evidence on the impact of incentives on 
response rates. In a study named the South Sudan Experimental Phone Survey, data were 
collected on living conditions, access to services, and citizen attitudes through monthly 
phone calls (14). The investigators randomly assigned enumeration areas to two 
incentives, a pre-paid credit of US$2.17 or $4.45 for each completed survey (14). 
Enumeration areas were also randomly assigned to receive either a basic “Nokia” phone 
or a Safaricom solar-rechargeable phone. Additionally, all respondents were informed 
they will be eligible to win a lottery of $100 each month after completing the survey.  




substantial geographical variations. Among respondents given “Nokia” phones, those 
offered $4.45 as incentives were 10% less likely to complete the survey compared to 
those given $2.17, indicating a negative association between incentives and response 
rates. However, there was no consistent pattern between the two categories of incentives 
among respondents using solar-rechargeable phones (14). A similar study in Tanzania did 
not show any impact of incentives on response rates (6). 
A study in Peru and Honduras also examined the impact of incentives on the 
attrition rate (defined as the proportion of participants who drop out of the survey 
completely) (6,7). Respondents were randomly assigned to receive 1 USD, 5 USD or no 
monetary incentive (in the form of airtime). In Peru, initial attrition rates were not 
substantially affected by the incentives. However, as the round of data collection 
progressed, attrition rates were lower among respondents with higher incentives. 
Receiving a free phone was a better incentive (in reducing attrition rates) compared to 
receiving free airtimes. In Honduras, attrition rates were lower among respondents who 
received higher incentives throughout all rounds of data collection. It is however, worth 
noting that respondents in Honduras had to answer three surveys per month, while those 
in Peru answered only one. In both countries, attrition rates were higher among the poor, 
elderly, the less educated population and among households in rural areas (7). In another 
study, respondents were given airtime of $0.76 for each completed survey, not only for 
compensation purposes but also to keep their SIM cards active (16).  
Timing, length and frequency of data collection: Survey timing (relative to 




phone data collection is planned to commence after baseline in-person interviews, 
respondents who were first to be interviewed during baseline may have to wait longer to 
start the phone interviews (16). Long time lapse between baseline and first round of 
phone data collection may result in loss of motivation, and respondents forgetting to 
prepare for the upcoming phone calls (16). To address this problem, phone surveys could 
start immediately after the baseline visit or a specific date could be planned where the 
first visited respondents could be called (16). The latter requires a lot of planning, enough 
supervisors and the ability to manage both baseline and phone data collection at the same 
time.  
Additionally the timing of airtime incentives is also important. Ideally, incentives 
should be sent to respondents when they are likely to have their phones on, i.e. 
immediately after the interview (16).   
Length of interviews can affect participation as shown in the L2L study in which 
there was a decline in response rates when more than 10 questions were added to the 
survey instrument (7). Longer interviews are not suitable for phone interviews. Several 
phone surveys conducted in sub-Saharan Africa took between 15 to 30 minutes (6,16,20). 
In most studies, respondents were called monthly (6,7,14,15). In other studies the phone 
interviews were more frequent (14,16). Mobile phone surveys may have an effect on 
respondents’ behavior. For example, calling patients to collect data on the availability of 
their medicines at home may remind them to purchase the medicines, an unintended 
consequence of the phone call. However, to the best of our knowledge, this unintended 




Validation visits: Validation visits may be conducted with a subset of phone 
interview respondents to validate data collected over the phone. In the L2L study, no 
statistically significant difference was found between in-person and phone call data. 
However, when SMS and IVR responses were compared to in-person responses, the 
differences observed were statistically significant (7). SMS and IVR responses indicated 
lower availability of household assets and infrastructure (e.g. sanitation facilities) 
compared to in-person interviews. However, self-perception of poverty and reported 
internet access were higher for SMS and IVR responses.   
2.3 Ethical considerations in conducting mobile phone surveys 
There are specific ethical issues that confront MPS. Dillon acknowledged the 
difficulty in protecting the confidentiality of respondents over the phone and 
recommended not using phone surveys for collecting sensitive information (16).  Ali et 
al. also discussed some the key ethical issues to consider when using MPS in LMICs 
(21). The authors called for the development of an ethics framework and guidelines the 
use of MPS for disease surveillance (21–23).  
  Some of the ethical issues discussed by the authors include: 
1. It is important for respondents to understand the purpose of the MPS. This is 
because most respondents are more familiar with the use of phone surveys for marketing 
and commercial purposes and not for research  
2. Though MPS can be implemented remotely, it is important for researchers to 




3. Understanding the local norms and practices associated with the use of mobile 
phones so as to align data collection approaches to local expectations 
4. Consideration of the type of technology used for survey delivery – SMS, IVR and 
CATI - and the consequences of each in terms of coverage, participation of minority and 
marginalized groups, likelihood of social desirability bias etc.  
5. Using appropriate language and terminology, and adequately explaining the study 
and obtaining the consent of respondents over the phone 
6. Building in adequate linguistic representation into MPS if delivered through 
random digit dialing or in environments where multiple languages exist.  
7. Timing of incentives: If incentives are offered after survey completion, 
respondents are more likely to complete survey, but they may also provide false 
responses. Some incentives may be provided to all respondents regardless of survey 
completion but there may be higher costs associated with this approach.   
8. What happens to the data after they have been collected in terms of ownership use 
and access?  E.g. the use of MPS data in the context of other existing data 
2.4 Comparing phone interviews with in-person interviews  
Though phone data collection had the potential to reduce social desirability bias 
that is common in in-person interviews, Ballivian et al. identified three main challenges 
associated with phone data collection compared to in-person interviews: obtaining 
samples that are representative of the study population, ensuring adequate response rates 
and collecting good quality data (7). This section will focus on the relevant 




2.4.1 Response rates and attrition   
Attrition rate is defined as the proportion of respondents who drop out of a survey 
completely, while response rate refers to the proportion of respondents who complete 
each survey (6). To the best of our knowledge there is no systematic review on studies 
that compare attrition rates and response rates for in-person and phone interviews. 
Similar to attrition rates for in-person interviews, attrition rates for phone interviews also 
vary widely. In a study by Aquilino et al., response rates for phone surveys were lower 
than response rates for in-person interviews (24). Nonetheless high response rates of 
above 90% have been reported for phone surveys, even in disaster settings (15,17,18).  
One cross sectional study used phone interviews with pharmacies and hospitals in 
Madagascar to collect data on the availability and prices of anti-epileptic medicines (25). 
A total of 91 out of the 104 targeted facilities were reached on the phone. Community 
support activities and the engagement of village elders have been used to increase 
response rates for phone interviews (16). Collecting multiple contact numbers of 
respondents have also been used as a strategy to improve response rates (14).  
A health and nutritional in-person survey among pregnant women in the 
Philippines had an attrition rate of 66% after 16 months of data collection (26). Another 
example of high attrition rate in in-person interview was the Kenya Ideational Change 
Survey on the roles of informal networks in contraceptive use which had an attrition rate 
of 28% for women and 41% for couples (27). Other in-person surveys in Kenya and 
Indonesia reported attrition rates of less than 20% (6,28). Attrition rates of as low as 2% 




2.4.2 Data validity 
Several studies have compared the validity of data collected over the phone, 
though these studies were not on price and availability of medicines. Some of these 
studies used correlation between data collected in-person and those collected via phone 
interviews to assess consistency between the two modes of data collection (29–31). 
Others tested for the level of agreement between data collected from these two methods, 
using kappa, a statistic that measures inter-rater agreement while taking into account the 
possibility of the agreement occurring by chance (29,32,33). Sensitivity (proportion of 
patients diagnosed with an outcome in in-person interviews who were also diagnosed 
with the same outcome using phone interviews), and specificity (proportion of patients 
without a diagnosis in in-person interviews who are also found not to have the diagnosis 
in phone interviews), were also used to access the reliability of phone interviews 
(29,31,34).   
Szolnoki and Hoffmann compared the results of in-person, phone and online 
surveys in studying the behavioral characteristics of wine consumers (35). The results 
from phone surveys were found to be more representative of the study population than 
results from online surveys but less so compared to results from in-person interviews. In 
a study called SMS for life, Githinji et al. used SMS technology to collect weekly data on 
the availability of the anti-malarial drug, artemether-lumefantrine and rapid diagnostic 
tests at health facilities (17). The accuracy of stock counts was 79% and the accuracy of 
stock out reports was 93%. An earlier pilot study in rural Tanzania, which was a pre-




technology was also used for malaria surveillance in Kenya, where the accuracy of the 
surveillance data collected was 58% (19). The moderate to high validity of phone data in 
these studies illustrate the high potential for this mode of data collection.  
Selection bias may be associated with phone data collection because people who are less 
familiar with the phones will have more difficulty using it to provide data (21).  
Unreliable network coverage not only affects response rates, but may also 
introduce bias in the study (14–16,20). Network coverage is likely to be correlated with 
wealth, distance from major towns and access to other utilities like water supply (16). 
Dillon suggested using phone interviews only in the areas where there is network 
coverage (16). Another solution to limited network coverage will be to set up call stations 
in communities so that scheduled calls are made on days when respondents will be near 
the call station. However, this approach may exclude those who are not able to get to the 
call station (16). In areas with inconsistent power supply, the provision of solar chargers 
or charging stations have been used (14,16).   
2.4.3 Supervision  
Phone surveys make it more convenient to supervise the performance of data 
collectors e.g. by listening to the interview and checking the quality of data collected, 
tasks which are more logistically challenging in field surveys (16). This also means less 
supervisors are needed for phone surveys compared to field surveys (which usually 
requires one supervisor for every three to four data collectors) (16). When the data is 
entered directly into computers, the process of making sure the questionnaire is filled 




are concerns about losing data due to power outage or other technical glitches, there are 
many ways to back up data routinely or reenter data if the calls are recorded (16).   
In phone surveys, the respondent can be called back easily to clarify responses 
obtained. Questions can also be changed easily to improve data collection or respond to 
emerging issues (6). This makes phone interviews very useful in volatile situations, for 
example when Dar es Salaam was hit by floods in 2011, a question was added to an on-
going phone data collection which helped estimate the proportion of people who had 
been affected by the flood (6). Phone interviews were also used to monitor the impact of 
the 2014 political crisis on internally displaced people in Mali (15). 
Phone interviews also allow for respondents to be updated on the study. For 
example, in the Listen to Africa study an SMS was sent to respondents in Tanzanian 
when a newspaper article came out about the study (6). Social media or other media may 
be other innovative ways to provide information to respondents.  
2.4.4 Cost of data collection 
Table 3.2, below compares the costs per interview of in-person surveys with three 
different technologies for phone data collection CATI, IVR, and SMS associated in the 
L2L study (in Peru). These costs were calculated for a group of 1,500 respondents who 
took part in 12 monthly surveys (7). Generally, phone interviews cost less, with SMS 
technology costing the least. CATI was the most expensive among the phone data 
collection technologies. Other studies reported lower costs for phone interviews. The cost 
per phone interview for a study in Tanzania was between $4.10 and $7.30 (depending on 




and 12 rounds of data collection in this study. Another study among Tanzanian farmers 
reported a similar cost per phone interview, $6.98 (16). In a cross-sectional study 
conducted in Lebanon that employed both cell phone interviews and in-person interviews 
to assess healthy behavior, the cost per mobile phone interview was $22.2 while the cost 
per in-person interview was $35.96 (36). 
Table 3.2. Survey cost (in USD, 2012) by mode of data collection (1,500 respondent) 
Type of survey Cost per 
interview ($) 
Cost per year (12 
monthly surveys) ($) 
In-person  40 720,000 
Phone surveys:   
- Computer assisted phone interviews 25 450,000 
- Interactive voice response 17 306,000 
- Short messaging services 8 144,000 
Source: Ballivian A, Azevedo J, Durbin W, Rios J, Godoy J, Borisova C, Ntsama SM. 
Listening to LAC: Using Mobile Phones for High Frequency Data Collection.  
Washington DC: The World Bank; 2013 
 
There is thus consistent evidence suggesting phone interviews are cheaper 
compared to in-person interviews. The cost per in-person interview of $40 reported in the 
L2L study though higher than the cost per phone interview in the same study, is much 
lower than the cost per in-person interview estimated by Croke et al to be between $50 
and $150 USD (depending on how complex the survey is and the distance to be covered) 
(6).  
2.4.5 Language 
Phone interviews offer more flexibility in conducting interviews in multiple 




errors (16). Body language and facial expressions of respondents cannot be observed 
during phone interviews though these may be assessed through voice changes (16). 
2.5 Mobile phone surveys in Kenya 
In sub-Saharan Africa, Kenya is one of the leading countries with high mobile 
phone ownership (6). Results from a survey in 2009 showed that 85% of respondents had 
used a mobile phone, but only 44% owned their own phone (37). A cross sectional survey 
in 2012 showed 100% and 61.2% mobile phone ownership among 219 health worker 
interviewees, and 1,177 patients and their care givers respectively (38). According to the 
more nationally representative Afrobarometer Survey of 2011, each household owns 
about 2.4 mobile phones, with 80% of Kenyans having their own mobile phones (11). 
Though 7% of Kenyans reported never using a mobile phone, 81% said they make at 
least one call a day using their mobile phones. Phone ownership rates above 80% are 
acceptable for reliable surveys to be conducted over the phone (6). This suggests that 
mobile phone ownership in countries such as Kenya is high enough for reliable mobile 
phone surveys to be conducted.  
Despite the relatively high mobile phone ownership, mobile phone surveys have 
not been common in Kenya, though mHealth has been used as health care interventions 
and not as a survey tool (39–43). The high ownership of mobile phones have taken 
tapped into by the financial sector in Kenya with innovative tools as well (44–46). The 
SMS technology was also used for malaria surveillance in Kenya, where the response rate 
of 96% was achieved (19).  




availability and price not only in Kenya but in LMICs. If high response rates can be 
achieved and accurate price and availability data can be collected by phone, incorporating 
this into the evaluation of access to medicines programs in low- and middle-income 
countries will reduce the cost of data collection while maintaining the same data validity 
as in-person data collection. This will make evaluating access to medicine programs more 
attractive to industry and other stakeholders.  
3. METHODS 
3.1 Study sites 
The data presented in this report were collected as part of an ongoing evaluation 
of the impact of a low-cost medicines access program (instituted by Novartis/Sandoz 
Pharmaceuticals and called Novartis Access) on the availability and price of medicines 
for NCDs at health facilities and households in the Kenya. This evaluation, a cluster 
randomized controlled trial is taking place in eight counties - Embu, Kakamega, Kwale, 
Makueni, Narok, Nyeri, Samburu and West Pokot which have been randomized into four 
control and four intervention counties. The selection of these counties had been described 
by Rockers et al. (5).    
3.2 Data collection 
Evaluation of Novartis Access baseline data were collected through in-person surveys at 
health facilities (public, private not-for-profit, and private for profit) and a random 
sample of households with NCDs in October 2016 prior to the implementation of the 




collected and participants were informed they might be called on phone to collect the 
same data collected in-person. 
3.2.1 Validation  
The phone surveillance took place between December 2016 and December 2017. 
Thus the phone surveillance period falls between Novartis Access baseline data collection 
in September 2016 and endline data collection in February 2018. Data collectors were 
trained on key concepts on price and availability of medicines, ensuring data quality, 
ethics of data collection, phone etiquette, maintaining confidentiality of respondents, 
administering informed consent, collecting data using CATI, etc. Data was collected 
using the survey instruments programed on a tablet, with the software application Survey 
CTO (47) (Annex 3.1 and Annex 3.2). The study instruments were pilot tested by the 
trained data collectors and revised based on the feedback received from the pilot test. 
Household data collection: A random sample of 400 of the households that took 
part in baseline data collection (representing 62.6% of 639 household participants) were 
included in the telephone surveillance. Replacement samples were drawn for household 
respondents who dropped out of the survey. A rotating one-third sample of the 400 
households were surveyed by phone each month. Using a shortened version of the 
baseline evaluation of Novartis Access instruments (Annex 3.2), data was collected via 
phone, on the availability of the NCD (asthma, breast cancer, diabetes and cardiovascular 
disease) medicines prescribed for these patients, the price at which these medicines were 
purchased, and where they were purchased (public hospital, public health center/clinic, 




were given 50 KES (about $ 0.50) of airtime for each interview. 
Health facility data collection: Data were collected from all of the health facilities 
that took part in baseline data collection. All of the health facilities and were surveyed by 
phone each month. Data was collected monthly on 25 medicines (all medicines for NCDs 
with the exception of amoxicillin dispersible tablets). The remaining 22 medicines were 
divided into three groups (Annex 3.3), and data were also collected for medicines in each 
of these groups every three months. This was done to minimize the burden of data 
collection on health facilities. Health facilities were given 100 KES (about $1.00) in 
airtime per interview. 
For both health facility and household phone interviews, an unannounced in-
person interview was conducted with a 10% subsample of respondents to validate the 
phone interview within 24 hours of the phone-based interview. For ease of follow up, this 
10% sub-sample was randomly selected from two control and two intervention counties. 
The duration of all interviews (both phone and in-person) were automatically recorded on 
the study instrument on Survey CTO. Data on types of mobile phones owned by 
respondents were collected during endline in-person interviews.  
3.2.2 Costs of phone and in-person interviews 
A bottom up itemization costing approach was used to assess costs based on 
standard economic methods (48). Information on all the major cost components, 
including phone airtime, cost of transportation, and personnel costs etc. were collected by 
reviewing study records, standard operating procedures, financial reports and budgets. 




was done separately for health facility phone interviews, household phone interviews, 
validation visits, baseline in-person interviews, and listing of health facilities and 
households (which preceded baseline data collection). Baseline data collection costs 
could not be disaggregated into health facility and household costs since the same 
resources and personnel were dedicated to both. For the same reasons, listing costs and 
costs associated with validation visits could not be separated into household and health 
facility costs. Costs were estimated from the perspective of researchers (data collection).  
Costs were classified according to the following input categories: assessor staff 
salaries, respondent gifts, transportation, airtime, office space, equipment, software, field 
guide costs, accommodation for data collectors, training costs, and printing and supplies. 
Staff costs were estimated based on the level of effort (percentage of their overall 
working hours) staff spent on each mode data of collection. Onetime upfront equipment 
costs for telephone surveillance were divided by 36 months (assuming a hypothetical 
surveillance duration of three years) to get the cost per month. For phone surveillance, 
costs were stepped down for each month (health facilities) and 3-month cycle 
(households and validation visits). Administrative costs were estimated as 19% of all 
direct costs, and overhead costs were 15% of all direct costs (including administrative 
costs).  
3.2.3 Qualitative data collection 
The aim of the qualitative data collection was to understand the perceptions of 
both data collectors and study participants on data collection through telephone and in-




data collectors led by a researcher who had substantial experience in qualitative data 
collection and analysis. In-depth interviews (IDIs) were conducted with the following 
respondents using semi-structured interview guides:  
i. Household level study participants  
ii. Health facility participants 
iii. Data collectors involved in phone and in-person data collection. 
Only household and health facility study participants who have participated in 
both phone surveillance data collection and in-person validation visits were interviewed. 
These study participants were purposively selected to reflect the different situations and 
characteristics listed in Table 3.3. 
The data collection instruments (Annex 3.4 and 3.5) was developed by a 
researcher who has experience designing and conducting qualitative studies on access to 
medicines. The instruments covered the experience of respondents collecting or 
providing data via phone or in-person interviews, the facilitators and challenges 
associated with both modes of data collection, and the preference of the respondents for 
one mode of data collection over the other.  
Table 3.3: Characteristics for recruiting participants for qualitative interviews 
Household level  Health facility level  Data collectors  
- Age (different age groups) 
- Gender (both men and 
women) 
- Disease (all 4 NCDs of 
focus) 
- Number of medicines 
prescribed (1 to several 
medicines) 
- Age (different age groups) 
- Gender (both men and 
women) 
- Type of facility (public, 
private non-profit, faith 
based) 
- Level of care (level II, III 
and IV) 






After administering informed consent, data collectors were first interviewed about 
their experience and perception about in-person and phone data collection. After a 
follow-up in-person data collection to audit data collected via a phone interview, the 
consent of the household and health facility study participants to take part in this 
qualitative data collection was sought. With the consent of the study participants, the 
interviews were audio recorded. Each interview lasted for about 30 to 45 minutes. The 
interviews with data collectors and facility level study participants were conducted in 
English, while interviews with household participants were conducted in local languages.  
3.3 Data analysis 
3.3.1 Validation 
Data were analyzed using SAS version 9.4 (The SAS Institute Inc.) (49). The 
correlation between price data collected through phone interviews and in-person was 
assessed using the Spearman’s Correlation Coefficient. The level of agreement between 
medicine availability as assessed through phone interviews and in-person interviews was 
compared using the kappa statistic. Since phone monitoring might affect is availability of 
medicines especially in households, baseline and midline Novartis Access evaluation data 
on availability of medicines were compared between the households monitored by phone 
and those not monitored to determine the possible effect on the phone monitoring on 
household behavior. Logistic regression was used to determine the effect of phone 
monitoring on the availability of medicines. The mean durations of telephone interviews 




3.3.3 Cost analysis 
Microsoft Excel 2016 was used to compute cost estimates. A full cost analysis 
was conducted. The cost per interview was estimated for health facility phone interviews, 
household phone interviews, validation in-person interviews (aggregate for both facility 
and household) and baseline in-person data collection (aggregate for both facility and 
households). The total cost of listing for facilities and households was also estimated.    
3.3.2 Qualitative data analysis 
Qualitative data obtained was translated to English when necessary and 
transcribed. Data was analyzed thematically using NVivo 11 QSR, assigning codes based 
in themes and categories of data observed. A coding tree was developed a priori and a 
posteriori. The main codes for the data analysis included the following: 
- Perceptions on providing or obtaining accurate and complete data over the phone 
(compared with in-person interviews) 
- Facilitating factors for collecting or providing data over the phone and in-person 
- Challenges of collecting or providing data over the phone and in-person 
- Preferences and satisfaction of data collectors and respondents with one data 
collection method over the other. 





4. RESULTS  
4.1 Background characteristics of study participants  
A total of 421 household respondents and 138 health facilities participated in the 
phone surveillance. There were more female household participants than males (68.8 vs 
31.2%) and less than 6% had at least a college level education. Validation visits were 
made to 105 households and 65 facilities. Tables 3.4 and 3.5 below show the 
demographic characteristics of respondents.  
The mean age of all household study participants was 58.1 years with a range of 
18 to 101. The majority (60.5%) of health facilities were level 2 facilities (dispensaries). 
At least 15 health facilities participated from each county with the exception of Kwale, 





Table 3.4: Background characteristics of household study participants 





Age in years: N = 410 N = 105 
      -   Mean (range) 58.1 (18 – 101) 61.9 (30 - 94)  
County: % (n) N=421 N=105 
- Embu 15.9 (67) 23.8 (25) 
- Kakamega 15.0 (63) 21.0 (22) 
- Kwale 16.9 (71) - 
- Makueni 15.4 (65) 28.6 (30) 
- Narok 10.0 (42) - 
- Nyeri 16.4 (69) 26.7 (28) 
- Samburu 4.5 (19) - 
- West Pokot 5.9 (25) - 
Education level: % (n) N=410 N=105 
- Preschool (less than 1 year completed)/None 26.8 (110) 19.1 (20) 
- Primary School (not completed) 25.6 (105) 25.7 (27) 
- Primary school 21.5 (88) 30.5 (32) 
- Secondary school 19.5 (80) 20.0 (21) 
- Higher than secondary school 5.6 (23) 3.8 (4) 
- Vocational School (Post primary) 1.0 (4) 1.0 (1) 
Gender: % (n) N= 410 N=105 
- Male  31.2 (128) 26.7 (28) 
- Female  68.8 (282) 73.3 (77) 
Wealth quintile: % (n) N=410 N=105 
- Quintile 1 18.5 (76) 8.6 (9) 
- Quintile 2 22.9 (94) 21.9 (23) 
- Quintile 3 21.5 (88) 22.9 (24) 
- Quintile 4 16.3 (67) 19.1 (20) 





Table 3.5: Types of health facility participants 
 Health facility respondents %(n) 
 Phone 
interviews 
Both phone interviews 
and in-person validation 
visits 
Level of care  N=124 (N=62) 
- Level 2 (Dispensaries) 60.5 (75) 56.5 (35) 
- Level 3 (Health centers) 16.1 (20) 17.7 (11) 
- Level 4 (County referral hospitals) 19.4 (24) 21.0 (13) 
- Level 5 (Teaching and referral 
hospitals) 
4.0 (5) 4.8 (3) 
Provider type  N=130 (N=65) 
- Public  43.1 (56) 43.1 (28) 
- Private non-profit  56.9 (74) 56.9 (37) 
County  N=130) (N=65) 
- Embu 17.7 (23) 21.5 (14) 
- Kakamega 11.5 (15) 21.5 (14) 
- Kwale 6.2 (8) - 
- Makueni 18.5 (24) 27.7 (18) 
- Narok 11.5 (15) - 
- Nyeri 22.3 (29) 29.2 (19) 
- Samburu 4.6 (6) - 
- West Pokot 7.7 (10) - 
 
Based on endline in-person interview data, all study participants had access to 
phones. Figure 3.2 presents phone ownership by wealth quintile in the entire study 
cohort. While most of the participants in the different wealth categories owned non-smart 
phones, smart phone ownership increases with increasing wealth. The majority of 
participants reported using mobile phones to receive or send text messages, a behavior 




had smart phones, 14.8% (19/128) had non-smart phones while 3% (4/128) had both.  
Figure 3.2: Phone ownership among the Novartis Access study cohort 
  
4.2 Validity of telephone interview results  
A total of 122 health facilities and 122 patients participated in both phone 
interviews and validation visits between December 2016 and December 2017. The mean 
response rate for phone interviews with health facilities was 88.2%. For households the 
mean response rate was 94.5%. Figure 3.3 shows the response rates achieved over time. 
Phone interviews with facilities and households took 30.9 minutes and 12.8 minutes, 
respectively, compared to 14.9 minutes and 8.3 minutes for in-person interviews, 
respectively. For both modes of data collection at the facility and household levels, no 











































Figure 3.3 – Response rates for phone interviews by month of data collection 
  
Table 3.6 presents the response rates by county. Though response rates were 
generally high across all counties, Samburu county had the lowest response rates for both 
household and health facility interviews (85.9% and 77.8% respectively).  


















































Household 98.9 94.5 93.7 98.5 87.2 96.0 85.9 89.8 





Medicines availability data showed a statistically significant agreement between 
data collected through phone and in-person interviews at health facilities (kappa=0.9019; 
CI 0.8848 – 0.9189), and households (kappa=0.4931, CI: 0.3877 – 0.5984). The 
correlation of price of medicines from phone and in-person interviews was also positive 
and statistically significant at health facilities (r=0.9; p<0.0001) and households (r=0.52, 
p<0.0001). Table 3.7 summarizes the key findings on the validity of phone interviews.  
At the household level, phone data on quantity of medicines purchased, and 
strength of medicine were statistically correlated with in-person data on the same 
variables. The correlation co-efficient (r) values of 0.52 and 0.75 indicate a moderate 
level of correlation. Similarly, there was a statistically significant, moderate level of 
agreement on the data on place of purchase collected from phone and in-person 
interviews. At the facility level, there was a strong statistically significant agreement 
between phone and in-person data collected on whether the recommended pack size of a 
medicine was available or not (Kappa=0.8878). Phone data on the actual pack sizes 
available in health facilities showed a moderate and statistically significant correlation 
with data collected in-person (r=0.55). Scatter plots for in-person and telephone data 









  Table 3.7 – Key findings on validity of phone interviews 
N/A = not applicable 
 
          
 






Number of interviews (N) 130 130 123 123 




Mean interview duration in minutes 12.8 8.3 30.9 14.9 
Level of agreement between 
availability reported over the phone and 
in-person 
kappa=0.4931,  
CI: 0.3877 - 0.5984 
kappa=0.9019,  
CI 0.8848 - 0.9189)  
Correlation between price data reported 
over the phone and in-person 
r=0.52, p<0.0001 r=0.9, p<0.0001 
Correlation between quantity of 
medicines purchased reported over the 
phone and in-person 
r=0.52,  p=0.0001 N/A 
Correlation between strength of 
medicines reported over the phone or 
in-person 
r=0.75,  p=0.0001 N/A 
Level of agreement between place of 
purchase reported over the phone and 
in-person 
Kappa=0.5276,  CI 
(0.4332 - 0.6220) 
N/A 
Level of agreement between the 
availability of recommended pack sizes 
of medicines in facility (Yes/No) 
N/A Kappa=0.8878, (CI 
0.8500 - 0.9257) 
Correlation between the pack size of 
medicines available in facility 




4.2.1 Impact of phone surveillance on behavior 
A logistic regression analysis showed no impact of phone surveillance on the 
probability of having at least one medicine at home. p=0.751 (Table 3.8). 
Table 3.8 – Impact of phone surveillance on availability of medicines in households 




OR (95% CI) 
Adjusted 
p value 
Probability of having at 
least 1 medicine at home 
(at midline) 
162 (81%) 296 (79.8%) 
0.9258 
(0.5744 – 1.4919) 
0.751 
N 200 371   
 
 Annexes 3.9 and 3.10 show that the time series phone surveillance data on 
availability tracks baseline and midline data at facility and household levels respectively.  
4.3 Costing of survey modalities  
Table 3.9, displays the costs associated with each mode and type of data 
collection. The cost per phone interview at health facilities and households were $19.73 
and $16.86 respectively, which is much lower than the cost per in-person interview at 








Table 3.9: Comparing costs of phone interviews with in-person interviews 
Costs (per month for 
health facilities and per 

























































































Assessor staff salaries $580  $1,740  $580  $23,065  $3,091  
Management staff 
salaries 
$850  $2,550    $59,250  $11,307  
Respondent gifts  $276  $215  $30  $2,169  - 
Transportation - - $200  $10,471  $655  
Airtime $57  $156  $12  $1,825  $40  
Other costs            
   Occupancy (Desk 
space) 
$160  $480    $350  $2,650  
   Equipment 
(computers, phones for 
managers, tablets, bags, 
notebooks, rain gear,) 
$63 $55.24 $4.62 $18,300    
Software (computer-
assisted software): $4  $11    $238    
Field guides    $90    $3,062    
Accommodation (in-
person data collection) 
    $160  $19,441    
Training location cost         $688  
Printing costs      $35.00         $614.00  $341  
Cost of all the supplies 
and equipment’s before 
project begun:  
        $16,431  
Total direct costs $1,989  $5,297  $1,022  $138,785  $35,203  
Administrative costs - 
assume 19% of all other 
direct costs 
$377.95  $1,006.50  $194.11  $26,369.15  $6,688.57  
Total direct + 
administrative costs 
$2,367.15 $6,303.86  $1,215.73  $165,154.15  $41,891.57  
OH – 15% of direct 
including administrative 
costs 
$355.07  $945.58  $182.36  $24,773.12  $6,283.74  
Grand total  $2,772.22  $7,249.44  $1,398.09  $189,927.27  $48,175.31  
Interviews           
Number of interviews 
conducted (per month 
for facilities and per 3 
months for households) 




Costs (per month for 
health facilities and per 

























































































Cost per interview 
(Total cost/# 
interviews) 
$19.73  $16.86  $38.84  $186.20    
Total number of 


















4.4 Qualitative results 
A total of 24 IDIs were conducted. This included IDIs with six data collectors, 
and nine each of health facility and household study participants.  
4.4.1 Facilitators of in-person and phone data collection 
Several of the facilitators of in-person and phone data collection reported by 
respondents were similar (Table 3.10). Village elders played multiple roles to facilitate 
both in-person and phone interviews. During in-person interviews, many field workers 
mentioned that village elders helped locate households of patients and offered places for 
data collectors to stay. Village elders sometimes also reportedly helped in building 
rapport with respondents and served as interpreters in both in-person and phone 
interviews. 
“Most of the time I use the village elder to go to this  particular respondent's home to 
explain to them why I want to talk to them, because sometimes for these people that do 
not understand Swahili very well and there are so used to talk in a another tongue. The 
moment I greet them in Swahili they will tell me wrong number. When for real it's not a 
wrong number, but because I saluted them in a language that they are not used to. So [if] 




will now tell the guide [village elder] to go to this respondent's home and talk to the 
respondent and explain why I was calling.” (Participant FO01 – Data Collector) 
Household respondents also mentioned familiarity with the Novartis Access 
Evaluation, and speaking same language as data collectors as facilitators. Other 
facilitators included trust, good relationships between data collectors and respondents, 
having reliable and multiple contact information of respondents, familiarity with the 
medicines terminology and the free airtime given to respondents after each interview.  
While data collectors thought it was not necessary to inform respondents before visiting 
in order to follow the study protocol, health facility staff especially felt informing them 
ahead of the visit or interview would have facilitated the interview process, as shown in 
the quotes below: 
 “The protocol, we had to visit, you know you make the call and then you visit the 
household, so the idea was, don't inform them that you are coming. So we had some 
people complain that how do you, I just give information, and if you are here, why didn't 
you just come. So we had that, actually it was common…” (IDI FO05, Data Collector) 
 
Generally, IDIs perceive both in-person and phone data collection can be 
enhanced by scheduling appointments with respondents beforehand.  
Some of the facilitators discussed what was unique to in-person interviews. 
According to IDIs, it was easier to ask questions and seek clarifications during in-person 
interviews. The data collectors mentioned that they were able to visually confirm the 
medicines at the household or facility level and the ability to look at the medical cards of 
patients when available for missing data. Another facilitator specific to in-person 





Table 3.10: Perceived facilitators and challenges to in-person and phone data collection 
 




 Village elders helped data 
collectors locate households of 
patients, and also serve as 
interpreters 
 FOs and respondents speak the 
same language  
 Having multiple contact 
information of respondents  
 Familiarity with medicine 
terminologies  
 Scheduling appointments with 
respondents in advance  
 
 Language barrier  
 Busy schedule of respondents 
(especially health facilities ) 
 Respondents having limited or no 
understanding of the purpose of 
the study 
 Respondents feeling they were 
giving too much information 
 Some variables were particularly 
challenging to collect data on: 
price, strength of medicine, place 
of purchase, pack size of 
medicine, name of medicine, and 
differentiating between generic 
and originator brands 
In-person 
interviews only 
 Ability to see the person you are 
talking to made asking 
questions and the general 
conversation easier 
 Ability of FOs to visually 
confirm the medicine and the 
data collected  
 Correctly planning field visits 
 Patients having medical cards 
with information of their disease 
conditions on it 
 Poor road networks  
 Bad weather 
 Time constraints  
 Relocation of study participants 




 Sending a list of medicines to 
respondents by SMS/WhatsApp 
so they can get the needed 
information ready before the 
call – helps navigate bad 
network  
 Familiarity with data collection 
over the phone 
 Relatively low cost 
 Less time consuming  
 
 Poor phone network 
 Inaccurate phone numbers or 
respondents changing their phone 
numbers 
 Limited power supply resulting in 
respondents not having their 
phones charged in order to receive 
a call  
 Hard to tell if respondents are 
giving accurate data 
 Data collector and respondent not 
having an in-person interaction 
 Different data collectors calling 





In-depth interview participants discussed aspects that were unique to phone data 
collection. To overcome the challenge of poor phone network, data collectors and their 
respondents used additional means of communication.  For example, facilities are sent a 
list of medicines (by email, SMS, or WhatsApp) and they fill in the requested information 
then send it back once they regain connection. IDIs also noted the flexibility of 
scheduling phone interviews, experience conducting phone surveys, the relatively low 
cost and the less time-consuming nature of phone interviews as advantages.  
4.4.2 Challenges associated with data collection via in-person and phone interviews 
While most of the health facility and household IDIs mentioned that they did not 
encounter any challenges providing data through in-person interviews or phone 
interviews others together with data collectors discussed some challenges. These are 
summarized in Table 3.8. As was in the case of facilitators, several of these challenges 
are similar for both modes of data collection while a few were specific to each. Data 
collectors frequently mentioned language barrier as a challenge. In cases where the 
interviewer and the respondent were not able to communicate in the same language the 
services of an interpreter were sought. Data collectors and health facility and household 
IDIs reported the busy schedule of respondents, particularly those in health facilities 
makes it hard for them to make time for the interview. Other challenges shared by all 
three categories of IDIs were limited understanding of the study by household and facility 
respondents, fear of respondents that the data collected may be used for other purposes 
unknown to them, and trying to paint the picture of poor availability thinking there is a 




“So there is that some somehow some fear, some lack of trust because now I am giving 
the prices of how much we sell, how much we buy, the name of the drugs we have, you 
see when you are giving such information, you might think may be thieves can know I 
stock these palliative drugs … so somehow there is that mistrust as you give the 
information.” (IDI HFM04, health facility on phone interviews) 
Many respondents said they do not have any challenges providing or collecting 
data on specific variables during in-person and phone interviews. The reported 
challenging variables discussed by others are similar for both in-person and phone modes 
of data collection.  These included: price, strength of medicine, place of purchase, pack 
size of medicine, name of medicine, and differentiating between generic and originator 
brands. The reasons for the difficulty collecting or providing data on these variables vary. 
For example, one data collector mentioned that some health workers, especially at 
dispensaries (level 2 facilities) did not have adequate knowledge on the difference 
between generics and originator products, which made it a challenging variable to collect 
data on. At the household level, the medicines dispensed to patients were repackaged, 
usually in brown paper envelops that are not appropriately labelled, making it difficult to 
determine the name and other parameters of the medicine.  Other reasons for the 
difficulty in collecting or providing data on these variables include inability of 
respondents to read the information available on medicine packages, recall difficulties 
(especially regarding price of medicines (where household respondents could not 
remember how much they bought their NCD medicine because they bought it together 
with other medicines), and patients not buying the medicines themselves to know the 
price. One data collector gave an example of how they were able to derive information on 




“And for the total supply, sometimes you actually have to use the dosage, so [you ask] 
how many do you take in a day. So that you know how many they mean by “I was given 
medicines for a month” (IDI FO01, data collector on phone interviews) 
Data collectors discussed several challenges which they uniquely associated with 
in-person data collection. These included poor road networks, bad weather, time 
constraints and relocation of study participants. The challenges uniquely associated with 
phone interviews included poor or inconsistent telephone network in some areas, not 
having the correct phone number (or respondents frequently changing their phone 
numbers), limited access to electricity (which made it difficult for some respondents to 
keep their phones charged in order to receive calls), difficulty in knowing if the 
respondent in a phone interview was giving accurate information or not, and being called 
by different data collectors.  
 “The other challenge with the phones interviews, it's very difficult to figure out if 
someone is telling you the truth, especially if you need them to observe something and tell 
it. And like when you are there face to face you can see them observing, it’s probably 
that. There is no way to be sure, unless it's video call.” (IDI FO04, data collector on 
phone interviews) 
 
“Because the phone can give you false information. I can tell you I have drugs and I 
don’t have the drugs, but if you come you check if it is there.” (IDI HHM06, household 
on phone interviews) 
 
In one extreme example, a health worker was transferred from one facility to 
another but kept participating in the telephone interview – giving false information until 
this was discovered during a validation visit.  
A health facility IDI reported rushing through phone interviews to save airtime 
(for data collectors) while another indicated how providers are perceived to be rude when 




 “Face to face you can create time even when busy and talk to the interviewer without the 
patient thinking you are not serving them like it is the case with phone interview. If you 
pick a phone call when patients are waiting they might think you are talking to friends or 
relatives and not serving them.” (IDI HFM07, health facility on phone interviews) 
4.4.3 Key differences in collecting data from health facilities and households 
For both in-person and phone interviews, data collectors were asked if they have 
experienced any differences collecting data from households and health facilities. The 
differences reported were mostly similar for both modes of data collection. The major 
difference mentioned was that the health workers were professionals who are well 
educated while household respondents were not always educated. For this reason, 
household respondents had more problems with language barrier and more difficulty 
understanding the study and medical terminology, while health facility staff more easily 
understood the purpose of the phone surveillance due to their medical background. 
Household respondents were reported to be very welcoming to data collectors. 
However, data collectors spent more time at health facilities during data collection. One 
data collector noted that this was due to the busy schedule of health facility respondents 
and the fact that there were no prior appointments scheduled with health facilities for 
validation visits whereas household respondents were called to make sure they are home 
before the validation visit. Additionally, in some cases, approval from management of 
health facility was required for data collection.  
One flexibility associated with data collection from health facilities was there 
were more health workers who would be able to provide data, while at households it was 




 “So when I'm asking a respondent in the household which is basically the patient about 
some medicine in a medical terminology, the health facility may understand, but the 
household may not. It makes the health facility survey easier to do compare to the 
household.” (IDI FO04, data collector on phone interviews) 
4.4.4 Perceptions on data accuracy 
All of the IDIs said that the data generated through face to face interviews is of 
high quality, because the field workers were able to confirm/countercheck all the 
information they were asking for. Some data collectors mentioned that they were not 
fully confident of the data collected through phone interviews, because they have seen 
variances come up during analysis and also sometimes the information patients provided 
seemed logically inaccurate. One data collector however said data accuracy also depends 
on the training of data collectors and the validation process. 
“I think I would say depends on a number of things, which gets down to the training, and 
the system you put in place to verify whether the data is accurate or not. I mean you 
cannot just say some people are going to collect data and you assume that all the 
information you're getting is correct. You have to have ways to try measure to what level 
the accuracy is.” (IDI FO04, data collector on phone interviews) 
 
While some health facility IDIs mentioned that the quality of data they provided 
through phone was the same as from a face to face interview, others said that the quality 
is not as good. One health worker mentioned that during phone interviews the health 
worker is not always honest.  
“I can say the one I give through the phone, if I can relate it in a scale of ten, could be 
six, because when I am being asked, sometimes am negotiating within my mind should I 
tell the exact price or not, but now once am with the person, am able to, if am being 
interviewed face to face am able to give the information as it is (IDI HFM04, health 





Most households perceived that the information they give over the phone is 
accurate.  
“And I confirmed that it’s [information collected over the phone] true. It’s the exact, it is 
not false.” (IDI HHM08, household on phone interviews) 
 
One household respondent however indicated as shown in the following dialogue 
between the interviewer and household respondent HHMO6, that they can give 
inaccurate data over the phone. 
HHM06:  “No, it is not true, because that is the owner’s secret…. 
Interviewer: Now that is why we are asking whether when we call, do you think it gives us 
the true information or a lot of it is false? 
HHMO6:  A lot of it is false. 
4.4.5 Preferences among respondents for in-person and phone data collection 
Most health facility workers and households preferred in-person interviews 
because of because it is easier to identify data collectors, and the data collectors can 
countercheck the data provided. Two health workers, three household IDIs and one data 
collector indicated their preference for phone interviews because they are quicker, easier 
to plan and offer more flexibility.  
“Yeah, in planning, it's easier to plan for phone surveillance, as long as you have the 
correct number, especially if you call and they expect you. It's easier. It's less expensive” 
(IDI FO05, data collector) 
 
Some data collectors however, mentioned that their preference depends on the 
type of study to be conducted. And that both modes of data collection have their benefits 




while short surveys could be conducted over the phone. Another mentioned in-person 
interviews will be better for households, because of their relatively lower literacy level 
and unfamiliarity with medical terminology, while health facilities could be interviewed 
on phone. 
“I would say, both of them are okay, It just depends on the amount of data that you 
require to collect, because if I require to collect massive data, I'll have to go with phone 
interviews, but if I have a few facilities to follow up, I will go with face to face. So both of 
them are okay.” (IDI FO03, data collector) 
4.4.6 Suggestions for improving face to face and phone interviews 
In-depth interview participants gave different suggestions to improve in-person 
interviews. A data collector suggested use a sampling strategy that allows one to 
interview respondents close to each other to save time and cost.  Another staff mentioned 
the importance of having a qualified and trust worthy data collectors who understand the 
importance of quality data. Also mentioned was making the process of reaching a 
participant easier, for example using GPS coordinates. Many health workers asked to be 
called before visits for them to able to make time and prepare for the interview or first 
find out which days they are less busy. Also some households asked to be called before 
visits, to make sure they were available and requested data collectors bring along samples 
of the Novartis Access products that they are talking about. 
Regarding phone interviews, some respondents said they had no suggestions to 
offer, and that everything is working well. A data collector suggested increasing the 
sample for validation visits. Another suggested giving participants a diary where they 
could write down where they bought the medicine, prices etc. So that when they make a 




included better education of study participants on the project, leaving a written 
information about the project with respondents to help them remember the project, 
sharing excel sheet list of medicines with respondents (in facilities) through WhatsApp, 
SMS or email so respondents can complete it and send it back, reducing the frequency of 
calls from monthly to once every three months (for health facilities), scheduling 
interview appointments with respondents to make sure they have their phones with them, 
updating the contact list frequently and having multiple contact numbers, for example 
contacts of family members and friends, and offering more incentives to respondents.  
5. DISCUSSION  
This study has generated useful findings on the feasibility of using phone surveys 
(both for research and surveillance purposes), more specifically, CATI technology to 
collect data on medicine sources, availability and prices in both health facilities and 
households. These findings and their implications are discussed below.  
5.1 Validity of phone interview data  
All of the participants in the evaluation of Novartis Access cohort owned or had 
access to a mobile phone. As reported by Ballivian et al., limited cell phone ownership 
may introduce selection bias in MPS (7). However, the 100% access to mobile phone 
among the randomly selected study cohort, together with the high response rates obtained 
(88.2% for health facilities and 94.5% for households) means bias due to limited phone 
ownership and poor response rates was minimal. Notwithstanding the mixed evidence on 




high response rates obtained was the use of incentives. Household respondents received 
50 KES ($0.5) while facility respondents received 100 KES ($1) worth of airtime for 
each data collection. We also started telephone surveillance about two months after 
baseline in-person data collection when the study was introduced respondents. Thus, 
surveillance started when respondents were less likely to have forgotten about the study 
or lost their motivation to participate, resulting in the high response rate (16). Though not 
regarding the collection of data on medicines, other phone surveys have reported 
response rates of close to 90% and above (15,17,18). The response rate of 88.2% at the 
facility level is very similar to the response rate of 87.5% achieved in collecting data on 
medicines availability in pharmacies and hospitals in Madagascar (25). This shows that in 
LMICs with high mobile phone penetration, MPS can be an effective method of data 
collection.  
The relatively lower response rates observed at the facility level may be due to the 
busy schedules of facility respondents and the longer interview durations. Additionally, 
data collection took longer, especially for phone interviews at facilities compared to 
households (30.9 vs. 12.8 minutes) which may have affected response rates at facilities. 
Furthermore, data was collected on at least 31 medicines (and for each medicine the 
originator brand, lowest priced generic and Novartis Access brand where applicable) in 
health facilities, compared to households where data were collected on at most seven 





To the best of our knowledge, this is the first study to compare validity of 
medicine price and availability data collected from phone interviews with in-person 
interviews. For both primary outcomes, price and availability of medicines, data collected 
over the phone showed strong validity with data collected in-person. There was a high 
level of agreement in availability of medicines as assessed through phone interviews and 
in-person interviews in both households and health facilities (kappa=0.49 and 0.9 
respectively). Price data collected through phone interviews also showed a strong 
statistically significant correlation with price data collected via in-person interviews for 
both households and health facilities (r=0.9 and 0.52 respectively). The high validity 
obtained indicates phone surveys can be a very useful tool in collecting quality routine 
data on the availability and prices of medicine in households and health facilities. Though 
not specific to data collection on medicines, several studies have demonstrated the 
validity of data collected via phone interviews (4,17,18,30–32,34,35). For example, Aziz 
et al, found a high correlation between phone interview and in-person results of using 
structured questionnaire to diagnose post-traumatic stress disorder (29).  
There is the possibility that routinely calling patients to collect data on their 
medicines may affect their medicine seeking behavior. For example, the phone calls may 
remind patients to purchase their medicines. However, in a randomized sub-study, we did 
not find any impact of the phone surveillance on availability of medicines at the 
household level p=0.751 (Table 3.7). This further highlights the validity of the phone 




5.2 Cost of phone and in-person interviews 
The cost estimates for both phone and in-person interviews are similar to what has 
been documented in literature in LMICs. Ballivan et al. reported the cost per CATI of 
$25 for household surveys, while $22.2 per phone interview was reported in Lebanon 
(7,36). These costs are a little higher than the $19.73 and $16.86 (for health facilities and 
household respectively) found in this study (7). Some studies in Tanzania however, 
reported cost per phone interviews of between $4.10 to $7.30 which is lower than the 
costings from this study (6,16).  
This study has also shown that phone interviews cost much less than in-person 
interviews both in households and health facilities. The cost per in-person interview at 
baseline was at least 10times more than the costs per phone interview at households and 
health facilities. Our findings are consistent with Mahfoud et al. who compared the cost-
effectiveness of in-person with phone data collection and showed that phone data 
collection saved about $14 per interview (36). Despite the lower cost of telephone 
interviews, there may be the need to conduct in-person interviews at baseline partly in 
order to collect phone numbers of study respondents and also inform them they would be 
called. This means the cost associated with initial baseline in-person data collection 
cannot be avoided unless there is an existing unbiased source of telephone numbers 
(6,7,20). Alternatively, phone numbers could be collected during listing of households 
and health facilities. In this study, listing costs were much lower than baseline in-person 
data collection costs (48,175.31 vs. 189,927 respectively). Telephone interviews alone or 




cost-effective opportunity for researchers and program implementers to collect good 
quality baseline data and to identify respondents.   
The incentives given to respondents in this study (US$0.5 and US$1 for 
household and health facility respondents respectively), represent a very small fraction of 
the total cost for each interview. This shows that incentives can be provided to potentially 
increase response rates without significantly increasing the overall budget for telephone 
data collection.  
5.3. Perceptions of data collectors and respondents on telephone and in-person 
interviews 
Responses from IDIs uncover the perceptions of data collectors and participants 
in the Novartis Access evaluation on providing or collecting data via in-person and phone 
interviews. The reported facilitators of both modes of data collection, the challenges 
associated with them and other relevant findings are discussed below.   
5.3.1 Facilitators of in-person and phone data collection  
Several of the facilitators reported by study participants were similar for both in-
person and phone interviews. The most prominent of these was the role of village elders 
in helping locate study participants, building trust between the participants and data 
collectors and also serving as interpreters. This shows that irrespective of the mode of 
data collection, additional help may be needed by data collectors, either remotely or in 
the field.  




to confirm the data collected, observe body language and facial expressions of the 
respondents and in some cases assist illiterate participants in reporting information. 
Observing the nonverbal communication aspects are important during interviews (16). 
The reported facilitators that are unique to phone data collection include its low cost, less 
time-consuming nature, and the ability of data collectors to use additional means of 
correspondence, including SMS/WhatsApp, to aid data collection. Though not part of the 
original design of the study, data collectors in some cases used communication via SMS 
and WhatsApp to navigate the challenges of poor network.  
5.3.2 Challenges associated with in-person and phone data collection 
The key challenges reported for both in-person and phone data collection were 
similar. These included language barriers, and the busy schedule of respondents. While 
language barriers were reported as a challenge for both modes of data collection, this 
barrier could be potentially addressed for phone data collection – where data collectors 
with different language skills call respondents from a call center. Another way of 
addressing language barrier, which was the case in this study, is the use of translators or a 
village elder to serve as a translator. This may take more time, invade the privacy of 
primary respondents, and may also have additional cost implications (16). Using 
translators may also lead to social desirability bias, especially when sensitive questions 
are asked. Furthermore, if the translation is not done accurately, errors may result from 
miscommunication.  
Some of the challenges associated with in-person data collection can significantly 




of study participants. In these cases, it may be worth considering data collection via 
phone interviews.  
Two important challenges associated with phone data collection mentioned were 
poor telephone network coverage and limited power supply. The poor phone network 
reported in this study were temporary network challenges, so eventually most of the 
participants were reached. Also, the network in Kenya is expanding. As mentioned 
earlier, inconsistent network coverage not only affects response rates, but can also 
introduce bias in the study. Network coverage is likely to be correlated with wealth, 
distance from major towns and access to other utilities like water supply (16,20). 
Network coverage can inform the design of a study as well as study location. For 
example, in the South Sudan Experimental Phone Survey, researchers targeted mostly 
households in urban areas, due to the poor network coverage of rural areas (14). This was 
also the case in the study on the impact of the 2012 crises on Internally Displaced People 
in Mali - network coverage was considered in choosing the areas where the study will be 
implemented (15). Charging stations could also be provided to ensure that respondents 
charged their phones to be able to provide data (16). However, in our study the 
respondents were selected using a representative sample based on census tracts.   
Another unique challenge reported for phone interviews is that body language and 
facial expressions of the respondents cannot be observed by the interviewer. Though it is 
still possible to assess these through voice changes, it is more difficult. It is also more 
difficult to protect the participant’s confidentiality if the data collectors are not physically 




as gender, domestic violence and corruption, may not be suitable for phone interviews 
(16). Though in cases in which the respondents could not be interviewed on their own the 
telephone may be the only way to communicate confidentially.  
Though several of the facilitators and challenges reported by participants for both 
modes of data collection are similar most of the participants believed data collected from 
in-person interviews are of higher quality compared to data collected via phone. Most 
health facility and household respondents also preferred to provide data through in-
person interviews.  
The reported differences in experience providing or collecting data from health 
facilities and households were mostly similar for both modes of data collection. This may 
imply both modes of data collection could work well for these two categories of 
respondents (health facilities and households). Nonetheless, the fact that household 
respondents had more problems with language barrier and more difficulty understanding 
the study and medical terminology, may mean that in-person data collection may be more 
beneficial at the household level.  
The findings discussed above suggest that telephone interviews can be a useful 
tool for collecting research and surveillance data. Depending on the technology available, 
and how familiar respondents are with phone use, other functionalities of phone surveys, 
such as sharing of pictures, videos, and WhatsApp communication can be explored. 
Phone interviews can be conducted as sub-studies or follow up studies involving in-




6. CONCLUSION  
The increasing ownership of mobile phones in LMICs present an opportunity for 
research and surveillance data collection using phone interviews. This study 
demonstrated high response rates and high validity for phone data collection. The 
qualitative results of this study showed that most of the facilitators and challenges for the 
two modes of data collection are similar. Respondents expressed more confidence in the 
accuracy of data collector through in-person interviews while acknowledging the 
advantages and disadvantages of each mode of data collection. In countries with high cell 
phone penetration the many advantages of phone data collection should be considered in 
designing studies on medicine price and availability as well as on other health system 
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Annex 3.1: Facility surveillance data collection instrument 
Medicine Price Data Collection Form - Surveillance 
Use a separate form for each facility 
 
Section A: Facility information 
Date : _______________           
Health facility unique survey ID: 
 
County: __________  
Name of health facility: 
 
Name of person(s) providing 
surveillance data if different from 
name of person who provided 
baseline data  








Name of data collector(s): 
Is this a telephone call or a facility visit? 
o Telephone call 
o Facility visit (Skip to Step 1b) 
 
Step 1a: Introduce yourself (data collection on phone) 
"My name is [First name, Last name], from Innovations for Poverty Action (IPA). Can I 
speak with [Name of Participant]? In September, we visited you to collect data on the 
availability and price of medicines for four chronic diseases (Asthma, breast cancer, 
diabetes, and cardiovascular diseases (hypertension, dyslipidemia and heart failure). As 
you would remember, this study is being conducted by Boston University in 
collaboration with IPA. We are following up to ask you a few questions on the 
availability and price of these medicines in your facility on phone. These questions are 
similar to the questions we asked you before. This survey will take about 20 minutes. Are 




NO (Not interested in participating) ________  (STOP!  Thank the participant 
for their time)  
NO, not now but later, …….. (Ask him/her to give you a time they can speak to 
you. Thank the participant for his/her time) 
YES ________  (proceed with interview)   
Thank you so much for giving us this opportunity to speak with you. We would be 
grateful if you could respond as honestly as possible. We may visit your facility in person 




Step 1b: Introduce yourself (data collection in person) 
"My name is [First name, Last name], from Innovations for Poverty Action (IPA). May I 
talk to [Name of Participant]? We recently called you on phone to collect data on the 
availability and price of medicines for four chronic diseases (Asthma, breast cancer, 
diabetes, and cardiovascular diseases - hypertension, dyslipidemia and heart failure). As 
you would remember, this is part of a study being conducted by Boston University in 
collaboration with IPA. We are following up a few of the facilities we called to confirm 
the information collected on phone on the availability and price of medicines in your 
facility. We would be grateful if you could show us the following medicines in your 
facility and also answer any additional question we have on them. Thank you so much for 




speak with us now?”  
NO (Not interested in participating) ________  (STOP!  Thank the participant 
for their time)  
NO, not now but later, …….. (Ask him/her to give you a time they can speak to 
you. Thank the participant for his/her time) 
YES ________  (proceed with interview)   
We would be grateful if you could show us the following medicines if you have them in 
your facility and answer a few questions on each.  
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Annex 3.2: Household surveillance data collection instrument 
 
Instrument ID: H-SURVEILLANCE 
Novartis Access Program 
Household Surveillance Instrument 
Target Audience:  
Household member with NCD 
 
Interviewer ID _________     
Interviewer Name _________        
Interview Date (DD/MM/YYYY) __________________ 
Time Start        _______      Time Finish   
 ___________ 
Supervisor initials  __________  
County: 
Enumeration Area: 
Household member ID: 
Household member name: 
 
Is this a telephone call or a household visit?  (Enumerator: Indicate if you are conduction 
a telephone call or a household visit) 
o Telephone call  
o Household visit (Skip to Step 1b) 
 
Instructions for the Interviewer 
Step 1a - Phone interview (if this is a household visit, skip to Step 1b):   
Phone number (on which the participant was actually reached): 
………………………………… 
Interviewer:  Read the following statement.  
“My name is [Name of Data Collector].  Can I please speak to Mrs/Mr/Ms/Master 




Wait for the response. If the person answering the phone is not the one you are looking 
for, ask whether he or she is around. If not, ask when the participant you are looking for 
will be able to take the call:  
 
If the person is not available for the interview, ask for the reason of 
unavailability 
Code 
1. Death (Be sure to express your condolence if this was the case) 1 
2. Hospitalization (Enumerator: Ask when the participant is likely to come 
back and book a new appointment) 
2 
3. Moved away permanently to a different county (If this is the case the 
participant will be dropped from the study) 
 
Please indicate the county the participant moved to and the reason for 
moving to this county: …………………………… 
3 
4. Not at home or unavailable (Enumerator: if the person is not available, ask 
when will be the best time to meet him/her and book a new appointment) 
4 
5. Other (please specify) 5 
 
When the person you are looking for has answered the phone continue: 
“I am calling on behalf of the IPA/Boston University. We had visited you to collect data in 
September. During this data collection, you informed us you had been diagnosed and 
prescribed medicines for the following diseases [mention the diseases as recorded from 
baseline data collection]. You also agreed to provide us with information on the medicines 
you use to treat these diseases. This interview will take 15 – 20 minutes. Can I talk to you 





NO (Not interested in participating) ________  (STOP!  Thank the participant for 
their time)  
NO, not now but later, ….. (Ask him/her to give you a time they can speak to you. 
Thank the participant for his/her time) 
YES ________  (proceed with interview)   
“Thank you for agreeing to give us the information. For a small subset of participants, we 
may also visit in person to confirm the data we are now collecting. Would that be OK?”  
NO 
YES 
“Can you please look for the medicines you currently have at home for treating the above 
NCDs so they are with you during this telephone interview?  These should not be empty 
medicine bottles or empty blisters but actual medicines.” (Give participant enough time to 
look for his/her medicines. Reschedule appointment if patient or his/her caretaker does not 
have the medicines with them at the time of the call) 
Step 1b – household visit (not for telephone calls) 
Introduce yourself (data collection in person) 
"My name is [First name, Last name], from Innovations for Poverty Action (IPA). May I 






If the person is not available, ask for the reason of unavailability Code 
1. Hospitalization (Enumerator: Ask when the participant is likely to come 
back and book a new appointment) 
1 
2. Not at home or unavailable (Enumerator: if the person is not available, ask 
when will be the best time to meet him/her and book a new appointment) 
2 
3. Other (please specify) 3 
 
If the person is available, you may continue: 
“We recently called you on phone to discuss the medicines you take for (mention the 
disease(s)). We are following up to confirm the information we discussed. I would be 
grateful if you could show me the medicines you currently have at home that you are using 
to treat this NCD(s) you have been diagnosed with.  Thank you so much for giving us this 
opportunity. This interview will take about 15-20 mins. Can I talk to you about your 
medicines now?” 
NO (Not interested in participating) ________  (STOP!  Thank the participant for 
their time)  
NO, not now but later, ….. (Ask him/her to give you a time they can speak to you. 
Thank the participant for his/her time) 
YES ________  (proceed with interview)   
Step 2: Proceed to the structured interview guide.  
2. During our data collection in September, (our last appointment), you informed us you 
were taking the following medicines for the NCDs you have. Can you show me if you have 















If medicine is not available, why 
not? 
o Not available at sales 
outlet(s) 
o Available but costs too much 
o Did not have time to buy 
o Doctor asked me to stop 
taking it 
o Other (specify) 
Medicine 1 NCD 1   
Medicine 2 NCD 1   
Medicine 3 NCD 2   
Medicine 4… NCD 3…   
 
3. Since our last appointment (data collection in September) have you been prescribed 
any new medicine for treating the disease(s), [name of NCD]? 
 
 NO  




prescribed (by INN) 
Disease  Available  If medicine is not available 
Why not? 
o Not available at sales 
outlet(s) 
o Available but costs too 
much 
o Did not have time to buy 
o Other (specify) 
Medicine 1 NCD 1   
Medicine 2… NCD 2…   
 
 
4. Since our last appointment (data collection in September) have you been diagnosed 
any new NCD (Asthma, Breast Cancer, Diabetes Hypertension Cardiovascular Disease) 
and prescribed a medicine for treating it? 
 
 NO 






Disease 2. Where were you 









3. Do you 
currently have at 
home any 
medicines that 









ble but costs too 
much 
3=Did not have 




   
CVD – 
Dyslipidemia  
   
CVD – Health 
failure  
   
Diabetes    
Breast cancer    
Asthma    
 
 
5. Medication Table: Now can you please tell me more about each of all these NCD 
medicine(s) you have at home? 
 






























Med 1        
Med 2        
Med 3        
Med 4        
Med 5        
 






7. If “YES” to question 6, what is your new address?  
INTERVIEWER:  “Thank you sincerely for your time.  We have completed this 
interview and are grateful for your help as we collect information to improve the new 
access to medicines initiative.”  RETURN TO THE COVER PAGE AND NOTE THE 





Annex 3.3: List of medicines rotated during each month of data collection 
 
Group 1 Group 3 
Amitriptyline 25mg Tablet/Capsule Captopril 25mg Tablet/Capsule  
Amoxicillin 250mg Tablet /Capsule Ceftriaxone 1 g/vial Injection 
Amoxicillin 500mg Tablet/Capsule Ceftriaxone 250mg/vial Injection 
Glibenclamide 5mg Tablet/Capsule 
Co-trimoxazole 8+40mg/ml 
suspension 
Omeprazole 20mg 20 mg 
Tablet/capsule Paracetamol 24 mg/ml Suspension 
Group 2   
Atenolol 50mg Tablet/Capsule    
Ciprofloxacin 500mg Tablet/Capsule   
Ciprofloxacin 250mg Tablet/Capsule   
Diazepam 5mg Tablet/Capsule   
Diclofenac 50mg Tablet/Capsule    







Annex 3.4: Qualitative semi-structured interview guides for households and facilities 
 
Novartis Access Evaluation – The feasibility of collecting price and availability data 
on medicines through telephone interviews 
In-depth Interview Guide for health facilities and households 
(This instrument is to be administered to Novartis Access Evaluation study participants 
who have participated in both telephone and in-person interviews) 
Interview start time (HH:MINS):……………………… 
Introduction  
Thank you for providing us data on the non-communicable disease medicines you are 
taking / have in stock both over the telephone and in-person. As part of this study, we are 
also comparing the process of data collection over the phone with data collection in 
person. I would like to ask you a few questions on your experience providing data over 
the telephone and in-person. We would be grateful if you could answer these questions as 
honestly as possible. Your responses will be used in designing future evaluations of 
access to medicines programs. This interview will take about 30 minutes. Please feel free 
to ask me if you have any questions or if you do not understand any question. You may 
decide to stop the interview at any time or not answer any specific question. If you would 
agree, the interview will be tape-recorded to ensure we obtain complete data and do not 
miss anything you will say. However, the interview and the recording will be kept 
confidential and will not be shared with anybody outside of the study team.   





Part 1: Providing data through face-to-face interviews 
We have interviewed you at least once both on phone and in person. The following 
questions focus on your experience when the data collector visited you in person to 
collect data on the availability and price of the medicines you stock / have been 
prescribed.  
1. Can you tell us about your experience providing data to the data collector through 
a face-to-face interview? Describe to me what happened – how the data collector 
visited your house/facility, how he asked for you and interviewed you.  
2. What factors made it easy for you provide data through a face-to-face interview? 
3. What are the factors that made it challenging for you to provide data through a 
face-to-face interview? 
4. Was there any information/variables that was particularly challenging to provide 
in a face-to-face interview? What were they? 
5. How confident are you on the accuracy of data you provided to the data collector 
face-to-face? 
6. Is there any other information you would like to share regarding face-to-face data 
collection? 
Part II: Providing data through telephone interviews 
The following questions focus on your experience when the data collector called you on 
phone to collect data on the price and availability of medicines you stock / have been 




1. Can you tell us about your experience providing data to the data collector over the 
phone? Describe to me what happened – how the data collector called you on the 
phone, how he asked for you and interviewed you.  
2. What factors made it easy for you provide data through a telephone interview? 
3. What are the factors that made it challenging for you to provide data through a 
telephone interview? 
4. Was there any information/variables that was particularly challenging to provide 
in a telephone interview? What was this information? 
5. How confident are you on the accuracy of data you provided to the data collector 
over the phone? 
6. Is there any other information you would like to share regarding providing data 
over the telephone? 
Part III: Providing data through telephone versus face-to-face interviews 
Now I would like to ask you a few questions about your preferences for providing data 
via telephone or face-to-face interviews 
1. Do you think there is any difference in providing data over telephone compared to 
providing data through a face-to-face interview? If yes, why? If no, why not? 
2. Which of these two (providing data over the telephone and providing data through 
face-to-face interview) do you prefer and why? 





4. Do you have any suggestions to make providing data through face-to-face data 
interview better? 
5. Is there any information you would like to share regarding the comparison of 
providing data over the phone compared to providing data via face-to-face 
interview? 
We have come to the end of the interview. Thank you so much for your time! 






Annex 3.5: Qualitative semi-structured interview guide for data collectors 
 
Novartis Access Evaluation – The feasibility of collecting price and availability data 
on medicines through telephone interviews 
In-depth Interview Guide for Field Officers (data collectors) 
Introduction 
As you are aware, Boston University/IPA as part of the Novartis Access Evaluation are 
studying the feasibility of collecting medicine price and availability data over the phone, 
compared to face-to-face data collection. As you have been involved in collecting data 
from health facilities and households both face-to-face and on phone, we would like to 
ask you a few questions on your experience. We would be grateful if you could answer 
these questions as honestly as possible. Your responses will be used in designing future 
evaluations of access to medicines programs. This interview will take about 30 minutes. 
Please feel free to ask me if you have any questions or if you do not understand any 
question. You may decide to stop the interview at any time or not answer any specific 
question. If you would agree, the interview will be tape-recorded to ensure we obtain 
complete data and do not miss anything you will say. However, the interview and the 
recording will be kept confidential and will not be shared with anybody outside of the 
study team.   
Thank you very much for your interest in participating 
Interviewer: ………………………………………………………….. 





Part 1: In-person data collection 
The following questions focus on your experience collecting data on the availability and 
price of the medicines in households and health facilities.   
7. Can you tell us about your experience collecting data through face-to-face interviews? 
Describe to me how this normally happens – how you visit households/facilities, how you 
identify your respondent and how the interview normally goes.   
8. What factors made it easy for you to collect data through a face-to-face interview? 
9. What are the factors that made it challenging for you to collect data through a face-to-
face interview? 
10. Were there any key differences in collecting data through face-to-face interviews with 
health facilities and households? 
11. Was there any information/variable that was particularly challenging to collect data on in 
a face-to-face interview? What were they? 
12. How confident are you on the accuracy of data you collected in face-to-face interviews? 
13. Is there any other information you would like to share regarding face-to-face data 
collection? 
Part II: Data collection over the telephone: 
The following questions focus on your experience collecting price and availability data 
from households and health facilities through telephone interviews.    
7. Can you tell us about your experience collecting data through telephone interviews? 
Describe to me what happened – how you normally call participants on the phone, how 
you identify participants and the interview process.   
8. What factors made it easy for you collect data through a telephone interview? 





10. Were there any key differences in collecting data through face-to-face interviews with 
health facilities and households? 
11. Was there any information/variable that was particularly challenging to collect data on in 
a telephone interview? What was this information? 
12. How confident are you on the accuracy of data you collected over the phone? 
13. Is there any other information you would like to share regarding collecting data over the 
telephone? 
Part III: Telephone versus face-to-face data collection 
Now I would like to ask you a few questions about your preferences for telephone or 
face-to-face data collection 
6. Do you think there is any difference in collecting data over telephone compared to 
providing data through a face-to-face interview? If yes, why? If no, why not? 
7. Which of these two (collecting data over the telephone and collecting data through face-
to-face interview) do you prefer and why? In this case, does it matter if you are collecting 
data from health facilities vs. households? Why? 
8. Do you have any suggestions to make collecting data over the telephone better? 
9. Do you have any suggestions to make collecting data through face-to-face data interview 
better? 
10. Is there any information you would like to share regarding the comparison of collecting 
data over the phone compared to face-to-face interview? 
We have come to the end of the interview. Thank you so much for your time! 




Annex 3.6: Duration of facility interviews (in minutes) by month of data collection  
 
Month 















































1 6 22.5 22.3 9.6 37.5 6 16.7 11.3 9.2 45.4 
2 10 28.4 25.9 4.3 56.1 11 18.7 15 6.7 56.1 
3 12 30 21.5 7.8 69.6 10 18.4 9.9 4.9 87.7 
4 11 27.2 23.4 12.8 53.9 12 10.9 9.1 4 25 
5 24 32.2 26.2 9.4 90.4 25 14.5 9.3 4.9 107.5 
7 8 30.5 25.7 8.1 58.8 8 13.5 11.2 4 34.6 
8 8 39.6 27.4 15.1 87 7 9 6.8 3 19.1 
9 7 38.4 41 19.3 61.2 8 17.8 15.6 8.1 38.7 
10 8 25.5 19.7 8.8 53.7 8 11.7 8.9 5.2 26.5 
11 7 30.5 26.7 9.2 53 8 15.2 10.8 3.3 43.1 
12 8 37.7 27.6 14.1 102.5 8 19 12.3 5 73.9 
13 7 27.2 22.7 7.6 88.3 6 13.4 9.1 4.2 34.1 







Annex 3.7: Duration of household interviews (in minutes) by month of data collection 
 
Month 















































1 5 7.7 6.7 4.2 13.9 5 10.3 7.9 3.5 25.4 
2 12 10.2 7 3.2 32.8 12 8.8 6.9 2.5 19.8 
3 14 11.4 8.7 5.3 30.9 14 10.2 7.4 1.6 28 
4 14 8.7 7.6 1.7 21.7 13 9.2 9.6 4.1 16.8 
5 12 10.8 7.7 2.4 44.9 12 8.2 7 1.6 18.5 
6 15 8.5 6.7 2 15.6 15 7.9 5.6 1.7 30.1 
7 9 14 8.3 2.4 36.8 9 5.5 5.4 1.4 16.1 
8 9 15.9 8.4 3.4 42.3 8 7.8 9.4 1.7 12.9 
9 8 16.1 13 8.4 30.5 8 10.3 7 3.9 30.2 
10 8 14.7 14.6 2.3 28.2 8 6.8 5.6 3.6 15.8 
11 10 22.8 22.8 4.3 54.2 10 7.9 8.2 2.9 15.6 
12 8 20.2 20 3.8 33.8 8 5.5 2.4 0.7 17.5 
13 6 9.4 5 3.4 21.5 6 7.8 6.5 2.3 16.7 






Annex 3.8a Scatter plot for price data (measured in Kenyan Shillings) collected through 



















Annex 3.8b Scatter plot for medicine pack size data collected through telephone and in-













Annex 3.8c Scatter plot for price data (measured in Kenyan Shillings) collected through 




















Annex 3.8d Scatter plot for medicine strength data collected through telephone and in-






Annex 3.8e Scatter plot for data on quantity of medicines purchased collected through 








































CHAPTER FOUR - IMPACT OF NOVARTIS ACCESS ON CONSUMPTION 
PATTERNS OF MEDICINES FOR NON-COMMUNICABLE DISEASES IN 
KENYA: A CONTROLLED INTERRUPTED TIME SERIES ANALYSIS 
EXECUTIVE SUMMARY 
Background: To improve access to medicines for non-communicable diseases 
(NCDs) in low- and middle-income countries, price schemes have been used as a strategy 
to increase affordability of medicines. The Mission for Essential Drugs and Supplies 
(MEDS), one of the major wholesalers in Kenya started a partnership with Novartis 
Pharmaceuticals in 2016 to provide medicines for four non-communicable diseases 
(asthma, breast cancer, diabetes, and cardiovascular diseases) at a price of 100 KES for a 
month of treatment. However, little is known about the effects of these initiatives on 
medicine consumption patterns. This study was a controlled interrupted time series study 
with the primary objective of evaluating the effect of the Novartis Access pricing scheme 
on the volume of consumption of generic and therapeutically equivalent medicines, using 
panel wholesale data set. The secondary objectives of this study were to determine the 
impact of Novartis Access on the consumption of medicines that are not in the national 
Essential Medicines List (EML) of Kenya; and to describe overall consumption patterns 
of NCD medicines in eight counties in Kenya.  
Methods: Sales data on nine Novartis Access medicines (comprising 14 different 
formulations) between October 2014 (24 months before the roll out of Novartis Access in 
November 2016) and June 2018 (20 months after the roll-out of Novartis Access) were 




Additionally, sales data for 27 other medicines for asthma, breast cancer, diabetes, and 
cardiovascular disease, including generic and therapeutic equivalents of the Novartis 
Access medicines were extracted. Data were extracted for sales going to facilities in the 
eight counties that are participating in an ongoing cluster-randomized controlled study 
evaluating the effect of Novartis Access on price and availability of medicines in 
households and health facilities. Kwale, Makueni, Nyeri and West Pokot counties were 
serving as intervention counties in which the Novartis Access medicines were distributed. 
Embu, Kakamega, Narok and Samburu served as control counties.  
All purchases were converted to total Defined Daily Doses (DDDs) per patient 
(defined by the World Health Organization) as the assumed average maintenance dose 
per day for a drug used for its main indication in adults). The effects of Novartis Access 
medicines on the consumption of their generic equivalents and therapeutic alternatives 
and on the consumption of non-EML medicines were estimated using segmented 
regression analysis. The total volume of purchase for each medicine over the study period 
was estimated and stratified by provider type, county and level of care. 
Results: The introduction of Novartis Access did not significantly change the 
overall level and trend of consumption of generic equivalents. The generic equivalent, 
amlodipine experienced a significant decrease of 23.57 DDDs in 1000s per quarter 
(p=0.0121) with the introduction of Novartis Access. The changes in the level and trend 
of consumption of other generic equivalents were not statistically significant. Neither 
were there significant changes in the level and trend of consumption of therapeutic 




DDDs in 1000s) and trend of consumption (1.18 DDDs in 1000s per quarter) of non-
EML medicines with the introduction of Novartis Access were not statistically significant 
(p=0.6220 and p=0.8413 respectively).The most consumed NCD medicines were 
nifedipine 20mg, furosemide 40mg and hydrochlorothiazide 50mg tablets. For almost all 
the medicines, public sector consumption was much higher compared to consumption by 
non-profit facilities (16,836.5 DDDs in 1000s compared to 11,296.2 respectively). The 
volumes of consumption of non-EML medicines were relatively small compared to the 
total volumes of medicines consumed. However, non-EML medicines were consumed by 
all provider types, at all levels of care and by many county governments. A high 
proportion of lower level facilities (levels 2 and 3) consumed medicines restricted to 
levels 4 and above in the EML. 
Discussion and conclusion: Though MEDS was set up initially to supply 
medicines to non-profit facilities, it has grown to become a major supplier of public 
facilities as well. The limited effect of Novartis Access on the consumption of generic 
and therapeutic equivalents may be as a result of the relatively higher prices of Novartis 
Access medicines and the limited marketing of Novartis Access. These same reasons may 
partly explain why Novartis Access did not affect the consumption of non-EML 
medicines. Generally, consumption patterns of NCD medicines were not always 
consistent with the EML. Measures need to be taken to encourage access to medicines 
programs by industry to target priority medicines of recipient counties. It is also 
important to align national EMLs and Standard Treatment Guidelines and revise these 




medicines. These will promote appropriate use of medicines and sustainability of access 






The objective of this controlled interrupted time series study was to determine the 
effect of a pricing scheme program (Novartis Access) on the consumption patterns of 
therapeutically equivalent medicines and medicines not listed in the Essential Medicines 
List (EML) in eight counties in Kenya using wholesale panel data. More specifically, the 
primary aims of this study were to determine the: 
i) impact of Novartis Access on the consumption patterns of generic equivalents of 
Novartis Access medicines and 
ii) impact of Novartis Access on the consumption patterns of therapeutic alternatives 
of Novartis Access medicines 
The secondary aims of the study were to: 
i) determine the impact of Novartis Access on the consumption patterns of 
medicines that are not in the Kenya EML (non-EML medicines) 
ii) describe the overall purchasing patterns of medicines for cardiovascular disease 
(hypertension, heart failure and dyslipidemia), diabetes, asthma and breast cancer. 
2. BACKGROUND  
2.1 The Novartis Access program  
In 2016 Novartis, a pharmaceutical company started a partnership with the 
Mission for Essential Drugs and Supplies (MEDS), a major wholesaler in Kenya to 
provide a basket of 15 medicines (in 24 different formulations) for four NCDs (asthma, 




treatment (1). Novartis plans to scale up this program, called Novartis Access to several 
other low- and middle-income countries (2). However, little is known about the intended 
and unintended impacts of initiatives such as Novartis Access on access to and 
consumption of medicines (3). Even though the World Health Organization has 
developed guidelines on drug donations which stipulates donations be based on local 
needs, there are no specific guidelines on the use of price schemes to improve access to 
medicines (4). The Access to Medicines Index, which ranks pharmaceutical companies 
based on their access initiatives does not in its rankings, take into account how the 
initiatives align with the national priorities of recipient countries (5).  
Boston University is using a cluster randomized design to evaluate the impact of 
the Novartis Access initiative on the availability and prices of NCD medicines in health 
facilities and households in the Kenya (6). These outcomes are determined by health 
facility and household in-person and telephone surveys. The baseline survey was 
completed in 2016 and the results have been reported (6–9). Based on cluster 
randomization of study counties to control and intervention counties established for the 
evaluation of Novartis Access, this study utilized a controlled interrupted time series 
analysis of panel medicines sales data to evaluate the impact of Novartis Access on 
medicine consumption patterns.  
2.2 The structure of the pharmaceutical procurement system in Kenya 
Before Kenya devolved its governance system in 2010, public sector procurement 
of medicines was centralized at the national level (10,11). All health facilities sourced 




paid for by the national government. After the devolution, county governments assumed 
the responsibility for managing health services including the purchase and distribution of 
medicines. Lower levels of care especially dispensaries (levels 2) and health centers 
(level 3) facilities which have limited procurement expertise rely on county governments 
for their medicines.  
In addition to KEMSA, there are other major wholesalers in the country. Since the 
devolution in 2010, county governments have some flexibility to purchase medicines 
from other wholesalers, especially MEDS. Counties purchase medicines that are neither 
available at KEMSA nor MEDS from other wholesalers, including Harleys, Phillips, and 
Surgipharm. It is not clear what the market share of these major suppliers are, though 
MEDS estimates that they supply about 40% of medicines to public and non-profit 
facilities, while KEMSA supply the vast majority of the rest (12). The majority of the 
clientele for MEDS and KEMSA have been public and non-profit health facilities (13). 
The other suppliers focus on the private sector including private pharmacies.  
The EML is meant to guide public procurement in Kenya (14,15). Thus, counties, 
and public and faith-based facilities are expected to use the EML as a guide when 
selecting medicines to procure. Medicines in the EML are specified by their International 
Non-proprietary Names (INN), dosage form, route of administration and strength, and the 
level of care at which they are expected to be available (14–16). With the inclusion of 
medicines on the EML based on disease burden, efficacy and cost effectiveness, the EML 
is expected to streamline procurement, improve the prescribing of medicines and 




The Mission for Essential Drugs and Supplies is a faith-based organization 
founded in 1986 with the mission of ensuring availability of quality, affordable essential 
medicines and medical supplies to faith-based health care facilities (18). Currently, 
MEDS also supplies government facilities in Kenya and other sub-Saharan African 
countries. MEDS has a quality control laboratory prequalified by the World Health 
Organization (WHO) (19). The organization is able to test all the medicines it procures. 
Because of this, MEDS has a high reputation among its clientele for supplying good 
quality medicines in addition to offering timely deliveries (13). Counties need to sign a 
contract with MEDS to be able to source medicines from them.   
Mission for Essential Drugs and Supplies has a well-developed information 
system for its medicines supply chain management. The organization has a database of 
sales to health facilities in the over 40 counties that purchase from it dating back to 2006 
(20). In achieving its mission, MEDS partners with several bilateral and multilateral 
organizations on various access to medicines programs. Some of these organizations 
include the United States Agency for International Development (USAID), the Swedish 
Development Cooperation (SIDA), Deutsche Gesellschaft für Internationale 
Zusammenarbeit (GIZ), the United Nation agencies etc. MEDS also collaborates with 
various pharmaceutical industries to improve access to essential medicines (18). 
2.4 Drug utilization studies in low- and middle-income countries 
The World Health Organization (WHO) defines drug utilization studies as studies 
of marketing, distribution, prescription and use of medicines in society, with special 




utilization studies fall in the categories of systems and structures surrounding drug use, 
the process of drug use including compliance to guidelines (such as the EML), and the 
determinants and outcomes of drug use (22,23).  
Sources of data for monitoring the consumption of medicines may include sales 
data from suppliers, prescribing data, dispensing data etc. (21,23). However, few drug 
utilization studies in low- and middle-income countries have used sales data (24–27). For 
example, a systematic review of drug utilization studies in the South East Asia region of 
the WHO yielded 318 publications, all of which were either hospital or community based 
(24,27). None of these studies used supplier data and only 21 (7%) assessed the pattern of 
use of medicines. Medicine consumption studies in African countries also used hospital-
based data or focused on medicines for acute conditions (28,29).  
Access and use of NCD medicines by patients have been reported to decrease 
with decreasing country income group with a wider access gap in low income counties 
(30). For example, in a study on the use of secondary prevention drugs for cardiovascular 
diseases, only 11.2% of patients in high income countries received no drugs, compared to 
45·1% in upper middle-income countries, 69·3% in lower middle-income countries, and 
80·2% in low-income countries (29). To improve access to NCD medicines in low- and 
middle-income countries, price schemes have been used as a strategy to increase 
affordability of medicines. The Access Observatory, a database of industry led access to 
medicines programs contains nine price schemes and three drug donation programs to 
improve access to medicines (31). Understanding how the Novartis Access program also 




inform the design and implementation of effective access to medicines initiatives, more 
specifically those focusing on price schemes. 
3. METHODS 
3.1 Study design 
This study was controlled interrupted time series study conducted in eight 
counties in Kenya. 
3.2 Study participants and setting 
The selection of the eight study counties has been described by Rockers et al. 
(6,7). First, out of the 47 counties in Kenya, three were excluded for security reasons. 
Second, only counties that purchased at least US$100,000 worth of medicines from 
MEDS a year before the introduction of Novartis Access were considered. This excluded 
an additional 32 counties. Finally, to eliminate shared borders and reduce the risk of 
leakage of Novartis Access medicines from intervention counties to control counties, four 
additional counties were excluded. The remaining eight counties - Embu, Kakamega, 
Kwale, Makueni, Narok, Nyeri, Samburu, and West Pokot – were cluster randomized to 
receive Novartis Access medicines or no Novartis Access medicines. 
3.3 Randomization 
The process of randomizing study counties has been described by Rockers et al. 
(6,7). Clusters of counties were randomized to either the intervention or the control group 




population; population density; proportion of the population in urban areas; poverty rate; 
number of health facilities; physicians per capita; health spending per capita; overall 
value of medicines ordered through MEDS in previous year; and proportion of value 
ordered through MEDS in previous year by private non-profit versus public health 
facilities. Kwale, Makueni, Nyeri, and West Pokot counties were randomized to the 
intervention group, while Embu, Kakamega, Narok, and Samburu counties were 
randomized to the control group.  
3.4 Intervention 
The intervention consisted of nine Novartis Access medicines (14 different 
formulations) for four NCDs (asthma, breast cancer, diabetes, and cardiovascular 
diseases). These medicines, which had a unique logo and “Novartis Access” written on 
the packaging were made available through MEDS at a price of 100 KES ($1.00) for a 
month of treatment (1). Novartis Access was rolled out in only intervention counties in 
November 2016. MEDS also sells the generic and therapeutic alternatives of Novartis 
Access medicines. The list of Novartis Access medicines and their therapeutic equivalents 
available at MEDS during the study period are shown in Annex 4.3.  
3.5 Procedures 
Sales data on nine Novartis Access medicines (comprising 14 different 
formulations) were extracted from the SYSPRO Enterprise Resource Planning database 
of MEDS. These nine Novartis Access medicines were those that were available at MEDs 




disease, diabetes, asthma and breast cancer including generic and therapeutic equivalents 
of the Novartis Access medicines were extracted. For the purposes of this study, a generic 
equivalent of a Novartis Access medicine is defined as a pharmaceutical product 
containing the same active ingredient as the Novartis Access medicine, in the same 
strength, dosage form and route of administration, usually intended to be interchangeable 
with the Novartis Access medicine or its originator brand. Therapeutic alternatives of 
Novartis Access medicines are defined as medicines containing active ingredients 
belonging to the same therapeutic class as the active ingredients in Novartis Access 
medicine, which may be used instead of Novartis Access medicines. All purchases from 
MEDS to public, non-profit and private health facilities within the eight study counties 
were included in the study.  
Data were extracted for sales going to facilities in the eight intervention and 
control counties that are participating in the evaluation of the Novartis Access study. For 
each medicine, data were extracted on the following variables: INN, strength, dosage 
form, route of administration, pack size, quantity purchased, purchasing facility and 
county and date of purchase. Data were collected on sales that took place between 
October 2014 (24 months before the roll out of Novartis Access) and June 2018 (20 
months after the roll-out of Novartis Access). Previous studies have used sales data as a 
marker of medicines consumption and the same assumption was made in this study (33).  
The Defined Daily Dose (DDD) for each study medicine was obtained from the website 
of the WHO Collaborating Center for Drug Statistics and Methodology in September 




per day for a drug used for its main indication in adults” (34). The level of care to which 
the purchasing facilities belong were obtained from the evaluation of Novartis Access 
baseline data and from the website of the Kenya Master Health Facility List, a publicly 
available online database of the Ministry of Health (35,36).  
Medicines were considered to being in the EML if they were listed in either the 
2010 or 2016 editions of the national EML (14,15). These were the two most recent 
editions of the EML in the country. When the level assigned to a medicine varied 
between the two EMLs, the lowest level assigned was used. 












Embu 19 5 1 6 3 34 
Kakamega 10 6 1 2  - 19 
Kwale 6  - 1 1  - 8 
Makueni 22 1 1 5  - 29 
Narok 16 2 1 1 1 21 
Nyeri 18 6 1 7 1 33 
Samburu 6  - 1 1   8 
West Pokot 4  - 1 1  - 6 
Total  101 20 8 24 5 158 
* Include health faculties owned by schools and colleges that mainly take care of students 
Table 4.1, shows the different types of health facilities in study counties that 
purchased from MEDS during the study period. A major proportion of MEDS’s clientele 
(101/158) are non-profit health facilities. With the devolution of governance, county 




3 facilities. Hence the relatively low number of public facilities directly purchasing from 
MEDS.  
3.6 Outcomes 
The primary outcomes were the volume of consumption (in DDDs) of the generic 
and therapeutic equivalents of Novartis Access medicines. The secondary outcomes were 
the volume of consumption of medicines (in DDDs) not included in the national EML 
(non-EML medicines).  
3.7 Statistical analysis 
Data were analyzed using SAS version 9.4 (The SAS Institute Inc.) (37). All 
purchases were converted into total DDDs, and expressed in 1000s. The monthly 
purchase data were aggregated into quarterly purchases, with the first quarter starting 
from October 2014.    
3.7.1 Impact of Novartis Access on consumption of generic equivalents  
This analysis focused on Novartis Access medicines and their generic equivalents 
available at MEDS during the study period. Six of the Novartis Access medicines 
(amlodipine, glimepiride, valsartan, metformin and tamoxifen tablets and salbutamol 
inhaler) had generic equivalents at MEDS. The effects of Novartis Access medicines on 
the consumption of their generic equivalents were estimated using segmented regression 
analysis (38,39). The intervention (launch of Novartis Access occurred after quarter 8 (24 
months) into the study period and the post intervention period consisted of 7 quarters (20 




Novartis Access, so no transition period was included in the regression model. Due to the 
high variability in purchasing patterns, the monthly purchase data was converted to time 
series quarterly consumption, starting from quarter 4 of 2014 to quarter 2 of 2018. 
Changes in levels and trends in quarterly medicine consumption were estimated 
controlling for baseline (before Novartis Access launch) trend. This was done using 
AUTOREG procedure with the Durbin-Watson test to check and correct for 
autocorrelation (40).  
To control for external factors other than the Novartis Access intervention that 
may have affected consumption patterns, a controlled analysis was also conducted 
comparing levels and trends in the consumption of generic equivalents of Novartis Access 
medicines in control and intervention counties. The estimates from this analysis can be 
considered to be more valid compared to the first analysis which controlled only for 
baseline trend (33,41). The quarterly consumption in control counties were subtracted 
from the quarterly consumption in intervention counties to obtain time series data points, 
which were used for this controlled analysis. First, the effect of Novartis Access on the 
overall consumption patterns of the six generic equivalents of Novartis Access medicines 
was estimated. The effect of Novartis Access on the consumption of each generic 
equivalents for amlodipine, metformin and salbutamol were then evaluated. No stratified 
analyses were conducted for the other three generic equivalents (glimepiride, valsartan 




3.7.2 Impact of Novartis Access on consumption of therapeutic alternatives  
This analysis focused on Novartis Access medicines and their therapeutic 
alternatives available at MEDS during the study period. For this analysis, therapeutic 
alternatives were determined based on the Anatomical Therapeutic Chemical (ATC) 
Classification system of the WHO (42). There were six Novartis Access medicines 
(amlodipine, bisoprolol, glimepiride, letrozole and valsartan tablets and salbutamol 
inhaler) that were matched with their therapeutic equivalents based on Level 2 of the 
ATC classification system which categorizes medicines based on both the body organs 
they act on and their pharmacologic or therapeutic properties. 





Medicine   Novartis 
Access 
equivalent  
C08 Calcium channel blockers Nifedipine tablets Amlodipine 
tablets 





C09 Agents acting on the renin-











Glicazide tablets,  
Glimepiride 
tablets 
R03 Drugs for obstructive airway 











The ATC Level 2 classifications for these therapeutic alternatives include calcium 
channel blockers, beta blocking agents, agents acting on the renin-angiotensin system 
(angiotensin receptor blockers/enzyme inhibitors), drugs used in diabetes, and drugs for 
obstructive airway diseases. Table 4.2 presents the specific medicines under each 
category, and their corresponding Novartis Access therapeutic alternative. The “drugs for 
diabetes” category focused on only sulfonylureas while the “drugs for obstructive airway 
disease focused on glucocorticoids).  
The same methods used to test for the effect of Novartis Access on generic 
equivalents were used to test the effect of Novartis Access on the consumption patterns of 
each of these groups of therapeutic alternatives. 
3.7.3 Impact of Novartis Access on the consumption of non-EML medicines   
Segmented regression analysis was used to estimate the effect of Novartis Access 
on the overall levels and trends in consumption of non-EML medicines. The proportions 
of facilities purchasing medicines they are not supposed to purchase were estimated, 
taking into account the level of care to which each medicine was assigned in the EML. 
Finally, the total volume of medicines consumption that were not in the EML (non-EML 
medicines) were estimated by county, provider and level of care. 
4. RESULTS 
4.1 Study medicines  
Table 4.3 below shows the total consumption of generic equivalents and 




intervention period (October 2014 to September 2016). Generally, the volume of 
purchases was higher in intervention counties. However, this should not bias the results 
of this study, which uses a time series analysis.   
Table 4.3 Volume of purchases of generic equivalents and therapeutic alternatives of 
Novartis Access medicines 
Medicines (generic and therapeutic 
equivalents of Novartis Access) 
 
Volume of purchase 
(DDDs) in 1000s 
Control  Intervention 
Calcium channel blockers 
  Amlodipine tab 101.25 418.82 
  Nifedipine tab 1114.67 2356.00 
Beta-blocking agents 
  Atenolol tab 179.11 582.98 
  Carvedilol tab 3.08 7.24 
  Propranolol tab 15.73 37.40 
Drugs acting on the renin angiotensin system  
  Enalapril tab 398.75 727.05 
  Losartan tab 323.04 502.21 
  Valsartan tab 0.00 0.00 
Drugs used in diabetes (Sulfonylureas) 
  Glibenclamide tab 744.95 1318.45 
  Gliclazide tab 2.05 54.99 
  Glimepiride tab 0.0 3.75 
Drugs used in diabetes (Biguanides) 
  Metformin tab 382.67 322.45 
Drugs for obstructive airway disease (inhalers for asthma) 
  Beclometasone Inhaler  20.60 92.00 
  Budesonide inhaler 56.48 44.18 
  Salbutamol inhaler 141.45 198.08 
Endocrine therapy (anti-cancers) 
  Tamoxifen tab 1.11 10.20 
Note: The six medicines in italics are generic equivalents of Novartis Access medicines. 






4.2.1 Impact of Novartis Access on the consumption of generic equivalents   
Figure 4.1, below shows the quarterly trend in the overall consumption of the six 
generic equivalents of Novartis Access medicines in intervention and control counties 
before and after the launch of the distribution of Novartis Access medicines. The 
reference line in Quarter 3 of 2016 indicates the launch of the distribution of Novartis 




Controlling for only baseline trend, there were no significant effects on the level 
and trend of consumption of generic equivalents of Novartis Access medicines (change in 
level = 1.49 DDDs in 1000s, p=0.9891; slope = -49.86 DDDs in 1000s per quarter, 




counties were compared with control counties, the change in level (97.00 DDDs in 
1000s) and trend (slope=-46.64 DDDs in 1000s per quarter) were not statistically 
significant (p=0.3970 and 0.0997 respectively).  
Table 4.4 shows the numeric changes in levels and trends of consumption of the 
individual generic equivalents of Novartis Access medicines while Figure 4.2 displays the 
consumption patterns of  these medicines in intervention and control counties (only for 
study medicines which had a corresponding generic Novartis Access brand).  
Table 4.4 Changes in levels (DDDs in 1000s) and trends (DDDs in 1000s per quarter) in 
consumption of generic equivalents of Novartis Access medicines 
 Controlling only for baseline 
trend in intervention counties 
Comparing intervention 
with control counties 















































Significant effects highlighted in bold 
Comparing intervention with control counties, amlodipine experienced no 
statistically significant increase in level but a significant decrease of 23.57 DDDs in 
1000s per quarter (p=0.0121) in the trend of consumption (Figure 4.2a). There were no 
significant changes in the level and trend of consumption of the other generic equivalents 













































































































4.2.2 Impact of Novartis Access on the consumption of therapeutic alternatives   
Table 4.5 shows the numeric changes in the level and trend of consumption of 
specific therapeutic equivalents of Novartis Access medicines while Figure 4.3 displays 
the quarterly consumption patterns of these medicines in control and intervention 
counties.   
Table 4.5 Changes in levels (in DDDs, in 1000s) and trends (in DDDs per 1000 patients 
per quarter) in consumption of therapeutic equivalents of Novartis Access medicines 
 
 
Controlling only for baseline 
trend in intervention counties 











Calcium channel blockers  









Beta blocking agents  
- Atenolol,  
- Carvedilol and  









Agents acting on the renin-
angiotensin system 
- Losartan and  









Drugs used in diabetes 
(sulfonylureas) 
- Glibenclamide and  









Drugs for obstructive airway 
disease (Inhalers for asthma) 
- Beclometasone and  










Novartis Access did not significantly affect the level and trend of consumption of 
any of these therapeutic equivalents, both controlling for only baseline trend and 
comparing with control counties. The graphs on the consumption patterns of these 
medicines (Figure 4.3) characteristically showed temporary spikes in consumption just 






































































































































































































Figures 4.3a–e (Continued) Graphs showing the quarterly consumption patterns of 












Annex 4.3 stratifies quarterly consumption over time by non-Novartis Access and 
Novartis Access brand and by therapeutic category: calcium channel blockers, beta 
blockers, angiotensin receptor blockers/enzyme inhibitors (for CVD medicines); 
sulfonylureas and biguanides (for diabetes medicines); inhalers for asthma and 
anticancers.  
4.2.3 Impact of Novartis Access on consumption of non-EML medicines 
Figure 4.4 shows the quarterly volume of consumption of non-EML medicines in 
intervention and control counties over the study period. Controlling for baseline trend 
alone, the increases in level (12.20 DDDs in 1000s) and trend (1.54 DDDs in 1000s per 
quarter) of consumption of non-EML medicines were not statistically significant 
(p=0.6237 and 0.7915 respectively). Also when consumption patterns of non-EML 








medicines in intervention counties were compared with control counties, the increases 
observed in the level (12.41 DDDs in 1000s) and trend of consumption (1.18 DDDs in 
1000s per quarter) were not statistically significant (p=0.6220 and 0.8413 respectively).   
Figure 4.4  
 
 
4.2.4 Overall consumption patterns of NCD medicines 
Table 4.6 shows the total volume of consumption of each medicine (DDDs in 











Table 4.6 Consumption of study medicines (DDDs in 1000s) by type of provider between 







Medicines for CVD           
Nifedipine 20mg tab 4,427.3 1,987.3 102.0 2.7 6,519.3 
Frusemide 40mg tab 3,007.0 817.0 44.0   3,868.0 
Hydrochlorothiazide 50mg tab 1,483.4 2,029.4 340.4   3,853.2 
Enalapril 5mg tab 1,340.3 585.1 98.3 0.3 2,023.9 
Atorvastatin 20mg tab 1,209.4 513.9 101.4   1,824.7 
Losartan 50mg tab 738.9 726.6 97.2 0.1 1,562.8 
Amlodipine 5mg tab 706.7 744.4 59.8   1,510.8 
Atenolol 50mg tab 488.2 608.7 1,89.5 2.1 1,288.4 
Spironolactone 25mg tab 240.7 107.0 29.7   377.3 
Digoxin 0.25mg tab 187.5 129.5 32.0   349.0 
Amlodipine 10mg tab 176.2 73.4 8.4   258.0 
Hydralazine 25mg tab 28.4 71.1 24.3   123.8 
Propranolol 40mg tab 47.2 47.2 5.4   99.8 
Methyldopa 250mg tab 74.1 15.3 1.1   90.5 
Carvedilol 12.5mg tab 39.9 11.5 4.3   55.7 
Valsartan 80mg tab 16.8 3.4 1.7   21.8 
Valsartan 160mg tab 17.9 1.1 2.7   21.7 
Isosorbide dinitrate 10mg tab 1.1 1.3 0.1   2.5 
Bisoprolol 5mg tab   0.2 0.3   0.5 
Anti-diabetics           
Glibenclamide 5mg tab 1,390.0 1,364.0 396.0 2.3 3,152.3 
Metformin 500mg tab 341.7 712.1 186.2 0.3 1,240.3 
Pioglitazone 30mg tab 68.4 59.6 102.1   230.0 
Gliclazide 80mg 30.0 8.5 107.0   145.6 
Metformin 1000mg tab 40.1 44.4 2.4   86.9 
Glimepiride 2mg tab 36.9 29.7 2.8   69.4 
Vildagliptin 50mg 17.2 4.4 0.6   22.2 
Glimepiride 4mg tab   0.9 3.2   4.1 
Glimepiride 1mg tab     0.1   0.1 
Anti-asthmatics           
Salbutamol Inhaler 100ug/dose  416.7 416.9 30.0 0.3 863.9 
Budesonide Inhaler 200ug/dose 89.6 112.7 2.3   204.6 
Beclometasone Inhaler 
100ug/dose 









Salbutamol 200ug rotacaps 16.8 0.2 0.3   17.2 
Salbutamol respirator solution 
0.5% 10ml bottle 
2.8 1.9 0.2   4.9 
Anti-cancer medicines           
Tamoxifen 20mg tab 14.7 7.9 0.8   23.4 
Letrozole 2.5mg tab 3.0 0.8 0.5   4.2 
Total 16,836.5 11,296.2 1,978.5 8.1 30,119.3 
% of total volume purchase  55.9% 37.5% 6.6% 0.03%  
 
Among CVD medicines, the calcium channel blocker nifedipine 20mg, and 
diuretics furosemide 40mg and hydrochlorothiazide 50mg had the highest volume of 
consumption (6,519.3, 3,868 and 3,853.2 DDDs in 1000s respectively). Among 
antidiabetic medicines, glibenclamide 5mg and metformin 500mg were consumed the 
most (3,152.3 and 1,240.3 DDDs in 1000s respectively). Salbutamol inhaler 100ug/dose 
was the most commonly consumed asthma medicine, followed by budesonide inhaler 
100ug/dose (863.9 and 204.6 DDDs in 1000s respectively). For almost all the medicines, 
public sector consumption was much higher compared to non-profit institutions with the 
total volume of consumption in the public sector being 16,836.5 DDDs in 1000s, 
compared to 11,296.2 among non-profit providers. Private facilities consumed the least 
volume.   
Table 4.7 shows the three most highly consumed from each disease category by 
county, while Annex 4.1 presents the total DDDs (in 1000s) of each medicine by county 






Table 4.7: Consumption of study medicines (DDDs per 1000 patients) by county between 
October 2014 and June 2018 (includes Novartis Access brands) 
 
   Total DDDs purchased (in 1000s) purchased between October 2014 























































CVD Medicines                 
Nifedipine 20mg tab 1264.7 550.0 483.3 2810.7 284.0 982.7 48.0 96.0 
Frusemide 40mg tab 449.0 515.0 772.0 683.0 197.0 1058.0 71.0 123.0 
Hydrochlorothiazide 
50mg tab 
1222.8 537.2 321.6 561.8 151.2 1021.2 24.6 12.8 
Medicines for 
Diabetes 
                
Glibenclamide 5mg 
tab 
808.1 243.0 92.4 627.9 63.2 1280.9 9.1 27.7 
Metformin 500mg 
tab 
418.6 76.8 21.7 201.8 39.1 462.7 6.4 13.2 
Pioglitazone 30mg 
tab 
64.1   6.6 7.8 2.3 149.3     
Medicines for 
Asthma 
                
Salbutamol Inhaler 
100ug/dose  
217.4 50.5 48.9 88.1 24.9 330.6 13.4 90.3 
Budesonide Inhaler 
200ug/dose 
105.8 5.3 0.8 36.6 4.4 42.8 2.3 6.8 
Beclometasone 
Inhaler 100ug/dose 
21.1 2.0 13.5 40.5 5.0 74.7 8.6 33.0 
Cancer medicines                 
Tamoxifen 20mg tab 1.8 6.2 0.3 5.4 0.2 9.5     
Letrozole 2.5mg tab 0.5         3.8     
Total 4,573.9 1986 1,761.1 5,063.6 771.3 5,416.2 183.4 402.8 
1 Intervention counties    
Volume of consumption by level of care are presented in Annex 4.2. Level 4 
facilities consumed the highest volume for many of these NCD medicines followed by 
Level 2. However, this should be interpreted with caution since there were several county 




General purchasing trends and the Essential Medicines List: Overall, the volume 
of non-EML medicines consumed as a fraction of total consumption was small (1.2%), 
with the majority of these non-EML consumptions being Novartis Access medicines. 
These include bisoprolol 5mg, glimepiride 1mg and 4mg, valsartan 160mg and 
vildagliptin 80mg. Tables 4.8a and 4.8b present the volumes of consumption of non-EML 
medicines by provider type and by county respectively. Pioglitazone 80mg was the only 
non-Novartis Access brand consumed while glimepiride 2mg and valsartan 80mg 
purchases were both a mix of Novartis Access brand and non-Novartis Access brands. It 
is also worth noting, among these eight medicines, pioglitazone had the highest volume 
of consumption (230 DDD in 1000s) and was consumed in the highest number of 
counties (five counties). In addition to health facilities, the county governments in each of 
these five counties were also direct purchasers of pioglitazone from MEDs. Though 
fewer in number, private facilities consumed the highest volume of pioglitazone. In terms 
of absolute volume of consumption, the public sector consumed more followed by the 
private sector (157.2 vs. 113.5 DDDs in 1000s respectively). The non-profit sector 
purchased the least volume. However expressing these volumes as a proportion of total 
consumption by each provider shows that consumption by the private sector is relatively 








Table 4.8a Volume of consumption (in DDDs per 1000 patients) of non-EML medicines 




Private Total  
Pioglitazone 30mg tab 68.4 59.6 102.1 230.0 
Glimepiride 2mg tab 36.9 29.7 2.8 69.4 
Vildagliptin 50mg 17.2 4.4 0.6 22.2 
Valsartan 80mg tab 16.8 3.4 1.7 21.8 
Valsartan 160mg tab 17.9 1.1 2.7 21.7 
Glimepiride 4mg tab 0.0 0.9 3.2 4.1 
Bisoprolol 5mg tab       0.0 0.2 0.3 0.5 
Glimepiride 1mg tab 0.0 0.0 0.1 0.1 
Total  157.2 99.3 113.5 369.9 
% of total consumption by provider 0.9% 0.9% 5.7% 1.2% 
 
There were county variations in the consumption of non-EML medicines. In 
absolute numbers, Nyeri purchased the highest volume, far more than any other county 
(280.8 DDDs in 1000s).  
Table 4.8b Volume of consumption (DDDs in 1000s) of non-EML medicines by county  
Medicine Embu Kwale Makueni Narok Nyeri 
Pioglitazone 30mg tab 64.1 7 7.8 2.3 149.3 
Glimepiride 2mg tab 2.0 0.0 0.0 1.1 66.4 
Vildagliptin 50mg 0.3 2 0.0 0.8 18.7 
Valsartan 80mg tab 0.0 0.0 0.0 0.1 21.7 
Valsartan 160mg tab 0.0 0.0 0.0 0.0 21.7 
Glimepiride 4mg tab 1.3 0.0 0.0 0.4 2.5 
Bisoprolol 5mg tab 0.0 0.0 0.0 0.0 0.5 
Glimepiride 1mg tab 0.0 0.0 0.0 0.0 0.1 
Total 67.6 9 7.8 4.7 280.8 





Embu consumed the second highest volume (67.6 DDDs in 1000s) while Narok 
consumed the least (4.7 DDDs in 1000s). The same trend was observed when the 
consumption of non-EML medicines is expressed as a proportion of total medicine 
consumption in each county. There was no consumption of non-EML medicines in 
Kakamega, Samburu and West Pokot.  










The lowest level of care, level 2 facilities consumed the highest volume of 
pioglitazone. Table 4.8c shows the volume of consumption of non-EML medicines by 
level of care. Both in absolute volume and as a proportion of overall consumption, level 2 
facilities consumed more than the other levels of care (74.3 DDDs in 1000s, and 1.7% 
respectively) except for level 5 facilities which consumed 77.5 DDDs in 1000s 
representing 2.3% of total volume of medicines consumption by level 5 facilities. 
Proportion of facilities consuming non-EML medicines: The consumption of non-
EML medicines was common across all levels of care. Annex 4.4 shows the number (and 
Medicine Level 2 Level 3 Level 4 Level 5 
Bisoprolol 5mg tab 0.0 0.0 0.0 0.2 
Glimepiride 1mg tab 0.0 0.0 0.0 0.0 
Glimepiride 2mg tab 0.0 0.0 2.2 27.8 
Glimepiride 4mg tab 0.4 0.0 1.3 0.0 
Pioglitazone 30mg tab 73.8 1.4 18.0 41.1 
Valsartan 160mg tab 0.0 0.0 0.0 1.1 
Valsartan 80mg tab 0.0 0.0 0.1 3.4 
Vildagliptin 50mg 0.1 0.0 0.3 4.1 
Total 74.3 1.4 21.8 77.5 
% of total medicine 
consumption by level of 
care 




proportion) of facilities purchasing medicines they are not expected to purchase based on 
the EML. Out of the 31 study medicines not allowed at levels 2, and 3 facilities, 26 and 
20 were respectively consumed by these facilities during the study period. All of the eight 
medicines not expected to be available at level 4 and 5 facilities were consumed by at 
least one of these facilities. In some cases, the proportion of facilities consuming these 
medicines were very high. For example, 78% (63/81) of level 2 facilities purchased 
Metformin 500mg which is in the EML, but is restricted to levels 4 and above; 65% (13) 
of level 3 facilities purchased glibenclamide 5mg, which is restricted by the EML to 
levels 4 and above and 27% (8) of level 4 facilities purchased pioglitazone which is not 
on the EML at all.  
5. DISCUSSION 
This study analyzed the effects of a pricing scheme program (Novartis Access) on the 
consumption patterns of generic and therapeutically equivalent NCD medicines and 
medicines not listed in the EML in eight counties Kenya using wholesaler data. The study 
contributes to the evidence base on the intended and unintended consequences of pricing 
schemes on medicines consumption. The findings of this study also contribute to our 
understanding of the feasibility to use wholesaler data to study the effects of access 
interventions.   
5.1 Impact of Novartis Access on consumption of generic and therapeutic equivalent 
medicines 
The introduction of Novartis Access had no significant overall effect on the 




Access significantly decreased the trend of consumption of amlodipine by 23.57 DDDs in 
1000s per quarter (p=0.0121). There was no effect on the other two generic equivalents – 
metformin and salbutamol. Neither was there any effect of Novartis Access on 
therapeutic alternatives. As reported in other studies, the introduction of new medicines 
or policies influence the consumption patterns of competitor medicines already on the 
market. (33,41,43–45). In many of these cases, the introduction of a new medicine 
resulted in a decrease in the consumption of equivalent medicines, while policies 
restricting the use of an old medicine resulted in an increase in consumption of equivalent 
medicines. A couple of factors may explain why the introduction of Novartis Access 
medicines did not reduce the consumption of generic equivalents (with the exception of a 
decrease in trend in the consumption of amlodipine). Even though Novartis Access is a 
pricing scheme to improve access to medicines, the actual wholesale price of Novartis 
Access medicines tended to be higher than the corresponding prices of generic 
equivalents. For example, the price of 60 tablets of Novartis Access metformin (151 
KES) was slightly higher than the price of its generic equivalent (76 to 114 KES) (46,47). 
With the reputation of MEDS as an institution that sells quality products, providers were 
likely to purchase the cheapest brand with confidence that it is still an effective product 
(10). There were also limited promotion of Novartis Access products to health facilities, 
partly because MEDS does not engage in the promotion of medicines. Finally, it is also 
possible that the one-year study duration was too short for the Novartis Access 
intervention to have significant effects on consumption patterns. These reasons may also 




5.2 Impact of Novartis Access on the consumption of non-EML medicines 
Even though there were increases in level (12.41 DDDs in 1000s) and trend (1.18 
DDDs in 1000s per quarter) of consumption of non-EML medicines upon the 
introduction of Novartis Access, these increases were not statistically significant. None 
the less, six of the medicines in the Novartis Access basket were not in the EML. These 
included bisoprolol 5mg, glimepiride 1mg and 4mg, valsartan 80 and 160mg and 
vildagliptin 80mg. These medicines represent 43% of the 14 Novartis Access medicine 
formulations available at MEDS during the study period. Glimepiride, valsartan and 
vildagliptin are not even in listed in the 2017 edition of the WHO Model EML, which 
countries use as a guide in developing their national EMLs (48). With the limited effect 
of Novartis Access even on medicines on the EML (e.g. amlodipine, metformin and 
salbutamol) it makes sense that the program did not have any significant effect on the 
consumption of non-EML medicines.  
One can also say that the Novartis Access program was weak in focusing on the 
priority needs of the recipient country. One factor that may make it challenging to align 
access initiatives with the EML in the case of Kenya, is the inconsistency between the 
medicines in the EML and the Standard Treatment Guidelines (STGs). With the 
exception of vildagliptin, all of the six Novartis Access medicine formulations that are not 
in the EML are in the STGs (14,15,49,50). The infrequent update of the EML and STGs 
in countries may also pose a challenge to aligning access initiatives to the contents of 
these documents. However, this challenge does not apply to Kenya since there was an 




the EML is out of date, companies can rely on the WHO Model EML, which is updated 
more frequently (48,51,52) 
The WHO Guidelines for Medicine Donations stipulates that donations should be 
relevant to the disease pattern in the recipient country (4). Furthermore, the guidelines 
recommend all donated medicines to be on the EML of the recipient country, or at least 
on the WHO Model EML if the national EML is not available. Similar to these donation 
guidelines, pricing schemes to improve access to medicines for high burden diseases 
should also ensure that the targeted lower cost medicines are consistent with national 
policies and are among the priority medicines of recipient countries.  
The Access to Medicines Index, ranks pharmaceutical companies based on their 
access to medicines initiatives (5). One of the areas the Index considers in its rankings is 
“equitable pricing”: “Companies are expected to apply equitable pricing strategies to a 
comparatively large proportion of their products, and in a comparatively large proportion 
of countries where disease burdens and inequalities are high” (5). This definition does not 
take into account whether the equitable pricing is applied to the priority medicines in 
recipient countries. More incentives are needed to ensure that pharmaceutical industries 
focus their access to medicines initiatives on the priority medicines of recipient countries. 
Focusing these initiatives on priority medicines is likely to promote rational use, and 
make these initiatives more sustainable.  
5.3 Overall consumption patterns  
The sales data provided descriptive information on the volume of consumption by 




public sector consumed more volumes compared to the non-profit sector. This is because 
MEDS initial mission was to serve faith-based hospitals, but it has now become a major 
supplier of public facilities as well.  
Another important observation is that consumption patterns seem to match the 
reported prevalence across counties. For example, Narok, Samburu and West Pokot, the 
three counties that purchased the least volumes of the study medicines had also been 
determined to have the lowest prevalence of diagnosis and treatment of hypertension, 
diabetes and asthma (3% in Narok, and 4% each in Samburu, and West Pokot) (53). 
Embu, Makueni, and Nyeri which consumed the highest volumes of these NCD 
medicines were also reported to have relatively higher prevalence of diagnosis and 
treatment of these NCDs (20%, 24% and 29% respectively). Among the study counties, 
Narok had the highest prevalence of diagnosis and treatment for hypertension, diabetes 
and asthma (30%) (53). However, Narok was the fifth largest purchaser of study 
medicines among the study counties. While this may indicate a treatment gap, it may also 
be due to the fact that facilities and the county government of Narok obtained their 
medicines from other wholesalers such as KEMSA.   
5.4 Consumption patterns and the Essential Medicines List 
There were two important observations regarding how medicine consumption 
patterns align with the EML. First, consumption of medicine that are not in the EML 
were relatively small compared to the total volumes of medicine consumption. However, 
non-EML medicines were consumed by all provider types, at all levels of care and by 




and 3) consumed medicines restricted to levels 4 and above in the EML. Each of these 
findings is discussed below.  
Though in relatively small in volume, the consumption of non-EML medicines 
was widespread across all facility types and levels of care in study counties. Prominent 
among these medicines was pioglitazone 80mg, which was consumed in unexpectedly 
large quantities in five counties by all types of providers and facilities at all levels of care. 
It is also very surprising that level 2 facilities consumed the highest volume of 
pioglitazone compared to levels 3, 4 and 5. This shows non-compliance to the EML and 
may compromise rational use of medicines. The proportion of total medicine 
consumption constituted by these medicines is highest in the private sector, an indication 
that the EML usually guides procurement in the public and non-profit sectors. The 
consumption of these medicines was also highest in Nyeri and Embu counties, with 
consumption in Nyeri more than four times the volume of consumption in Embu (280.8 
vs. 67.6 DDDs in 1000s). It is not clear to what extent the devolution of the health care 
system has contributed to this trend. The national government has the mandate of 
developing and enforcing standards such as the EML (11). However, enforcing these 
standards in a devolved governance system may be challenging especially if there are no 
incentives for counties and health facilities to comply.  
A high proportion of lower level facilities stocked medicines that were assigned 
level 4 and above in the EML. Even though this represents non-compliance with the 
EML, it may also be an indication of a high and unmet demand for NCD medicines at 




interventions such as reviewing the EML to assign NCD medicines to lower levels of 
care combined with providing appropriate training of staff to use these new medicines.    
5.5 Strengths and limitations 
This study utilized a controlled interrupted time series analysis of procurement 
data to examine medicine utilization patterns for NCDs. Comparing patterns in Novartis 
Access intervention counties with control counties may have controlled for external 
factors that could influence consumption patterns e.g. population and economic growth, 
staff going on strike etc. There were no data on stock-outs of study medicines at MEDS 
which could have also influenced consumption patterns. However, previous studies have 
reported limited stock-outs of NCD medicines at MEDS (54). Additionally, it was 
assumed that medicines purchased at MEDS were actually dispensed to patients. Events 
such as expiry and pilferage of medicines at the facility level may however invalidate this 
assumption.  
6. CONCLUSION 
This study has generated useful evidence on the overall consumption patterns of NCD 
medicines in Kenya, and how these patterns were influenced by the Novartis Access 
program.  
The introduction of Novartis Access statistically significantly decreased the trend of 
generic amlodipine consumption. No other statistically significant effect on the level and 
trend of consumption of other generic and therapeutic equivalents of Novartis Access 




prices of some Novartis Access medicines and the limited promotion of Novartis Access.  
Though the Mission for Essential Drugs and Supplies (MEDS) was set up initially to 
supply medicines to non-profit facilities, it has grown to become a major supplier of 
public facilities as well. Generally, the relative consumption patterns among study 
counties are consistent with their disease burden. Consumption patterns were not always 
consistent with the EML especially with the antidiabetic, pioglitazone. More steps need 
to be taken to encourage access to medicines programs by industry to target priority 
medicines of recipient counties. This will promote appropriate use and sustainability of 
these initiatives. Regular update of the EML to take account of therapeutic advances may 






1. Rockers PC, Wirtz VJ, Vian T, Onyango MA, Ashigbie PG, Laing R. Study protocol 
for a cluster-randomised controlled trial of an NCD access to medicines initiative: 
evaluation of Novartis Access in Kenya. BMJ Open. 2016 Nov 1;6(11):e013386.  
 
2. Novartis launches “Novartis Access”, a portfolio of affordable medicines to treat 




3. Rockers PC, Wirtz VJ, Umeh CA, Swamy PM, Laing RO. Industry-Led Access-To-
Medicines Initiatives In Low- And Middle-Income Countries: Strategies And Evidence. 
Health Aff (Millwood). 2017 01;36(4):706–13.  
 
4. Guidelines for Medicine Donations - Revised 2010 [Internet]. World Health 




5. Access to Medicine Index 2018: Methodology 2017 [Internet]. Access to Medicines 




6. Rockers PC, Wirtz VJ, Vian T, Onyango MA, Ashigbie PG, Laing R. Study protocol 
for a cluster-randomised controlled trial of an NCD access to medicines initiative: 
evaluation of Novartis Access in Kenya. BMJ Open [Internet]. 2016 Nov 25 [cited 2017 
Jun 1];6(11). Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5168521/ 
 
7. Rockers PC, Laing RO, Ashigbie PG, Onyango MA, Wirtz VJ. Impact of Novartis 
Access on availability and price of non-communicable disease medicines in Kenya: A 
cluster-randomised controlled trial. Yet Publ.  
 
8. Syed N, Rockers PC, Vian T, Onyango M, Laing RO, Wirtz VJ. Access to 
Antihypertensive Medicines at the Household Level: A Study From 8 Counties of Kenya. 
Glob Heart [Internet]. 2018 Sep 20 [cited 2018 Oct 24]; Available from: 
http://www.sciencedirect.com/science/article/pii/S2211816018301340 
 
9. Ashigbie PG, Rockers PC, Laing RO, Cabral H, Siyoi F, Wirtz VJ. Availability and 
price of medicines for acute and chronic diseases in health facilities and retail drug 
outlets in eight counties in Kenya. [Boston, Massachusetts]: Boston University School of 





10. Muhia J, Waithera L, Songole R. Factors Affecting the Procurement of 
Pharmaceutical Drugs: A Case Study of Narok County Referral Hospital, Kenya. Med 





11. Kenya health policy 2014-2030 - Towards attaining the highest standard in health 
[Internet]. Ministry of Health; 2014 [cited 2016 Sep 16]. Available from: 
https://www.afidep.org/?wpfb_dl=80 
 
12. Mutwiri M. Mission for Essential Drugs and Supplies, Personal communication. 
2018.  
 
13. Kariuki J, Njeru MK, Wamae W, Mackintosh M. Local Supply Chains for Medicines 
and Medical Supplies in Kenya: Understanding the Challenges. Afr Cent Technol Stud 
Incl Biotechnol Ser No 0012015. 2015 Aug;30.  
 
14. Kenya Essential Medicines List 2010 [Internet]. Ministry of Medical Services and 
Ministry of Public Health & Sanitation; 2010 [cited 2017 Dec 1]. Available from: 
http://apps.who.int/medicinedocs/documents/s18694en/s18694en.pdf 
 
15. Kenya Essential Medicines List 2016 Edition. Ministry of Health, Republic of Kenya; 
2016.  
 
16. Model List of Essential Medicines - 19th Edition [Internet]. WHO; 2015 [cited 2016 




17. Li Y, Ying C, Sufang G, Brant P, Bin L, Hipgrave D. Evaluation, in three provinces, 
of the introduction and impact of China’s National Essential Medicines Scheme. Bull 
World Health Organ. 2013 Mar;91:184–94. 
  
18. Mission for Essential Drugs and Supplies. Our History. [cited 2016 Oct 22]; 
Available from: http://www.meds.or.ke/index.php/about/our-history 
 
19. WHO list of prequalified quality control laboratories [Internet]. World Health 
Organization; 2018 [cited 2018 Nov 18]. Available from: 
https://extranet.who.int/prequal/sites/default/files/documents/PQ_QCLabsList_26.pdf 
 
20. 2015 Annual report and financial statements. Mission for Essential Drugs and 





21. Dukes MNG, World Health Organization, editors. Drug utilization studies: methods 
and uses. Copenhagen: World Health Organization, Regional Office for Europe; 1993. 
218 p. (WHO regional publications).  
 
22. Shalini S, Ravichandran V, Mhanty B, Dhanaraj S, Saraswathi R. Drug Utilization 
Studies - An Overview. Int J Pharm Sci Nanotechnol [Internet]. 2010 Jun [cited 2018 Sep 
27];3(1). Available from: http://ijpsnonline.com/Issues/803_full.pdf 
 
23. Introduction to Drug Utilization Research [Internet]. WHO 2003; 2003 [cited 2018 
Sep 27]. Available from: http://apps.who.int/medicinedocs/pdf/s4876e/s4876e.pdf 
 
24. Bachhav SS, Kshirsagar NA. Systematic review of drug utilization studies & the use 
of the drug classification system in the WHO-SEARO Region. Indian J Med Res. 2015 
Aug;142(2):120–9.  
 
25. Cheraghali AM, Idries AM. Availability, affordability, and prescribing pattern of 
medicines in Sudan. Pharm World Sci. 2009 Apr 1;31(2):209–15. 
  
26. Sanda-Ana-Tellez Y, Mantel-Teeuwisse AK, Lufkens HGM, Wirtz VJ. Effects of 
over-the-counter sales restriction of antibiotics on substitution with medicines for 
symptoms relief of cold in Mexico and Brazil: time series analysis | Health Policy and 
Planning | Oxford Academic [Internet]. 2016 [cited 2018 Oct 8]. Available from: 
https://academic.oup.com/heapol/article/31/9/1291/2453002 
 
27. Mittal N, Mittal R, Singh I, Shafiq N, Malhotra S. Drug Utilisation Study in a 
Tertiary Care Center: Recommendations for Improving Hospital Drug Dispensing 
Policies. Indian J Pharm Sci. 2014;76(4):308–14. 
  
28. Thiam S, Thior M, Faye B, Ndiop M, Diouf ML, Diouf MB, et al. Major Reduction 
in Anti-Malarial Drug Consumption in Senegal after Nation-Wide Introduction of 
Malaria Rapid Diagnostic Tests. Pied S, editor. PLoS ONE. 2011 Apr 6;6(4):e18419.  
 
29. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, et al. Use of 
secondary prevention drugs for cardiovascular disease in the community in high-income, 
middle-income, and low-income countries (the PURE Study): a prospective 
epidemiological survey. The Lancet. 2011 Oct 1;378(9798):1231–43. 
  
30. Cameron A, Roubos I, Ewen M, Mantel-Teeuwisse AK, Leufkens HG, Laing RO. 
Differences in the availability of medicines for chronic and acute conditions in the public 
and private sectors of developing countries. Bull World Health Organ. 2011 Jun 
1;89(6):412. 
  
31. Access Observatory. Access Observatory 2018 Report Results and Reflections on 




US: Boston University; 2018 [cited 2018 Sep 27]. Available from: 
https://www.accessobservatory.org 
 
32. Ivers NM, Halperin IJ, Barnsley J, Grimshaw JM, Shah BR, Tu K, et al. Allocation 
techniques for balance at baseline in cluster randomized trials: a methodological review. 
Trials. 2012 Dec;13(1):120. 
  
33. Santa-Ana-Tellez Y, Mantel-Teeuwisse AK, Leufkens HGM, Wirtz VJ. Effects of 
over-the-counter sales restriction of antibiotics on substitution with medicines for 
symptoms relief of cold in Mexico and Brazil: time series analysis. Health Policy Plan. 
2016 Nov;31(9):1291–6.  
 
34. WHOCC - Definition and general considerations [Internet]. WHO Collaborating 
Center for Drug Statistics Methodology. 2016 [cited 2016 Dec 4]. Available from: 
https://www.whocc.no/ddd/definition_and_general_considera/ 
 
35. Ministry of Health, Kenya. Kenya Master Health Facility List [Internet]. 2016 [cited 
2018 Oct 6]. Available from: http://kmhfl.health.go.ke/#/facility_filter/results 
 
36. Boston University. Evaluation of Novartis Access in Kenya [Dataset] [Internet]. 




37. [SAS/STAT] software [Internet]. Cary, NC USA: SAS Institute Inc.; 2002. Available 
from: https://www.sas.com/ 
 
38. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis 
of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002 
Aug 1;27(4):299–309.  
39. Santa-Ana-Tellez Y, Mantel-Teeuwisse AK, Dreser A, Leufkens HGM, Wirtz VJ. 
Impact of Over-the-Counter Restrictions on Antibiotic Consumption in Brazil and 
Mexico. Fredricks DN, editor. PLoS ONE. 2013 Oct 16;8(10):e75550.  
 
40. SAS Institute Inc. . SAS/ETS® 13.2. User’s Guide, The Autoreg Procedure. Cary NC 
SAS Inst Inc. 2014;164.  
 
41. Interrupted time-series analysis yielded an effect estimate concordant with the cluster-







42. ATC/DDD Index Structure and principles [Internet]. WHO Collaborating Center for 
Drug Statistics and Methodology; 2018 [cited 2018 Oct 18]. Available from: 
https://www.whocc.no/atc/structure_and_principles/ 
 
43. Rational Prescribing in Primary Care (RaPP): A Cluster Randomized Trial of a 
Tailored Intervention [Internet]. [cited 2018 Oct 12]. Available from: 
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0030134 
 
44. Signorovitch J, Birnbaum H, Ben-Hamadi R, Yu AP, Kidolezi Y, Kelley D, et al. 
Increased Olanzapine Discontinuation and Health Care Resource Utilization Following a 
Medicaid Policy Change. J Clin Psychiatry. 2011 Jan 25;72(6):787–94.  
 
45. Consequences of the 1989 New York State Triplicate Benzodiazepine Prescription 
Regulations | JAMA | JAMA Network [Internet]. [cited 2018 Oct 12]. Available from: 
https://jamanetwork-com.ezproxy.bu.edu/journals/jama/fullarticle/392990 
 
46. Indicative Prices Effective 1st January 2017. Mission for Essential Drugs and 
Supplies; 2017.  
 
47. Mission for Essential Drugs and Supplies. Sales Data [Dataset],. Nairobi, Mission for 
Essential Drugs and Supplies; 2018.  
 
48. WHO Model List of Essential Medicines, 20th List [Internet]. WHO; 2017 [cited 
2018 May 4]. Available from: 
http://www.who.int/medicines/publications/essentialmedicines/20th_EML2017.pdf?ua=1 
 
49. Protocol for the identification and management of hypertension in adults in primary 




50. National Clinical Guidelines for the Management of Diabetes Mellitus [Internet]. 





51. Laing R, Waning B, Gray A, Ford N, ’t Hoen E. 25 years of the WHO essential 
medicines lists: progress and challenges. The Lancet. 2003 May 17;361(9370):1723–9.  
 
52. 19th WHO Model List of Essential Medicines [Internet]. World Health Organization; 






53. Laing R, Wirtz VJ, Rockers PC, Onyango MA, Ashigbie PG. Baseline results of 
evaluation of Novartis Access. Boton: Boton University School of Public Health; Jun 20, 
2017.  
 
54. Ministry of Health, Ministry of Public Health and Sanitation. Access to Essential 
Medicines in Kenya - A Health Facility Survey [Internet]. 2009 [cited 2016 Nov 13]. 































































CVD Medicines                 
Nifedipine 20mg tab 1264.7 550.0 483.3 2810.7 284.0 982.7 48.0 96.0 
Frusemide 40mg tab 449.0 515.0 772.0 683.0 197.0 1058.0 71.0 123.0 
Hydrochlorothiazide 
50mg tab 
1222.8 537.2 321.6 561.8 151.2 1021.2 24.6 12.8 
Enalapril 5mg tab 515.4 114.2 45.8 703.1 103.0 492.0 14.6 36.0 
Atorvastatin 20mg tab 219.1 46.6 203.4 398.8 27.6 921.7 4.6 2.9 
Losartan 50mg tab 337.8 132.6 44.6 346.0 17.5 643.0 8.5 32.9 
Amlodipine 5mg tab 123.6 120.6 92.8 111.5 33.3 1002.5 3.8 22.8 
Atenolol 50mg tab 147.4 48.5 131.0 157.8 56.5 718.1 21.1 8.1 
Spironolactone 25mg tab 69.3 22.7 21.0 103.0 8.0 137.3 7.7 8.3 
Digoxin 0.25mg tab 95.0 20.0 16.5 23.0 17.5 158.5 9.5 9.0 
Amlodipine 10mg tab 4.0 8.0 32.6   2.0 157.8   53.6 
Hydralazine 25mg tab 8.3 3.6 1.9 9.4 0.8 98.6 0.6 0.8 
Propranolol 40mg tab 12.3 4.5 6.2 43.0 4.9 28.1 0.7 0.0 
Methyldopa 250mg tab 11.1 2.5 17.6 24.9 5.9 21.4 4.0 3.1 
Carvedilol 12.5mg tab 1.5 2.9 4.9 23.6 0.9 19.9 0.0 1.9 
Valsartan 80mg tab         0.1 21.7     
Valsartan 160mg tab           21.7     
Isosorbide dinitrate 10mg 
tab 
0.8 0.3 0.0 0.4 0.0 1.0 0.0   
Bisoprolol 5mg tab           0.5     
Medicines for Diabetes                 
Glibenclamide 5mg tab 808.1 243.0 92.4 627.9 63.2 1280.9 9.1 27.7 
Metformin 500mg tab 418.6 76.8 21.7 201.8 39.1 462.7 6.4 13.2 
Pioglitazone 30mg tab 64.1   6.6 7.8 2.3 149.3     
Gliclazide 80mg 4.0   2.6 4.1 0.7 133.6   0.4 
Metformin 1000mg tab 8.7 9.0 6.6 4.8   44.0   13.8 
Glimepiride 2mg tab 2.0       1.1 66.4     
Vildagliptin 50mg 0.3   2.4   0.8 18.7     
Glimepiride 4mg tab 1.3       0.4 2.5     

























































Medicines for Asthma                 
Salbutamol Inhaler 
100ug/dose  
217.4 50.5 48.9 88.1 24.9 330.6 13.4 90.3 
Budesonide Inhaler 
200ug/dose 
105.8 5.3 0.8 36.6 4.4 42.8 2.3 6.8 
Beclometasone Inhaler 
100ug/dose 
21.1 2.0 13.5 40.5 5.0 74.7 8.6 33.0 
Salbutamol 200ug 
rotacaps 
0.2     3.2   12.9 0.3 0.6 
Salbutamol respirator soln 
0.5% 10ml Bottle 
1.3 0.3 0.2 0.8 0.3 1.7 0.1 0.1 
Cancer medicines                 
Tamoxifen 20mg tab 1.8 6.2 0.3 5.4 0.2 9.5     
Letrozole 2.5mg tab 0.5         3.8     






Annex 4.2: Consumption of medicines (DDDs in 1000s) by level of care 
 
Medicines Level 2 Level 3 Level 4 Level 5 
Medicines for CVD         
Nifedipine 20mg tab 575.3 80.7 1395.3 308.7 
Frusemide 40mg tab 192.0 34.0 599.0 322.0 
Hydrochlorothiazide 50mg tab 736.8 65.8 1370.8 722.0 
Enalapril 5mg tab 279.1 14.5 412.0 172.0 
Atorvastatin 20mg tab 191.4 7.6 168.2 367.2 
Losartan 50mg tab 324.3 7.1 396.5 180.7 
Amlodipine 5mg tab 216.5 3.9 239.2 426.2 
Atenolol 50mg tab 301.3 2.6 334.0 101.0 
Spironolactone 25mg tab 15.0 2.3 66.7 67.7 
Digoxin 0.25mg tab 10.5 4.5 89.5 70.0 
Amlodipine 10mg tab 1.4 2.0 12.0 60.0 
Hydralazine 25mg tab 11.0 0.6 39.5 30.0 
Propranolol 40mg tab 27.1 3.5 18.3 3.0 
Methyldopa 250mg tab 5.5 1.3 7.1 3.1 
Carvedilol 12.5mg tab 11.3  1.6 2.5 
Valsartan 80mg tab   0.1 3.4 
Valsartan 160mg tab    1.1 
Isosorbide dinitrate 10mg tab 0.3  0.3 1.1 
Bisoprolol 5mg tab    0.2 
Anti-diabetics     
Glibenclamide 5mg tab 916.9 23.5 650.2 206.3 
Metformin 500mg tab 463.5 9.5 301.3 187.6 
Pioglitazone 30mg tab 73.8 1.4 18.0 41.1 
Gliclazide 80mg 5.0 2.2 1.8 2.6 
Metformin 1000mg tab 0.6 0.1 20.7 23.1 
Glimepiride 2mg tab   2.2 27.8 
Vildagliptin 50mg 0.1  0.3 4.1 
Glimepiride 4mg tab 0.4  1.3  
Glimepiride 1mg tab   0.0  
Anti-asthmatics     
Salbutamol Inhaler 100ug/dose  119.2 11.4 269.9 50.4 
Budesonide Inhaler 200ug/dose 5.9 0.2 89.9 33.7 
Beclometasone Inhaler 100ug/dose 13.0 0.3 43.0 4.6 
Salbutamol 200ug rotacaps 0.3 0.1   




Medicines Level 2 Level 3 Level 4 Level 5 
Anti-cancer medicines     
Tamoxifen 20mg tab 2.0  6.5 0.2 
Letrozole 2.5mg tab 0.8  0.3 0.2 







Annex 4.3: Consumption of Novartis Access medicines and their generic and therapeutic 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Annex 4.4 Proportions of facilities that purchased medicines they are not supposed 














CVD Medicines         
Amlodipine 10mg tab 2 (2.5) 1 (5) - - 
Amlodipine 5mg tab 35 (43.2) 6 (30) - - 
Atenolol 50mg tab 46 (56.8) 10 (50) - - 
Atorvastatin 20mg tab 27 (33.3) 10 (50) - - 
Bisoprolol 5mg tab 0 (0) 0 (0) 0 (0) 1 (25) 
Carvedilol 12.5mg tab 8 (9.9) 0 (0) - - 
Digoxin 0.25mg tab 9 (11.1) 5 (25) - - 
Enalapril 5mg tab 54 (66.7) 9 (45) - - 
Frusemide 40mg tab 51 (63) 10 (50) - - 
Hydralazine 25mg tab 27 (33.3) 5 (25) - - 
Hydrochlorothiazide 50mg tab 42 (51.9) 6 (30) 14 (48.3) 3 (75) 
Isosorbide dinitrate 10mg tab 6 (7.4) 0 (0) - - 
Losartan 50mg tab 36 (44.4) 7 (35) - - 
Methyldopa 250mg tab 13 (16) 5 (25) - - 
Nifedipine 20mg tab 62 (76.5) 14 (70) 21 (72.4) 3 (75) 
Propranolol 40mg tab 35 (43.2) 4 (20) - - 
Spironolactone 25mg tab 7 (8.6) 2 (10) - - 
Valsartan 160mg tab 0 (0) 0 (0) 0 (0) 1 (25) 
Valsartan 80mg tab 0 (0) 0 (0) 2 (6.9) 2 (50) 
Anti-diabetics         
Glibenclamide 5mg tab 55 (67.9) 13 (65) - - 
Gliclazide 80mg 8 (9.9) 4 (20) 1 (3.4) 1 (25) 
Glimepiride 1mg tab 0 (0) 0 (0) 1 (3.4) 0 (0) 
Glimepiride 2mg tab 0 (0) 0 (0) 2 (6.9) 2 (50) 
Glimepiride 4mg tab 1 (1.2) 0 (0) 2 (6.9) 0 (0) 
Metformin 1000mg tab 2 (2.5) 1 (5) 4 (13.8) 1 (25) 
Metformin 500mg tab 63 (77.8) 13 (65) - - 
Pioglitazone 30mg tab 7 (8.6) 1 (5) 8 (27.6) 2 (50) 
Vildagliptin 50mg 1 (1.2) 0 (0) 1 (3.4) 1 (25) 
Anti-asthmatics         
Beclometasone Inhaler 100ug/dose - - - - 

















Salbutamol 200ug rotacaps 2 (2.5) 2 (10) 0 (0) 0 (0) 
Salbutamol Inhaler 100ug/dose  - - - - 
Salbutamol respirator soln 0.5% 10ml 
Bottle 
- - - - 
Anti-cancer medicines          
Letrozole 2.5mg tab* 3 (3.7) 0 (0) 1 (3.4) 1 (25) 
Tamoxifen 20mg tab* 8 (9.9) 0 (0) 4 (13.8) 1 (25) 
*Not assigned any level in the EML 





CHAPTER FIVE - GENERAL DISCUSSION 
1. GENERAL DISCUSSION 
This chapter discusses the key findings from the studies presented in Chapters 2, 3 
and 4, and their policy and programmatic implications in terms of access to medicines for 
non-communicable diseases (NCDs) in Kenya and other low- and middle-income 
countries. 
Target 3.4 of the Sustainable Development Goals aims to “by 2030, reduce by one-
third pre-mature mortality from NCDs through prevention and treatment, and promote 
mental health and wellbeing” (1). The three studies in this dissertation examined various 
aspects of access to NCD treatment. Chapter 2 focused on the availability and prices of 
NCD medicines in health facilities in eight counties in Kenya, while Chapter 3 evaluated 
the feasibility of collecting medicine price and availability data through telephone 
interviews compared to in-person interviews, and examined the costs associated with 
each mode of data collection. Finally, Chapter 4 examined the effect of Novartis Access, 
a pricing scheme, on the consumption patterns of generic and therapeutic equivalent 
medicines (using sales data from the Mission for Essential Drugs and Supplies (MEDS) a 
major wholesaler in Kenya). Major lessons can be harnessed from the studies presented 
in these three chapters: 
1. The availability of NCD medicines was generally much lower than the global 
target of 80% across all provider types, with public facilities, in particular primary care 





2. Prices of NCD medicines varied substantially, across and within facilities, 
provider type, level of care and by county. Prices were generally higher among private 
providers compared to public providers. Median price ratios for NCD medicines were 
higher than those for medicines used to treat acute conditions.  
3. More public facilities gave medicines for free compared to non-profit and private 
facilities (47.3%, 9.4% and 0% respectively).  
4. There was widespread non-compliance with the Kenya National Essential 
Medicines List (EML), looking at both the availability of medicines in health facilities 
and consumption trends. The Novartis Access program was not in full alignment with the 
priority medicines of the country (medicines on the EML).  
5. Phone interviews can be a cheaper and more convenient alternative to collect 
reliable data on the availability and price of medicines at health facilities and households. 
Data on the availability and price of medicines collected through telephone interviews 
showed strong validity compared with data collected through in-person interviews 
(Chapter 3).  
6. The implementation of Novartis Access did not have any overall effect on the 
consumption of generic equivalents. Only the generic equivalent, amlodipine experienced 
a statistically significant decrease in trend of consumption (Chapter 4). 
7. Sales data can also be used to measure consumption pattern of medicines as part 




1.1 Low availability of NCD medicines in health facilities 
A comprehensive global monitoring framework (GMF) for the prevention and control 
of NCDs was adopted at the 66th World Health Assembly in 2013 (2). Under this 
framework, Member States of the World Health Organization (WHO) selected 25 
indicators to assess the outcomes, risk factors and efforts of countries to address the 
burden of NCDs. One of these critical indicators was the availability of medicines in 
health facilities. According to the GMF, countries should “by 2025, achieve 80% 
availability of the affordable basic technologies and essential medicines, including 
generics, required to treat major non-communicable diseases in both public and private 
facilities” (2,3). The results in Chapter 2 showed that only 55% of facilities in Kenya had 
essential NCD medicines (medicines included in the EML) available and far less (25%) 
had NCD medicines included in the standard treatment guidelines (STGs) available (the 
STGs contained other medicines in addition to EML medicines). Though availability was 
highest in the private sector (61.7 and 29.3% for EML and STG medicines, respectively), 
it was still much lower than the 80% target. Other studies in Kenya and other low- and 
middle-income countries have also reported suboptimal availability of NCD medicines in 
health facilities compared to medicines for acute conditions (4–8).  
The extremely low availability of NCD medicines in the public sector is particularly 
troubling for two reasons. First, it has been shown that most of the diagnoses for NCDs 
take place in the public sector (9). With the limited availability of medicines in public 
facilities, patients are left on their own to search for their NCD medicines from private 




track of the records of patients as they move between the two types of providers. It is also 
difficult to retain patients in care. It has been shown that initiating treatment immediately 
after diagnosis improves the rate of treatment initiation, retention in care and health 
outcomes of HIV patients (10).  
Secondly, consistent with previous evidence, I found that medicine prices are higher 
in the private sector compared to the public sector in Kenya (11–14). Furthermore, public 
facilities gave medicines for free compared to non-profit and private facilities. Patients 
purchasing NCD medicines from the private sector, whether for-profit or non-profit, may 
incur high out-of-pocket expenditure on medicines, which may affect adherence to 
treatment. The differences in medicines prices across public, non-profit and private drug 
outlets are discussed in more detail under the section on “Variations in medicines prices”. 
I did not examine the reasons for the low availability of NCD medicines in health 
facilities. One important factor that may be contributing to the low availability of NCD 
medicines at lower levels of care is the EML restriction that most NCD medicines should 
only be available at level 4 (county referral) facilities and above. The following section 
discusses how lower-level facilities find it difficult to balance adhering to this EML 
restriction with meeting the demand for NCD medicines in their facilities.  
1.2 The consumption and availability of medicines that are designated to higher 
levels of care (level 4 and above) at lower levels 
One strength of this study was that it evaluated both availability and consumption 
trends by level of care, making it possible to determine the usage of NCD medicines at 




the Kenya EML. The restriction of many basic NCD medicines to higher levels of care 
(level 4 and above), is not unique to Kenya; other low- and middle-income countries have 
similar restrictions (15,16). The goal for restricting medicines such as those for NCDs to 
higher levels of care is to ensure their appropriate use, since there are more skilled staff to 
provide the needed pharmaceutical care at higher levels of care. However, restricting 
basic medicines for hypertension, diabetes and asthma to higher levels of care may 
compromise access to these medicines that are used lifelong.  
From the study presented in Chapter 2, many of the medicines restricted to levels 4 
and above were found to be available in lower level facilities with the probability of 
levels 2 and 3 facilities having these medicines in stock ranging from 0.13 (for 
amlodipine 5mg) to 0.8 (for omeprazole 20mg). More than half of levels 2 and 3 facilities 
were stocking furosemide 40mg and metformin 500mg. This is consistent with 
consumption patterns from MEDS data (Chapter 4): furosemide 40mg tablets was 
consumed by 63% (51) of level 2 facilities and 50% (10) of level 3 facilities; metformin 
500mg tablets was consumed by 77.8% (63) of level 2 and 65% (13) of level 3 facilities. 
This suggests there is relatively high demand for these NCD medicines at these lower 
level facilities. Lower level care facilities are often closer to their patients and it will be 
challenging to achieve universal health care coverage (UHC) if these basic NCD 
medicines continue to be restricted to higher levels of care. With the increasing burden of 
NCDs, basic NCD medicines should be made available at lower levels of care with 
appropriate training of health staff to ensure their appropriate use. It has been argued that 




care provision at hospital outpatient clinics. For instance, South Africa has moved HIV 
care into primary care, closer to where patients live (17,18). This study shows that the 
current NCD care delivery in Kenya is focused on hospital outpatient clinics; availability 
of NCD medicines were high at hospital level. Providing NCD medicines only at hospital 
level represents a barrier to access.  
Kenya is in the process of implementing UHC, which is also an opportunity to rethink 
the delivery of NCD care (19,20). The Kenya Health Sector Strategic Plan for 2013-2018 
already identifies frequent stock outs as one of the factors affecting quality delivery of 
health services (21). The Kenyan government has also highlighted the area of health 
products and technologies (essential medicines, medical supplies, vaccines, health 
technologies etc.) as one of the eight key action areas in its National Health Policy (22). 
More research (both quantitative and qualitative) is needed to explore the root causes of 
low availability of NCD medicines, especially at the primary care level in the public 
sector, to inform the development of evidenced-based interventions to address this 
challenge. 
1.3 Variations in prices of NCD medicines 
There was high variability in prices of NCD medicines, with prices of the same 
medicine and same manufacturer varying substantially across and within provider type 
and level of care. Several previous studies have shown medicine prices are higher in the 
private sector compared to the public sector (11–14). This study stratified prices not only 
by public and private sectors but also examined the differences between the for-profit 




facilities gave medicines for free compared to non-profit facilities and for-profit drug 
outlets (47.3%, 9.4% and 0% respectively), which means patients are likely to pay more 
for NCD medicines from both for-profit and non-profit providers especially because of 
the low availability of medicines in the public sector. 
Median price ratios for NCD medicines also varied substantially. A study conducted 
by Health Action International (HAI) in Kenya between January and May 2018 found 
very high and variable mark-ups on medicines (23). For example, in the public sector, 
median retail mark-ups were 177% for locally produce medicines and 35% for imported 
medicines. Among faith-based non-profit providers, retail median mark-up was 343% for 
locally produced medicines and 257% for imported products. The HAI study also 
reported wide variations in mark-ups for individual brands of medicines and showed that 
mark-ups are higher in the non-profit sector compared to the public sector. These findings 
are consistent with the findings from our study in which the mean price ratio of 
medicines for non-profit providers (3.61) was higher than the mean price ratio in the 
public sector (2.29) though this difference was not statistically significant. The mean 
price ratio for NCD medicines was significantly higher than the mean price ratio for acute 
medicines in non-profit facilities (4.3 vs. 2.01) and for-profit drug outlets (3.46 vs. 1.66) 
but this was not the case in public facilities. This indicates mark ups might be particularly 
higher on NCD medicines in non-profit and for-profit drug outlets.  
Analysis of MEDS sales data in Chapter 4 shows that facilities and counties may be 
showing a preference for lower priced products. What is not clear is if this low cost is 




even if facilities and counties benefit from low procurement prices, they still add mark-
ups resulting in high patient prices. This is consistent with literature that shows that 
discounts and low wholesale prices are often not passed on to patients (24). Hence, the 
importance of measuring user prices as we did in our study. The Ministry of Health of 
Kenya is in talks with pharmaceutical companies to control medicine prices by placing 
price labels on medicine packages (25). The roll-out of this strategy should be done with 
adequate monitoring to determine the effectiveness of the price labels. In addition to this 
intervention, the government of Kenya should also discuss the implementation of other 
price control strategies that may be appropriate for the country (26,27). As the 
government of Kenya is rolling out UHC price controls especially on medicines is key to 
make UHC sustainable.  
1.4 Non-compliance with the Essential Medicines List 
The goals of National Essential Medicine Policies and national EMLs include 
promoting appropriate use of medicines (good prescribing and dispensing practices, and 
minimizing cost) (28–31). A study in China showed the implementation of an EML 
improved prescribing and dispensing practices, and reduced expenditure on medicines 
(32,33). For the EML to achieve its desired objectives it has to be enforced. The analysis 
of availability data in Chapter 2 and consumption patterns from MEDS in Chapter 4, 
showed that health facilities and counties in Kenya did not always adhere to the EML.  
Consumption of non-EML medicines constituted 1.2% of total sales by volume, with 
the private health facilities consuming more, 5.7% of total consumption by these 




valsartan, (twelve formulations) that were not in the EML were available at all levels of 
care, though with a low probability of availability (ranging from 0.01 to 0.20). 
Availability was higher at private drug outlets which are not mandated to comply with the 
EML. This is consistent with findings from the analysis on consumption patterns (in 
Chapter 4). Health facilities and counties consumed non-EML medicines from MEDS, 
including bisoprolol, glimepiride, pioglitazone, valsartan and vildagliptin (in eight 
formulations). The most commonly purchased was pioglitazone 80mg (purchased in five 
counties by all types of providers and by facilities at all levels of care). Overall, the 
probability of finding non-EML medicines at health facilities was low compared to 
medicines on the EML. Additionally, these medicines constituted a relatively low 
proportion of purchases from MEDS. However, the behavior of not complying with the 
EML was widespread – across counties, levels of care and provider type. For instance, 
13% (18) of levels 2, 3, 4 and 5 facilities purchased pioglitazone which is not on the 
EML. It is possible, that other non-EML medicines that were not surveyed are purchased 
regularly.   
 Research is needed to understand the specific factors that are driving this behavior 
and policies implemented to address them. With the devolution of healthcare, counties 
have flexibility in purchasing their medicines, however, they are expected to follow 
national standards such as the EML (22).  
There is inconsistency between the Kenya EML and the STGs (34–37). Various NCD 
medicines such as bisoprolol, glimepiride, captopril, ramipril, and valsartan which are not 




undermine the implementation of the concept of essential medicines in the country and 
may be one of the factors contributing to the widespread non-compliance with the EML. 
Many countries base their STGs on their national EML, ensuring that the two documents 
are consistent (15,16,38–40). As Kenya implements UHC and a social health insurance 
program (National Health Insurance Fund), the harmonization of these two documents 
has become even more important in standardizing the delivery of quality health care and 
making reimbursement decisions (19,20). 
1.5 Effects of the Novartis Access program  
Novartis Access was launched during the 2015 United Nations General Assembly 
when the SDGs were adopted to highlight their commitment to the SDGs (41).  
Novartis Access is a price scheme offering a basket of 15 NCD medicines at a cost of 
US$1 per month. Little is known how pricing schemes affect the availability and 
affordability of medicines at facility and household level (42). A randomized controlled 
trial has studied the effect of Novartis Access and found no overall impact on the 
availability of portfolio medicines (adjusted β [aβ] 0·05, 95% CI -0·01-0·10) or their 
price (aβ 0·48, CI -1·12-0·72) at the facility level. However, there was a significant 
increase in the availability of amlodipine (adjusted odds ratio 2·84, CI 1·10-7·37) and 
metformin (adjusted odds ratio 4·78, CI 1·44-15·86) (43). At the household level, 
Novartis Access did not have any effect on the availability of medicines. This dissertation 
also focused on the impact of Novartis Access on other effects that have not been studied 
so far: the impact on the consumption of generic and therapeutically equivalent medicines 




The introduction of Novartis Access in Kenya did not affect the overall consumption 
of generic equivalents. The change in level (97.00 DDDs in 1000s) and trend (slope=-
46.64 DDDs in 1000s per quarter) in the consumption of generic equivalents were not 
statistically significant (p=0.3970 and 0.0997 respectively). Amlodipine was the only 
medicine among the generic and therapeutic equivalents of Novartis Access medicines 
that was affected – experiencing a statistically significant decrease of 23.57 DDDs in 
1000s per quarter (p=0.0121) in the trend of consumption. This limited impact of 
Novartis Access may be due to the relatively high prices of Novartis Access medicines. 
Referring to the example of metformin, the price of 60 tablets of Novartis Access 
metformin (151 KES) was slightly higher than the price of its generic equivalents (76 to 
114 KES) (44,45). In other to be effective, price schemes to improve access to medicines 
should take into account the prevailing market prices of their generic equivalents. The 
limited promotion of Novartis Access may also explain limited impact. It is also possible 
that the duration of this study was too short to observe the impact of Novartis Access.  
While access initiatives such as Novartis Access are laudable, they may also be 
associated with unintended consequences which will need to be managed. The Novartis 
Access program did not have any impact on the level and trend of consumption of non-
EML medicines. The increases in level (12.41 DDDs in 1000s) and trend of consumption 
(1.18 DDDs in 1000s per quarter) observed for non-EML medicines were not statistically 
significant (p=0.6220 and 0.8413 respectively). However, six of the Novartis Access 
medicine formulations sold at MEDS were not in the EML,  including bisoprolol 5mg, 




medicines: glimepiride, valsartan and vildagliptin are not even listed in the 2017 edition 
of the WHO Model EML, which countries use as a guide in developing their national 
EMLs (46). The WHO agrees industry-led access initiatives can improve access to 
medicines and other health technologies but also acknowledges these initiatives may 
come at additional costs for countries if not properly implemented (47).  
Among other strategies to prevent these unintended consequences, the WHO advises 
countries to ensure that these initiatives serve public need and adhere to national policies, 
regulations, health strategic plans and development agendas (47). In the case of Kenya, 
the inconsistency between the EML and the STG regarding the medicines they contain 
may be a challenge when aligning access initiatives to national policies, more specifically 
to the EML. With the exception of vildagliptin, all of the six Novartis Access medicine 
formulations that are not on the EML are in the STGs (34–37). The infrequent update of 
the EML and STGs in countries may also pose a challenge to aligning access initiatives 
to the contents of these documents. This challenge does not apply to Kenya since there 
was an updated EML in June 2016 and Novartis Access was implemented later that year. 
Even if the national EML is out of date, companies can rely on the WHO Model EML, 
which is updated more frequently (46,48,49)   
In addition to WHO’s advice to countries, pharmaceutical companies should be 
incentivized to align their access initiatives to local priority needs. As mentioned in 
Chapter 4, the Access to Medicine Index, which ranks pharmaceutical companies based 
on their access to medicines initiatives does not consider the focus of access initiatives on 




recommends that all donated medicines to be on the EML of the recipient country, or at 
least on the WHO Model EML in the absence of a national EML (51). This should be a 
criterion for medicines used for pricing schemes as well.  
1.6 The potential of phone interviews and sales databases for surveillance, 
evaluation and research data collection  
The GMF urged Member States of the WHO to develop national targets and 
indicators and monitor these indicators (2). Availability and affordability of medicines 
are key components of these access indicators. The 2016 Lancet Commission on 
Essential Medicines also recommends the creation and maintenance of information 
systems for collecting routine data on the availability and affordability of essential 
medicines in both public and private sectors (31). Furthermore, access initiatives such as 
Novartis Access also need to be monitored and evaluated for both their intended and 
unintended consequences to generate evidence to optimize their impact. This study has 
demonstrated that telephone interviews offer a cost-effective method of collecting 
research and surveillance data on the availability and prices of medicines in health 
facilities and households in settings with high phone ownership.  
The high response rates of 88.2% for health facilities and 94.5% for households 
obtained in this study are consistent with the 90% plus response rates from other studies 
(52–54). Though these other studies did not collect data on the availability and prices of 
medicines, they were conducted in low- and middle-income countries. It is worth 
mentioning that in our study, incentives of 50 ($0.50) and 100 ($1.00) Kenyan Shillings 




evidence on the impact of incentives on response rates, it is possible that these incentives 
influenced the high response rates (55–57).  
In our study, medicine availability data collected from phone interviews showed a 
high level of agreement with data collected in-person in both households and health 
facilities (kappa=0.49 and 0.90 respectively). Kappa statistic of 0.41 to 0.60 is described 
as moderate, 0.61 to 0.80 as substantial, and 0.81 to 1.00 as almost perfect agreement 
(58). Additionally price data collected through phone interviews showed a strong 
significant correlation with price data collected in-person for both households and health 
facilities (r=0.90 and 0.52 respectively). Other studies which did not focus on the 
availability and prices of medicines have also demonstrated the high validity of data 
collected via phone interviews (53,54,59–64). Also consistent with findings from other 
studies are the cost estimates for phone interviews in our study ($19.28 and $16.86 per 
telephone interview for health facilities and household respectively) which was much 
lower than the cost estimate for in-person interviews ($186) (55,65). The incentive of 
50KES and 100KES for household and health facility respondent respectively represent a 
very small fraction of the cost associated with each phone interview, indicating that small 
incentives can be used to improve response rates without additional substantial cost to 
telephone data collection. The qualitative results from our study showed that most of the 
facilitators and challenges for both modes of data collection are similar. However, phone 
interviews were reported to be much more convenient. Poor phone network, having 
inaccurate phone numbers for respondents and limited power supply are some of the 




planning for telephone interviews.  
The findings summarized above strongly support the conclusion that telephone 
interviews, can be a useful tool for monitoring medicines availability and affordability 
under the GMF for NCDs. Access initiatives could also be monitored and evaluated with 
less cost and effort using telephone interviews. If there is a reliable source of phone 
numbers, telephone interviews alone can be used for data collection. Otherwise an initial 
baseline in-person interview may be needed to collect phone numbers of respondents. In-
person validation data collection may also be conducted for a sub-sample of respondents, 
especially at the beginning of data collection in order to validate data collected over the 
phone.  
The government of Kenya could consider phone data collection as a means of 
monitoring the implementation of UHC, the introduction of price labels on medicines, 
and the availability and prices of medicines in the country. Telephone interviews can 
generate time series data which can offer a rigorous method for evaluating medicines 
consumption and use (66). Depending on the technology available, and the familiarity of 
respondents with phones, other features of telephone communication, including sharing 
of pictures can be explored. Respondents can also complete and submit study instruments 
from their smart phones without necessarily talking to data collectors over the phone.  
Sales data are another useful source for monitoring and evaluating medicines 
consumption. The study presented in Chapter 4 used sales data to examine general 
consumption patterns of NCD medicines, to evaluate the effect of the Novartis Access 




according to the EML. There is a fair amount of literature on measuring medicines 
consumption using sales data (67–71). However, to the best of my knowledge this is the 
first study using sales data to study the spill-over effects of an access initiative in a lower-
middle income country. Many medicine wholesale companies have well developed 
information systems which could serve as useful secondary data sources for assessing 
national indicators under the GMF for NCDs.  
2. RECOMMENDATIONS 
The key lessons from these studies serve as basis for a set of recommendations that 
aim to improve access to NCD medicines under the GMF and the promotion of UHC.  
1. More research is needed to understand factors contributing to low availability of 
NCD medicines in Kenya and similar countries, especially in the public sector. Research 
is also need to better understand potential interventions designed to improve availability.  
2. Certain NCD medicines should be made available at primary care facilities with 
adequate training of health staff to promote their appropriate use. 
3. Medicines in the STGs should be consistent with medicines in the EML in Kenya. 
Harmonizing the two documents should improve the standard of care in the country. 
4. Policies need to be implemented to control the very high variability of medicine 
prices in Kenya. In addition to price labels the Ministry of Health is already considering, 
the government should also consider other context appropriate price control measures 
(26,27) 
5. Research should be conducted on the factors that promote the consumption of 




6. Implementers of access initiatives and beneficiary countries should work together 
to ensure that price schemes are aligned with the priority needs of the country and focus 
on the EML of recipient countries.  
7. Telephone data collection is a feasible alternative to in-person data collection and 
should be employed in monitoring and evaluating policies and access to medicine 
programs such as access initiatives, interventions to control medicine prices, and other 
indicators under the GMF on NCDs. More research is needed to optimize its use as a 
monitoring and measurement tool under different national situations.   
8. Much can be learned about medicine consumption patterns using sales data. 
Countries should take advantage of this potentially cheap and reliable source of data to 
generate useful evidence for decision making.  
3. STRENGTHS AND LIMITATIONS 
This study had several strengths. First, is to evaluate the availability of medicines, 
taking into consideration the level of care medicines are assigned in the EML. Second, it 
also evaluates availability and purchasing patterns separately for medicines included in 
the EML and those not in the EML, highlighting important differences.  
This study had important limitations. The cross-sectional nature of the study on price 
and availability of medicines in Chapter 2 does not allow for the establishment of 
associations or the evaluation of trends in availability and prices over time.   
This study on consumption patterns in Chapter 4 utilized a controlled interrupted time 
series analysis of sales data to examine medicine utilization patterns for NCDs. 




have controlled for external factors that may influence consumption patterns e.g. 
population and economic growth, strikes and elections. There were no data on stock-outs 
of study medicines at MEDS which could have also influenced consumption patterns. 
However, previous studies have reported limited stock-outs of NCD medicines at MEDS 
(11). Additionally, it was assumed that medicines purchased at MEDS were actually 
dispensed to patients. Events such as expiry and pilferage of medicines at the facility 
level may however invalidate this assumption. Finally, our findings regarding the high 
response rates for telephone interviews in Chapter 3 may not be generalizable to settings 
with low telephone ownership or very poor network or limited supply of electricity to 
keep phones charged.  
4. CONCLUSIONS 
These studies have highlighted some major challenges in access to NCD medicines in 
Kenya. Availability of medicines is a major challenge in the country, especially at 
primary care level in the public sector. The restriction of most NCD medicines to higher 
levels of care in the national EML may be one of the reasons for their low availability. 
Prices of NCD medicines vary substantially, across and within provider type, by level of 
care and by county. The higher price ratios of NCD medicines in the private sector may 
be an indication of higher mark-ups in this sector. Since there is low availability of NCD 
medicines in the public sector patients are required to purchase them in the private sector 
where prices are higher.  
There is widespread non-compliance with the EML with many facilities purchasing 




national EML. Interventions need to be implemented to address these challenges to 
ensure effective implementation of Universal Health Coverage in the country.  
The implementation of Novartis Access had limited impact on the consumption of 
generic and therapeutic alternatives. The relatively higher price of some Novartis Access 
medicines may be responsible for this limited impact. Price is an important factor to 
consider when designing price schemes aimed at improving access to medicines. 
Furthermore, these studies have shown that phone interviews are a convenient and 
reliable means for collecting data on the availability and price of medicines. This 
potential should be explored in the monitoring and evaluation of access to medicines. 
Sales data also offers another source of data for learning about medicine consumption 
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Exhibit 1 – Policy memo to the Ministry of Health of Kenya 
MEMORANDUM 
To: Dr. Joseph Kibachio Mwangi (Head of NCD Unit, Ministry of Health, Kenya) 
From: Paul Ashigbie, Boston University 
Date: November 24, 2018 
Subject: Improving access to medicines for non-communicable diseases in Kenya 
Introduction 
Kenya faces a high burden of non-communicable diseases (NCDs). One-half of 
total hospital admissions and over 55% of hospital deaths in Kenya are due to NCDs (1). 
About 2.2% of the population between the ages of 20-70 have diabetes which leads to 
20,000 deaths every year (2). According to the Kenya Stepwise Survey for Non-
communicable Diseases Risk Factors 2015 Report, the prevalence of hypertension in 
Kenya stands at 24% (1). Availability and prices of medicines are two critical indicators 
for assessing the efforts of countries to address the burden of NCDs (3). This policy 
memo analyzes the current situation of access to medicines for NCDs in Kenya, and 
makes evidence-based recommendations to the Ministry of Health on how to make these 
medicines more available in health facilities and at affordable prices.  
The current situation of availability and prices of NCD medicines  
1. Low availability of NCD medicines in public and private sector facilities 
According to the Comprehensive Global Monitoring Framework (GMF) for NCDs, 




and essential medicines, including generics, required to treat major non-communicable 
diseases in both public and private facilities” (3,4). Several studies, including one 
conducted by Boston University School of Public Health (BUSPH) in collaboration with 
Innovations for Poverty Action, Kenya (IPA) have demonstrated low availability of 
medicines for NCDs in Kenya, far below the international target of 80% (5–8). The 
BUSPH/IPA study which took place in eight counties showed that the mean availability 
of essential medicines for NCDs (medicines included in the Essential Medicines List, 
EML) was only 55%. This figure was far less (25%) for NCD medicines included in the 
national Standard Treatment Guidelines (STGs) (the STGs contained other medicines in 
addition to the essential medicines). Availability was lowest in public facilities and at 
lower levels of care. Though availability was highest in the private sector (61.7 and 
29.3% respectively for EML and STG medicines), it was still much lower than the 80% 
target. Other studies in Kenya have also reported suboptimal availability of NCD 
medicines compared to medicines for acute conditions in health facilities, especially in 
the public sector and in primary care facilities (5,6,8). One particular study conducted in 
2009 showed that medicine (for both acute and NCDs) stock-outs were about three times 
more common in public facilities compared to non-profit private facilities (46% vs. 14%) 
(9).  
The low availability of NCD medicines in the public sector is more troubling for two 
reasons. First, it will make it difficult to retain NCD patients in care. Most NCD patients 
in Kenya are diagnosed in the public sector, where NCD medicines are less available for 




diagnosis improves the rate of treatment initiation, retention in care and health outcomes 
of HIV patients (11). Secondly, patients will have to purchase their medicines in the 
private sector where prices are higher (9,12–14). This results in high out-of-pocket 
expenditure on medicines, which affects household finances and adherence to treatment. 
Poor households may be pushed further into poverty or forego necessary treatment. In 
order to effectively address the low availability of NCD medicines, especially in the 
public sector, more research is needed to understand the root causes of this challenge and 
evidence-based interventions designed to address them.  
2. Increasing NCD medicines availability at all levels of care 
The EML of Kenya restricts most NCD medicines to levels 4 (county referral 
hospitals) and above (15,16). From the BUSPH/IPA study, a significant proportion of 
level 2 and 3 facilities had in stock NCD medicines otherwise restricted to levels 4 and 
above. The proportion of levels 2 and 3 facilities having these medicines in stock ranged 
from 13% (for amlodipine 5mg) to 80% (for omeprazole 20mg) (7). More than one half 
of levels 2 and 3 facilities were stocking furosemide 40mg and metformin which are also 
restricted to facility levels 4 and above. Similar findings were obtained when 
consumption patterns from a major supplier were examined: furosemide 40mg tablets 
was purchased by 63% (n=51) of level 2 facilities and 50% (n=10) of level 3 facilities; 
metformin 500mg was purchased by 77.8% (n=63) of level 2 and 65% (n=13) of level 3 
facilities. These findings suggest there is relatively high demand for these NCD 




medicines to higher levels of care is to ensure their appropriate use, the restriction may 
compromise access to these medicines. As Kenya rolls out universal health care coverage 
(UHC), the country should also rethink the delivery of its NCD care (17,18). Lower level 
care facilities are often closer to their patients and it will be challenging to achieve UHC 
if basic NCD medicines continue to be restricted to higher levels of care. With the 
increasing burden of NCDs, basic NCD medicines should be made available at lower 
levels of care with appropriate training of health staff to ensure their appropriate use. This 
recommendation was also issued in the 2015 report of the Stepwise Survey on NCDs:  
“Build the capacity of the health workforce while ensuring the availability, access, 
affordability and quality of safe, efficacious medicines and basic technologies for 
screening, diagnosis, treatment and monitoring of common NCDs such as hypertension 
and diabetes at primary health care” (1). It has been argued that the successful scale up 
of HIV care delivery could not have been made with locating care provision at hospital 
outpatient clinics. For instance, South Africa has moved HIV care into primary care 
closer to where patients level (11,19,20). 
3. Price and affordability of NCD medicines  
The BUSPH/IPA study showed wide variations in the prices of NCD medicines, with 
prices of the same medicine varying substantially across and within provider type and 
level of care. Prices were generally higher among private providers compared to public 
providers (7). Additionally, more public facilities gave medicines for free compared to 
non-profit and for-profit private facilities (47.3%, 9.4% and 0% respectively) but without 




suggests no effective policies guiding the free dispending of medicines. The study 
compared medicine prices in Kenya with international reference prices from the 
International Medical Products Price Guide, published by Management Sciences for 
Health (21). The price ratio for NCD medicines was significantly higher than the price 
ratio for acute medicines in non-profit private facilities (4.3 vs. 2.01) and drug outlets 
(3.46 vs. 1.66) but this was not the case in public facilities. This indicates mark ups might 
be particularly higher on NCD medicines in non-profit private facilities and private drug 
outlets. Another study conducted in Kenya by Health Action International between 
January and May 2018 confirmed that mark-ups are higher in the non-profit private 
sector compared to the public sector (22). These findings are consistent with those from 
another study conducted in 2009 - prices of medicines are lower in public facilities 
compared to faith based and private facilities (9). 
The Ministry of Health is in talks with pharmaceutical companies to control 
medicines prices by placing price labels on medicine packages (23). The roll-out of this 
strategy should be done with adequate monitoring to determine the effectiveness of the 
price labels in all sectors (public, non-profit and for-profit private sector) and all levels of 
care. The government also needs to discuss additional price control measures that may be 
may be appropriate for its setting (24,25). As the Kenya is rolling out UHC, price 
controls especially on medicines is key to make UHC sustainable.  
4. Selection of NCD medicines in health facilities 
The BUSPH/IPA study found widespread non-compliance with the EML in terms of 




Although the volume of consumption of non-EML medicines constituted only 1.2% of 
total volume of sales from a major wholesaler, these medicines were purchased in five 
out of the eight study counties, at all levels of care and by all types of providers. Five 
NCD medicines – bisoprolol, captopril, glimepiride, ramipril, and valsartan – that were 
not in the EML were available at all levels of care and found in 1 to 20% of facilities. It is 
important to determine the factors responsible for this behavior since purchases outside of 
the EML can lead to inefficiencies and inappropriate use. Though not exclusively, 
Novartis Access (a pricing scheme to improve access to NCD medicines) appears to have 
contributed to the non-compliance with the EML. Six of the Novartis Access medicine 
formulations available on the market were not in the EML. (26). The World Health 
Organization advised countries to ensure that access to medicine initiatives such as 
Novartis Access adhere to national policies, and local developmental agendas (27). 
The goals of National Essential Medicine Policies and national EMLs include 
promoting appropriate use of medicines (good prescribing and dispensing practices, and 
minimizing cost (28–31). A study in China showed the implementation of the EML 
improved prescribing and dispensing practices, and reduced expenditure on medicines 
(32,33). But for the EML to achieve its desired objectives it has to be enforced. The 
inconsistency between the EML and STGs in Kenya may be one of the factors making it 
difficult to enforce the EML (15,16,34,35). NCD medicines such as bisoprolol, 
glimepiride, captopril, ramipril, and valsartan which are not listed in the EML are listed 
in the STGs. Many countries base their EML on their national STG, ensuring that the two 




service delivery documents is even more critical as the country implements UHC (17,18).  
Recommendations 
Based on the evidence presented, the following recommendations are offered to 
enable Kenya address the challenges related to availability and prices of medicines, 
combat its high burden of NCDs and achieve Target 3.4 of the Sustainable Development 
Goals which aims to “by 2030, reduce by one-third pre-mature mortality from NCDs 
through prevention and treatment, and promote mental health and wellbeing” (41).   
1. Research should be conducted to understand the factors responsible for low availability 
of NCD medicines especially in the public sector, and interventions designed to improve 
their availability.  
2. Basic NCD medicines should be made available at lower levels of care with adequate 
training of health staff to promote their appropriate use. This is likely to increase patient 
retention in care and also prevent patients from confronting high medicine prices in the 
private sector.  
3. Policies need to be implemented to control the very high variability of medicine prices in 
Kenya. In addition to price labels the Ministry of Health is already considering, the 
country needs to discuss other price control measures that may be appropriate for its 
setting. 
4. Research should be conducted on the factors affecting consumption of non-EML 
medicines in public and non-profit facilities and interventions developed to address this 
challenge. 
5. Medicines listed in the STGs should be based on the EML. Harmonizing these two 





6. The government should work with stakeholders to ensure that access to medicines 
initiatives are aligned with national priorities such as the EML.  
Challenges and limitations 
Care for NCDs has been restricted to higher levels of care for a long time. 
Reforms such as allowing NCD medicines at lower levels of care will need to be 
accompanied with training of staff and where applicable making available laboratory 
equipment that may be needed for diagnosis and monitoring of patients. Improving 
access to NCD medicines especially in the public sector will also imply governments, 
both national and county level, dedicating more resources for this purpose.  
Conclusion 
There is enough evidence to show that access to NCD medicines is a challenge in 
Kenya. Increasing availability and affordability of NCD medicines, in particular lower 
levels of care (levels 2 and 3) in public sector facilities is necessary to increase access. 
Key recommendations include the harmonization the STG and the EML, making basic 
NCD medicines available at lower levels of care with appropriate training of health staff 
to ensure their appropriate use, ensuring that access to medicine initiatives focus on 
medicines in the EML and interventions such as price labels on medicine packages and 
other context appropriate price control measures to address the variability in medicine 
prices. Furthermore, more research needs to be conducted to understand the reasons 
behind the low availability of NCD medicines in health facilities and the factors 
contributing the consumption of non-EML medicines and policies implemented to 
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Exhibit 2 - Telephone interviews for collecting data on medicines: A policy brief 
Introduction 
This policy brief recommends the use of phone interviews as an alternative or 
supplement to in-person interviews to collect survey, surveillance or evaluation data on 
the availability and prices of medicines in health facilities and households. This 
recommendation is based on evidence that shows the high validity of data collected 
through phone interviews, the relatively lower cost associated with telephone interviews 
(compared to in-person interviews) and the convenience of this mode of data collection.  
The need for routine data for decision making in health care  
One of the targets of Sustainable Development Goal 3, which focusses on health 
is to: “Achieve universal health coverage, including financial risk protection, access to 
quality essential health-care services and access to safe, effective, quality and affordable 
essential medicines and vaccines for all” (1). Many initiatives are being implemented 
towards achieving this goal, including those with specific focus on access to medicines. 
For example, Access Accelerated, a cross-sector collaboration involving 
biopharmaceutical companies, the World Bank, and other stakeholders was launched in 
2017 with the focus of improving access to treatment for non-communicable diseases 
(NCDs) in support with SDGs (2–4). Novartis Access an initiative to provide low cost 
NCD medicines to patients in low- and middle-income countries (LMICs) was launched 
during the 2015 United Nations General Assembly when the SDGs were adopted (5). 




health services including medicines (6–8). Of paramount importance is monitoring the 
outcomes and impacts of these programs to ensure they are actually meeting their stated 
objectives. The 2016 Lancet Commission on Essential Medicines recommends the 
creation and maintenance of information systems for collecting routine data on the 
availability and affordability of essential medicines in both public and private sectors (9). 
Under the comprehensive Global Monitoring Framework for NCDs, Member States of 
the WHO are expected to monitor 25 indicators which include availability and 
affordability of NCD medicines (10). However, the seemingly high cost and effort 
involved in rigorously evaluating the impact of these initiatives have been a disincentive 
to program implementers, donors and governments (11,12). 
Evidence on the validity of data collected from phone interviews 
The drastic increase in mobile phone ownership in low- and middle-income 
countries (LMICs) in recent years has made mobile phone surveys an attractive option for 
collecting research and surveillance data (13). In 2016, there were 96 mobile phone 
subscriptions per 100 people in LMICs which is close to the worldwide subscription rate 
of 100.7 per 100 people (14,15). There has been limited use of phone interviews for 
surveys and surveillance in LMICs even though these countries, need quality data at low 
cost, often have less safe environments, and limited infrastructure (road network) needed 
for in-person interviews (13,16–18).  
Compared to in-person interviews, phone interviews are a cheaper and more 
convenient alternative to collect data on the availability and price of medicines. However, 




data collection comparable to in-person interviews. A recent study conducted by Boston 
University School of Public Health (BUSPH) in collaboration with Innovation for 
Poverty Action (IPA) addressed this question and compared the validity of data on the 
availability and price of medicines collected through telephone interviews with data from 
in-person interviews in households and health facilities (19). The phone technology used 
in this study was human operator or computer-assisted phone interview (CATI) in which 
respondents were interviewed by a person using a phone and the interviewers utilize a 
software program, Survey CTO, to record the survey responses (18,20). The findings 
from this study are summarized below: 
i) High response rates of 88.2% for health facilities and 94.5% for households  
ii) Medicine availability data collected from phone interviews showed a moderate to 
almost perfect level of agreement with data collected in-person in both households 
and health facilities (kappa=0.49 and 0.9 respectively). Kappa statistic of 0.41 to 0.60 
is described as moderate, 0.61 to 0.80 as substantial, and 0.81 to 1.00 as almost 
perfect agreement (21).  
iii) Price data collected through phone interviews also showed a strong significant 
correlation with price data collected in-person for both households and health 
facilities (r=0.9 and 0.52 respectively). 
iv) The cost associated with phone interviews ($19.28 and $16.86 per telephone 
interview for health facilities and household respectively) was much lower than the 
cost of in-person interviews ($186). 
v) Most of the factors that facilitated or served as barriers for both modes of data 




responses for in-person data collection to be an advantage and poor road networks 
and the high level of effort involved in travel as disadvantages. Telephone interviews 
were regarded as taking less resources including cost and time, though they did not 
allow for visual confirmation of medicines information.  
The findings presented above are consistent with results from similar studies 
comparing telephone interviews with in-person interviews though these studies did not 
focus on medicines. For example, other studies in Kenya, Mali and Tanzania have all 
shown more than 90% response rates (17,22,23). There is mixed evidence regarding the 
impact of giving incentives to respondents on response rates (16,24,25). In the Boston 
University study, incentives of 50 ($0.50) and 100 ($1.00) Kenyan Shillings were given 
to respondents after each data collection. More research is needed to identify type of 
incentives that enables high response rates. Other studies also demonstrated the high 
validity of data collected via phone interviews (13,26–31). Telephone interviews can 
generate time series data which can offer a rigorous method for evaluating medicines use 
(32). The cost estimates obtained from the Boston University study are within what has 
been documented in literature (24,25,33–35).  
Recommendations 
Based on the evidence presented above, the following recommendations on the 
use of phone interviews for data collection are offered to researchers, policy makers, and 




1. Telephone data collection is a feasible alternative to in-person data collection and should 
be employed in monitoring and evaluating policies and programs aimed at improving 
access to medicines, particularly in setting with high phone ownership. 
2. More research is needed to optimize the use of telephone interviews as a monitoring and 
measurement tool, for example in further understanding the role of incentives in 
improving response rates, exploring other functions of phones including video calls, 
collecting research data through pictures etc. 
3. In-person validation data collection may also be conducted for a sub-sample of the 
respondents, especially at the beginning of data collection in order to validate data 
collected over the phone. 
Limitation and barriers 
Phone interviews are not recommended in settings where phone ownership is less 
than 80% (25). However, this barrier can be navigated by distributing phones to their 
respondents (16,17,24,35). If there is a reliable source of phone numbers, representative 
samples can be created exclusively by calling potential respondents to access their 
inclusion criteria and interest to participate in the study (25,36). However, this method 
requires high rates of mobile phone ownership and also the availability of an unbiased 
source of phone numbers. In the absence of an unbiased source of phone numbers, an 
initial baseline in-person interview may be needed to collect phone numbers of 
respondents for follow-up data collection (24,25). There are specific ethical issues that 
confront collecting data via phone interviews. Due to the difficulty in protecting the 
confidentiality of respondents over the phone, phone surveys may not be ideal for 





Telephone interviews offer a cost-effective method of collecting research and 
surveillance data on the availability and prices of medicines in health facilities and 
households in settings with high phone ownership. The evidence summarized above 
strongly support the fact that telephone interviews, which are much more convenient and 
less expensive can be a useful tool for monitoring and evaluating medicines availability 
and affordability. Program implementers, policy makers and researchers should consider 
telephone interviews as a reliable method for collecting data. The impact of access 
initiatives such as Novartis Access could be assessed using phone interviews for their 
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